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II Abbreviations 
 
 
ADA adenosine deaminase 
ATP adenosine triphosphate 
bp base pair 
cAMP cyclic adenosine monophosphate 
CoDP cordycepin diphosphate 
CoMP cordycepin monophosphate 
CoTP cordycepin triphosphate 
CTD C-terminal Domain  
CTP cytidine triphosphate 
CUT cryptic unstable transcript 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
DNA deoxyribonucleic acid 
GO gene ontology 
GTP guanosine triphosphate 
hnRNA heterologous nuclear RNA 
mRNA messenger RNA 
NPC nuclear pore complex 
nt nucleotide 
NTP nucleotide triphosphate 
OD600 optical density at λ = 600 nm 
PAP poly(A) polymerase 
PIC pre-initiation complex 
RNA ribonucleic acid 
rRNA ribosomal RNA 
snoRNA small nucleolar RNA 
snRNA small nuclear RNA 
RNP ribonucleoprotein 
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TdT termina deoxynucleotidyl transferase 
TEC transcritpin elongation complex 
tRNA transfer RNA 
UTP uridine triphosphate 
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III Summary 
 
Cordycepin is an analogue of the nucleoside adenosine and displays various biological 
activities, including anti-microbial, anti-fungal and anti-proliferative. The absence of a 
3’ hydroxyl group leads to termination of RNA synthesis when this drug is incorporated 
into a RNA strand during transcription or pre-mRNA polyadenylation. The aim of this 
thesis was to gain further insight into the molecular mode of action of cordycepin in the 
budding yeast Saccharomyces cerevisiae and to identify new factors involved in RNA 
synthesis pathways. Initially, we analysed the molecular effects of cordycepin on RNA 
metabolism in wild-type strains. Consistent with the proposed function as a RNA chain 
terminator we found that cordycepin caused a general decrease of mRNA levels. However, 
we also identified additional, unexpected effects of the drug: dramatic changes of mRNA 
3’ ends, which likely occurred independently from the termination of the polyadenylation 
reaction, and furthermore, the appearance of elongated transcripts. Most interestingly, we 
provide evidence that cordycepin incorporation into poly(A) tails of unstable transcripts 
may inhibit RNA surveillance by the TRAMP-exosome pathway leading to a stabilisation 
of the respective RNAs. In an attempt to identify all cellular pathways that are targeted by 
cordycepin we performed systematic and genome-wide screening. This identified genes 
that affected the ratio of ATP/CoTP and genes that stabilise mRNAs. Our analyses suggest 
that the relative levels of these nucleotide triphosphates determine cordycepin toxicity and 
that inhibition of RNA synthesis was the primary cause for growth inhibition. More 
unexpectedly, we identified the SWR1 chromatin remodelling complex and its substrate, 
the histone H2A variant Htz1p, which could be linked to RNA surveillance activities in our 
analyses. Further functional tests revealed that many of the identified genes exhibited 
aberrant global poly(A) tail length distribution and genetic interactions with the 3’ end 
factor RNA14 pointing to a potential role in pre-mRNA synthesis and processing. Finally, 
we established that cordycepin sensitive growth linked elevated levels of polyphosphate to 
the inhibition of poly(A) polymerase, which could indicate a regulatory role for 
polyphosphate in gene expression in yeast. This work establishes novel physiological roles 
for cordycepin and identifies new targets and pathways that mediate the effect of the drug. 
Thus, our results may be helpful to further understand and exploit the therapeutic potential 
of cordycepin on the one hand and to connect the cellular targets of cordycepin to mRNA 
synthesis and pre-mRNA processing pathways on the other hand. 
 Zusammenfassung 
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IV Zusammenfassung 
 
Cordycepin ist ein Adenosinderivat, welches diverse biologische Aktivitäten aufweist, 
einschliesslich einer Hemmwirkung gegen Mikroben, Pilze und Zellproliferation. Das 
Fehlen der 3’ Hydoxylgruppe führt zur Termination der RNA Synthese, sobald Cordycepin 
während der Transkription oder der Polyadenylierung der prä-mRNA in den RNA Strang 
eingebaut wird. Das Ziel dieser Arbeit war, den genauen Wirkungsmechanismus von 
Cordycepin in der Hefe Saccharomyces cerevisiae zu analysieren und dabei bisher 
unbekannte Faktoren zu identifizieren, die in den Prozess der RNA Synthese involviert 
sind. In einem ersten Schritt untersuchten wir die molekularen Effekte von Cordycepin auf 
den RNA Metabolismus im Wildtyp. Das Adenosinderivat verursachte eine generelle 
Abnahme der RNA Level. Dies ist konsistent mit der angenommen Wirkung von 
Cordycepin, dass die RNA Synthese terminiert wird. Darüber hinaus identifizierten wir 
unerwartete Effekte von Cordycepin: zum einen starke Veränderungen am 3’ Ende der 
mRNA, welche sehr wahrscheinlich unabhängig vom Abbruch der Polyadenylierung 
zustande kommen. Zum anderen das Auftreten von verlängerten RNA Transkripten. Die 
Analysen ergaben ausserdem, dass der Einbau von Cordycepin in den Poly(A) Schwanz 
von instabilen Transkripten den RNA Überwachungsmechansimus inhibieren könnte, der 
durch den TRAMP-Komplex und das Exosom gesteuert wird, was zu einer Stabilisierung 
von diesen RNA Transkripten führt. In einem Versuch, alle zellulären Prozesse, die von 
Cordycepin attackiert werden, zu identifizieren, haben wir einen systematischen, 
genomweiten Screen durchgeführt. Wir identifizierten Gene, die das Verhältnis von ATP 
zu CoTP beeinflussen und Gene, welche mRNA stabilisieren. Unsere Ergebnisse deuten 
darauf hin, dass die relativen Mengen von beiden Nukleotidtriphosphaten die Toxizität von 
Cordycepin bestimmen und dass die Inhibierung der RNA Synthese die Hauptursache für 
die Wachstumshemmung ist. Zudem identifizierten wir den SWR1 Komplex und sein 
Substrat Htz1p, eine Histonvariante von H2A. Beide wurden durch unsere Ergebnisse mit 
dem RNA Überwachungsmechanismus in Verbindung gebracht. Funktionelle Tests 
ergaben, dass viele der identifizierten Gene eine anormale Längenverteilung der Poly(A) 
Schwänze aufwiesen. Gleichzeitig interagieren viele Gene genetisch mit RNA14, einem 
Faktor, der an der Bildung des 3’ Endes der RNA beteiligt ist. Beide Beobachtungen lassen 
darauf schliessen, dass diese Gene eine Funktion innerhalb der prä-mRNA Synthese und 
deren Prozessierung aufweisen. Schliesslich haben wir festgestellt, dass sensitives 
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Wachstum in Anwesenheit von Cordycepin eine erhöhte Polyphosphatkonzentration an 
einer Inhibierung von Poly(A)polymerase koppelt. Dies könnte auf eine Funktion von 
Polyphosphat in der Regulation von Genexpression in Hefe hindeuten. Die vorliegende 
Arbeit postuliert neue physiologische Funktionen von Cordycepin und identifiziert neue 
Gene oder Prozesse, welche die Wirkung von Cordycepin herbeiführen. Unsere Resultate 
könnten deshalb dazu beitragen, das therapeutische Potential von Cordycepin weiter 
auszuschöpfen und die biologische Wirkung von Cordycepin mit der mRNA Synthese und 
der prä-mRNA Prozessierung in Verbindung zu bringen. 
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V Introduction 
 
1 Cordycepin 
 
1.1 The genus of the fungus Cordyceps 
 
Cordycepin is a compound which was first isolated from the culture media of the fungus 
Cordyceps militaris (Cunningham et al., 1950). Cordyceps is a genus of ascomycete fungi, 
which consists of around 400 species. All of them are parasites of insects or fungi and 
often exhibit a high degree of host specificity. When a Cordyceps attacks a host, the 
mycelium invades the host tissue and eventually replaces it. The fungus ruptures the host 
body and forms the sexual perothecial stroma that is connected to the dead larva and which 
grows upward to emerge above the soil surface (figure 1). What exactly kills the host is not 
clear, however, it might be the accumulation of the biomass or the toxins produced by the 
fungus. Several Cordyceps species are producing cordycepin, but the best known species 
of the genus is Cordyceps sinensis, because it is one of the most famous traditional Chinese 
medicines. The complex of the fungus and the larva body which is called Dong Chong Xia 
Cao (winter worm summer grass) has been used as a health food and tranditional medicine 
in China for hundreds of years. Now it is available in different forms: crude extracts, water, 
ethanol, methanol and ethyl acetate extracts, pure compounds or whole fungi (with or 
without the dead hosts). It has been assigned to have various beneficial effects on humans: 
anti-aging, pro-sexual, anti-cancer, anti-metastatic, anti-oxidant, anti-inflammatory, 
insecticidal, anti-microbial, and immune boosting; it helps against respiratory, renal, liver, 
neural and cardiovascular diseases. For most of these effects, the scientific evidences are 
rather poor (Paterson, 2008). 
The fungus is endemic to the alpine habitats of the Tibetan Plateau above 3000 m in 
south-western China, and there has been large-scale harvesting of the wild material. The 
fungus has officially been classified as an endangered species. The price of natural 
products of C. sinensis is over 12000 US $/kg and the market is increasing (Paterson, 
2008). As a consequence, living strains have been isolated from natural Cordyceps and 
cultivated in large quantity by bioreactor technology, which is a promising method to 
encounter the needs of human consumption and to reduce the pressure on natural resources 
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of the species. In vitro culture of the fungus has been employed increasingly and it is 
generally accepted that cultivated C. sinensis possesses the same benefits and properties as 
C. sinensis natural herbs. 
Various bioactive components in Cordyceps species have been reported. These 
include cordycepin and other adenosine derivatives, ophicordin (antifungal agent), L-
tryptophan, polysaccharides and ergosterol (Wu et al., 2005). C. sinensis first gained 
worldwide attention when it was revealed that several Chinese runners who broke world 
records in 1993 had included this fungus in their diet as part of their training program 
(Paterson, 2008). 
Especially Chinese research groups have been investigating the various effects of 
Cordyceps on the human body also in recent studies (Zhu et al., 1998; Li and Tsim, 2004). 
Solid or liquid fermentation has been widely used for the production of Cordyceps 
mycelial body mass and components and therefore, there has been an increasing number of 
studies on the liquid fermentation of C. sinensis or some other valuable Cordyceps species 
(Xiao et al., 2004; Kim and Yun, 2005; Mao et al., 2005). Most of these studies try to 
optimise nutrients and conditions for mycelial growth and the yield of cordycepin 
production. Ammonium feeding (5 – 10 mmol/l) to the mycelial culture of C. sinensis has 
been shown to enhance the intracellular cordycepin accumulation and the 
exopolysaccharide production (Leung and Wu, 2007).  
 
 
 
Figure 1 Cordyceps species on insect hosts. (Paterson, 2008) 
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1.2 Chemical structure of cordycepin 
 
Cordycepin, or 3’ deoxyadenosine, is a derivative of the nucleoside adenosine differing 
from the latter by the absence of the OH group in the 3’ position of its ribose entity (figure 
2). It was first isolated by Cunningham et al. (1950) from the liquid medium of the fungus 
Cordyceps militaris (Cunningham et al., 1950). The mold was co-cultured with the bacteria 
Bacillus subtilis (B. subtilis) and found to inhibit the growth of the bacterium after 15 days 
slightly, and after 24 days to a more pronounced degree. A crystalline compound was 
isolated from the culture filtrates, which appeared to be responsible for the observed 
inhibitory effect. This compound was named ‘cordycepin’. Surprisingly, it had no 
inhibitory effect on the growth of other prokaryotes as for example Staphylococcus aureus 
and Escherichia coli. Initially, a wrong structure was assigned to cordycepin (Bentley et 
al., 1951). The authors concluded from physical properties of the compound and the 
product of different chemical reactions that the sugar moiety of cordycepin was a 3-D-
deoxyapiose, a branched-carbon chain 3’ deoxypentose, which was named cordycepose 
(figure 2). The branch-chain CH2OH was assigned to C-4’ instead of C-5’ of the furanose 
ring resulting in the wrong sugar moiety. Additional evidence substantiating cordycepose 
as a branched-chain 3-deoxypentose was presented 1955 (Raphael and Roxburgh, 1955). 
The authors reported the total chemical synthesis of cordycepose and its conversion to the 
crystalline p-nitrophenylosazone. The osazone of the synthetic branched-chain sugar had 
the same melting point as that one obtained from the cordycepose isolated from the 
metabolite cordycepin. A mixture of them showed no depression in melting point, which 
was considered additional proof that the structure assigned to the carbohydrate moiety of 
cordycepin was indeed a branched-chain sugar. 
The first indication that the sugar moiety of cordycepin was not a branched-chain 
sugar was reported in 1963 (Klenow, 1963a). When cordycepin isolated from culture 
filtrates of C. militaris was added to cultured Ehrlich ascites tumor cells, three additional 
major peaks appeared in the elution profile of an anion-exchange chromatography of the 
acid-soluble fraction. These three peaks had very similar chemical properties to nucleotides 
of the base adenine and could be identified as cordycepin mono-, di-, and triphosphate. The 
monophosphate of cordycepin was dephosphorylated in presence of snake venom 
5’ nucleosidase with the same rate than an equimolar amount of 2’ dAMP. Assuming that 
the structure of cordycepin was as proposed (Bentley et al. 1951) and therefore does not 
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contain a 5’ hydroxyl group, Klenow’s result indicated that the specificity of snake venom 
5’ nucleotidase included the hydrolysis of phosphate of branched-chain sugars with 
hydroxymethyl groups. This seemed to be highly unlikely. Subsequent physical and 
chemical studies (Kaczka et al., 1964b; Suhadolnik and Cory, 1964; Hanessian et al., 1966) 
have shown that the structure of the carbohydrate moiety of cordycepin as proposed by 
Bentley et al. (1951) was incorrect and that cordycepin is a 3’ deoxynucleoside.  
The isolation of cordycepin from culture filtrates of Cordyceps militaris has been 
simplified and the yield has been improved over the years (Kredich and Guarano, 1960; 
Kaczka et al., 1964a; Frederiksen et al., 1965; Chassy and Suhdolnik, 1969), the latter of 
those reports was regarded as a standard extraction method for many years, until the 
chemical synthesis of cordycepin replaced the extraction procedure. 
 
 
1.3 Biochemical properties of cordycepin 
 
The biochemical properties of cordycepin were of high interest. Intriguing was particularly 
the ovservation, that cordycepin inhibited the growth of B. subtilis but not of other 
bacteria. In the early 60s it was suggested that cordycepin might inhibit the de novo purine  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Chemical structures assigned to cordycepin. 
A Initially proposed chemical structure with the sugar moiety cordycepose (Bentley et al., 
1951). B Correct structure of cordycepin as a derivative of adenosine. 
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biosynthesis in B. subtilis (Rottman and Guarino, 1964a). In the presence of cordycepin, 
less phosphate is incorporated into RNA and DNA, and only the additional supply of 
adenine or guanine can effectively reverse this effect (Rottman and Guarino, 1964b). In a 
subsequent study, it was shown that cordycepin is phosphorylated to cordycepin 
monophosphate in B. subtilis and that this form of the nucleotide inhibited the activity of 
the enzyme phosphoribosyl pyrophosphatate amidotransferase (Rottman and Guarino, 
1964c).  
A possible anticancer activity of cordycepin was first described in Ehrlich ascites 
cancer cells. Cordycepin increases the survival time of mice bearing the Ehrlich ascites 
tumor (Jagger et al., 1961). When tumor cells and cordycepin were administered at the 
same time, followed by daily injections of cordycepin for 7 days (15 – 200 mg/kg body 
weight), a significant increase in survival time of the mice was observed. Even when the 
tumor has been allowed to develop 5 days prior to cordycepin treatment starts, the animals 
survived significantly longer than control animals (Jagger et al., 1961). Trying to find the 
biochemical mechanism for this anti-tumor effect of cordycepin, the nucleotide distribution 
was analysed in the tumor cells. This study revealed that these cells were able to 
phosphorylate cordycepin to the mono-, di-, and triphsophates in a very efficient process 
(Klenow, 1963a). 80% of the added cordycepin was converted into either mono-, di-, or 
triphosphates within 30 minutes (Klenow, 1963b). Besides a first strong evidence for 
emending the sugar moiety of cordycepin to a 3’ deoxypentose, this important observation 
also unveiled the first biochemical property of cordycepin in the cell: its ability to become 
part of the nucleotide pool. Follow-up studies revealed a concentration dependent effect of 
cordycepin: low concentrations (0.5 – 1.0 µmol/ml) of cordycepin resulted in the 
accumulation of cordycepin-triphosphate (CoTP) in the cells and did not inhibit the 
incorporation of phosphate into DNA, whereas higher concentrations (2 µmol/ml and 
higher) led also to the formation of cordycepin monophosphate (CoMP) and –diphosphate 
(CoDP), which is accompanied by a rapid decrease of nucleotide levels in the cells 
followed by a pronounced inhibition of incorporation of phosphate into nucleic acids 
(Klenow, 1963b). Both effects could be prevented by simultaneous addition of adenosine, 
but not 2’ deoxyadenosine (Klenow, 1963b). This lead to the conclusion, that the formation 
of CoMP and CoDP were the more immediate inhibitory substances rather than CoTP. 
This theory was supported by results with experiments using cordycepin-N-oxide which is 
slowly reduced to cordycepin in suspension with tumor cells (Frederiksen and Klenow, 
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1962). RNA synthesis was blocked after 1.5 hours, DNA synthesis after 3 hours 
(Frederiksen, 1963). It was concluded that CoDP probably causes the inhibition of DNA 
synthesis and CoTP is responsible for RNA synthesis inhibition (Frederiksen, 1963).  
In a subsequent report it was shown that under experimental conditions in which 
CoTP accumulated there is no significant inhibition in the incorporation of phosphate into 
the DNA of the tumor cells, but a strong inhibition in the incorporation of adenine into 
DNA (Klenow and Overgaard-Hansen, 1964). These findings led to the assumption that 
CoTP does not inhibit the process of DNA synthesis, but rather a step in the metabolic 
pathway required for the conversion of adenine into adenosine (Klenow and Overgaard-
Hansen, 1964). In subsequent analysis, CoTP was added to the supernatant of tumor cells 
and it could be demonstrated that the reaction ATP + ribose-5-phosphate → 
ribosephosphate pyrophosphate (PRPP) + AMP catalysed by the enzyme ribosephosphate 
pyrophosphokinase is inhibited (Overgaard-Hansen, 1964). Since PRPP is a key enzymatic 
activity required for growth and is also an obligatory reactant in the de novo synthesis of 
purines, pyrimidines and pyrimidine nucleotides, it is reasonable to assume that the 
inhibition caused by cordycepin in Ehrlich ascites tumor cells may be partially attributed to 
the inhibition that CoTP exerted on the synthesis of PRPP (Overgaard-Hansen, 1964). This 
proposed inhibition model was very similar to the model for the bacteria B. subtilis 
(Rottman and Guarino, 1964c). 
However, the inhibition of RNA synthesis came in focus as the main target effect of 
cordycepin. The effect of CoTP on RNA polymerase from tumor cells was studied and in 
an enzyme assay, addition of CoTP almost completely prevented incorporation of AMP 
into RNA, but radio-labelled phosphate incorporation in DNA could not be detected 
(Klenow and Frederiksen, 1964a). This observation was subsequently followed up by in 
vivo data. Under conditions in which CoTP accumulated in tumor cells, the incorporation 
of phosphate into RNA was inhibited by 50% after 60 minutes (Klenow and Frederikson, 
1964b). This inhibitory effect of cordycepin did not occur uniformly: the cytoplasmic and 
the nucleochromosomal RNA fractions were inhibited profoundly, whereas the 
nucleoplasmic RNA fraction did not display any inhibition (Klenow and Frederikson, 
1964b).  
Incorporation of formate, glycine, hypoxanthine, adenine and guanine into purine 
RNA-precursors was studied in ascites tumor cells. In presence of cordycepin the 
incorporation of these five compounds into purine RNA-precursors was inhibited more 
than 80% (Shigeura and Gordon, 1965). Since the incorporation of a de novo purine 
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precursor or intact purine into RNA is inhibited, and not the formation of the precursor, it 
appears that the RNA polymerase might be inhibited (Shigeura and Gordon, 1965). This 
was demonstrated by enzyme assays with RNA polymerase isolated from Micrococcus 
lysodeikticus. CoTP inhibits the polymerisation reaction, whereas CoMP and CoDP do not 
have an effect (Shigeura and Gordon, 1965). CoTP inhibits, besides the synthesis of RNA 
also poly(A) formation, but does not inhibit the formation of poly(U) or DNA. 
Cordycepin addition also revealed a cytotoxic effect on human tumor cells (H. Ep. 
No. 1) in culture (Rich et al., 1965). Adenosine administration prevented growth inhibition, 
but could not reverse the inhibition once it has occurred. It was suggested that adenosine 
competes with cordycepin for phosphorylation, however, marked effects of cordycepin on 
RNA, DNA or protein content in vivo, or the incorporation of cordycepin into RNA or 
DNA could not be demonstrated. However, an opposing result was published in the same 
year demonstrating that cordycepin is readily phosphorylated into CoTP and incorporated 
into RNA and DNA of the human cancer cells, presumably at the 3’ termini (Cory et al., 
1965). These results together with other studies (Shigeura et al., 1966) led to the model that 
cordycepin is taken up by the cells, phosphorlyated to CoTP and appears to inhibit RNA 
synthesis by incorporation into the terminal position of RNA. Thereby it may block further 
growth of the polynucleotide chain because of the lacking 3’ OH group. CoTP can be 
inserted into a growing RNA chain by the normal 5'-3' phosphodiester bond, but the next 
5'-3' bond can not be formed. Cordycepin was specified as a RNA chain terminator, an 
activity that was previously demonstrated for the adenosine derivative 
2',3' dideoxyribonucleotide and other nucleotide derivatives lacking the 3’ OH group 
(Atkinson et al., 1969). 
None of the phosphorylated cordycepin nucleotides acted as a substrate for the 
enzyme ribonucleotide reductase isolated from Lactobacillus leichmannii and Escherichia 
coli (E. coli) indicating that Cordycepin is not converted to 2’,3’ dideoxycordycepin 
(Chassy and Suhadolnik, 1968). In HeLa cells, in was observed that cordycepin inhibited 
total RNA synthesis by 50% already at a concentration of 25 µg/ml (Siev et al., 1969). 
DNA synthesis, in contrast, remained unaffected even at higher concentrations. This 
insensitivity of DNA and protein synthesis showed that cordycepin did not directly 
interfere with general cell metabolism and that the reported inhibition of DNA synthesis 
(Frederiksen, 1963) probably via inhibition of purine synthesis (Overgaard-Hansen, 1964). 
This probably is not the primary inhibitory effect of CoTP, but may be a secondary 
consequence of the inhibition of RNA synthesis. 
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The insensitivity of C. militaris against its own cordycepin has also interested 
scientists. It could be shown, that cordycepin was not taken up by C. militaris, neither in 
the early stages of growth nor at the time of cordycepin production (Chassy and 
Suhadolnik, 1969). Apparently, once cordycepin is excreted into the medium, it is not 
taken up by the cell again, which is probably a mechanism of self-protection. In the case of 
E. coli, it has been shown that this bacterium lacks an endogenous adenosine kinase 
activity (Neuhard and Nygaard, 1987), which explains the insensitivity against cordycepin. 
 
 
1.4 Effect on RNA polymerases and poly(A) polymerases 
 
In the year 1965, it was reported for the first time in in vitro experiments, that CoTP is 
incorporated into RNA by partially purified RNA polymerase from M. lysodeikticus 
(Shigeura and Gordon, 1965) and from this time on, it has been generally accepted that the 
main mode of action of cordycepin is its inhibitory effect on RNA polymerases. The open 
question was which polymerase showed the strongest inhibition towards CoTP and this 
question has still not been answered completely until today.  
In HeLa cells the addition of cordycepin affected both the amount and size 
distribution of nucleolar RNA, whereas nucleoplasmic RNA seemed unaffected in size and 
amount (Siev et al., 1969). The amount of labelled 18S RNA decreased to 25% of control, 
the production of 28 S RNA was completely suppressed and the formation of incomplete 
45S RNA could be detected. This led to the suggestion that 18S RNA is located close to 
the 5’ end of the 45S precursor RNA, and could also be produced from incomplete 
precursor molecules. 28S RNA must be located near the 3’ end and the complete synthesis 
of the precursor is a prerequisite for 28S RNA production. 
In contrast to these observations, Penman and co-workers showed that cordycepin 
mainly affected mRNA production leading to the conclusion that cordycepin might have 3 
different effects on RNA synthesis (Penman et al., 1970): The first is complete inhibition, 
which is characteristic for the synthesis of mRNA (Penman et al., 1970). The second effect 
is premature termination of nascent RNA and release of the defective RNA chain and 
occurs in the nucleolus (Siev et al., 1969). A third response is insensitivity, which was 
assigned to the synthesis of nuclear heterogeneous RNA. 
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A decade later, in vitro studies with purified RNA polymerases from HeLa cells 
and E. coli showed that CoTP inhibited the activity of eukaryotic and prokaryotic 
polymerases to the same extent (Maale et al., 1975), although cordycepin did only inhibit 
growth of HeLa cells, but not that of E. coli. The poly(A)-synthesising enzymes purified 
from HeLa cells and E. coli in this study were not more sensitive to CoTP than to the 
naturally occurring 2’ deoxyadenosine (Maale et al., 1975).  
In 1976, kinetic constants for CoTP were published for the first time with the RNA 
polymerases from the yeast Saccharomyces cerevisiae (S. cerevisiae) (table 1) (Horowitz 
et al., 1976). According to the calculated kinetic constants, the inhibition of effect of CoTP 
towards the different RNA polymerases in vitro differed significantly. The inhibitory effect 
of CoTP on RNA polymerase II was the highest. Inhibition of poly(A) polymerase was 
comparable with that observed with RNA polymerase III and interestingly, RNA 
polymerase I was completely insensitive to CoTP. This result suggested that at least in 
yeast, polyadenylation might not be the major target of CoTP and that cordycepin affected 
the polymerases to a different extent. These findings were not consistent with previously 
presented suggestions (Siev et al., 1969), although in vivo observations in yeast have not 
been carried out yet. 
 
 
enzyme Km (µM) ATP Ki (µM) CoTP 
RNA polymerase I 32 - 
RNA polymerase II 12 0.3 
RNA polymerase III 32 3.0 
poly(A) polymerase 56 4.6 
 
Table 1 Calculated kinetic constants with enzymes purified from S. cerevisiae 
(Horowitz et al., 1976). 
 
One year later, kinetic parameters for mammalian enzymes were presented (Müller 
et al., 1977). In this study, the effect of CoTP on isolated DNA polymerases was also 
tested. Mammalian α and β DNA polymerases were both not affected by CoTP 
underscoring the model that the inhibition of DNA synthesis was not the primary effect of 
CoTP. Mammalian RNA polymerases (table 2) were selectively blocked as was observed 
with the RNA polymerases from S. cerevisiae (Horowitz et al., 1976), but the inhibitory 
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constants were not comparable to the constants determined for the yeast polymerases. 
Since the inhibition of all enzymes was competitive with respect to ATP, the authors 
suggested using the Ki/Km value, which gave insight into the inhibition relative to their 
respective affinities. The lower the Ki/Km value is the stronger is also the inhibitory 
potency of a substance. The three different RNA polymerases were moderately inhibited 
by CoTP. The inhibitory effect of CoTP was higher towards RNA polymerase II (ratio 
1.67) than towards RNA polymerase I and III (ratios 2.52 and 2.71). The potency of CoTP 
to inhibit poly(A) polymerase or terminal riboadenylate transferase was significantly 
higher. Moreover, in enzyme studies with CoTP and poly(A) polymerase, the resulting 
product oligo(pA)6-CoMP had no more initiator capacity for the enzyme, substantiating 
that the incorporated CoMP acted as chain terminator (Müller et al., 1977).  
 
 
enzyme Km (µM) ATP Ki (µM) CoTP Ki/Km 
RNA polymerase I 16.8 42.3 2.52 
RNA polymerase II 23.9 39.9 1.67 
RNA polymerase III 27.1 73.4 2.71 
poly(A) polymerase 34.7 7.3 0.21 
terminal ribo-
adenylate transferase 21 16 0.75 
 
Table 2 Influence of CoTP on RNA polymerases, poly(A) polymerase and terminal 
riboadenlyate transferase (Müller et al., 1977). 
 
The authors tried to show the same inhibition pattern also in an in vivo situation. 
But the used concentration of cordycepin produced different consequences. At a low 
concentration (< 1 µM) of the compound cell proliferation was not influenced, although 
cordycepin was incorporated into RNA. Higher concentrations (5 µM) caused a drastic 
reduction of the amount of polysomes, indicating a strong influence of cordycepin on the 
availability of mRNA in the cytoplasm (Müller et al., 1977). 
In contrast to the proposed kinetic constants, Rose and co-workers published in the 
same year, that 60 µg/ml CoTP caused an inhibition of RNA polymerase II activity 
isolated from rat liver of only 5%, whereas RNA polymerase I activity was inhibited by 
70% (Rose et al., 1977). However, poly (A) polymerase was inhibited most although the 
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“chromatin associated” poly(A) polymerase was around 30 times more sensitive to CoTP 
than is the “free” poly(A) polymerase. The presented results were contradictory to the 
kinetic parameters presented in the same year (Müller et al., 1977), but were consistent 
with the observed in vivo findings (Siev et al., 1969). 
Further in vitro studies with isolated rat liver nuclei revealed that CoTP was 
capable to significantly inhibit also the synthesis of 5S RNA and tRNA at concentrations 
between 50 µg/ml and 200 µg/ml (Leonard and Jacob, 1979), which has previously been 
suggested at least for 5S RNA (Müller et al., 1977). This result clearly demonstrated that 
all three RNA polymerases could be inhibited by the ATP analogue and that none of them 
is insensitive as proposed previously (Horowitz et al., 1976).  
CoTP inhibits also RNA polymerases I and II isolated from the slime mold 
Distyostelium discoideum in a competitive manner to ATP, although inhibition towards 
polymerase I is a bit stronger (Saneyoshi et al., 1981). The Michaelis constant Km for RNA 
polymerase II and CoTP was estimated to be 5.6 µM and the inhibition constant Ki 0.8 
µM. Similar inhibition values were calculated for 3’ dUTP and 3’ dCTP, both of which are 
thought to act as chain terminators for RNA polymerases. Towards RNA polymerases I 
and II isolated from cherry salmon liver, CoTP had almost the same inhibitory effects 
(Nakayama and Saneyoshi, 1985). Analysis with RNA polymerase and poly(A) 
polymerase from vaccina virus indicate that poly(A) polymerase is much more sensitive 
towards CoTP than RNA polymerase (Shuman and Moss, 1987), but in vivo studies of the 
effect of CoTP have not been presented.  
In a newer study presenting also a new method for kinetic parameter determination, 
the Km and Ki constants of ATP and CoTP were determined for influenza and yeast 
poly(A) polymerase (table 3) (Hooker et al., 2001). For the yeast poly(A) polymerase, the 
Ki value for CoTP was significantly lower than the Km value for ATP resulting in 
significant inhibition of yeast poly(A) polymerase at relatively low concentrations of 
CoTP, whereas the Ki value determined for inhibition by CoTP was similar to the Km value 
for ATP with influenza polymerase According to their measurements, the poly(A) 
polymerases from different species do not show the same sensitivity towards CoTP and 
influenza poly(A) polymerase seems to be surprisingly resistant to CoTP (Hooker et al., 
2001). Similar low Ki values for CoTP have been previously found with chromatin 
associated poly(A) polymerase from rat liver and poly(A) polymerase from yeast 
(Horowitz et al., 1976; Rose et al., 1977). 
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enzyme Km (µM) ATP Ki (µM) CoTP Ki/Km 
yeast poly(A) polymerase 50 0.6 0.012 
influenza poly(A) polymerase 186 117 0.629 
 
Table 3 Kinetic constants for poly(A) polymerases from yeast and influenza virus 
(Hooker et al., 2001).  
 
A different inhibition mechanism for CoTP was proposed in 1978. It was found that 
CoTP is not incorporated into poly(A) RNA by poly(A) polymerase in vitro and therefore 
did not act as a chain terminator as previously reported (Müller et al., 1977; Horowitz et 
al., 1976), but rather inhibited poly(A) synthesis by competing with ATP for the active 
binding site (Koch and Niessing, 1978). In an extensive study with yeast poly(A) 
polymerase and various different nucleotides, it could be demonstrated that poly(A) 
polymerase indeed incorporates CoTP into an RNA primer (Martin and Keller, 1998). The 
RNA primer was elongated only by a single CoTP indicating that cordycepin acts as an 
RNA chain terminator. CoTP was transferred very efficienty by poly(A) polymerase, in the 
enzyme assay 100% of the RNA primers were elongated by CoTP. Dideoxynucleotides, 
which also terminate RNA chain elongation, were incorporated less efficiently. These 
results suggested using CoTP and poly(A) polymerase for labelling 3’ ends of RNA in 
vitro, for example in poly(A) tail length analysis. 
In summary, it can be concluded that CoTP highly inhibits the activity of 
poly(A)polymerase as most of the studies clearly demonstrate the highest inhibition on this 
enzyme, but surprisingly not in every organisms. The results of the RNA polymerases I, II 
and III are contradictory and moreover, the in vivo observations of different RNA levels 
are as well not consistent. In the case of yeast, CoTP showed the strongest inhibitory 
potency on RNA Pol II and poly(A) polymerase was only moderately inhibited (Horowitz 
et al., 1976). However, a newer study exposed CoTP as a potent inhibitor of the yeast 
poly(A) polymerase (Hooker et al., 2001). Newer data on yeast RNA polymerases are 
unfortunately not available. 
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1.5 Biological activities of cordycepin 
 
Cordycepin is a nucleoside with a broad spectrum of biological activities, which are 
described in the following chapters in more detail. 
The effectiveness of cordycepin in mammals is limited by its rapid deamination to 
the inactive metabolite 3’ deoxyinosine (figure 3). The reaction is catalysed by adenosine 
deaminase (ADA), an abundant and highly active enzyme present in many tissues and in 
the blood (Agarwal et al., 1975). Co-administration of coformycin (CF) or 
2’ deoxycoformycin (dCF), both of which are potent inhibitors of adenosine deaminase 
(Agarwal and Parks, 1977) (figure 4), markedly increased the efficacy of cordycepin both 
in vitro and in vivo (Adamson et al., 1977). In cancer patients, deoxycoformycin (as 
pentostatin) is active in the treatment of prolymphocytic and hairy cell leukaemia, even for 
those patients with prior chemotherapy (Döhner et al., 1993; Ho et al., 1990). 
Although the combination of cordycepin with an ADA inhibitor can improve the 
bioactivity of cordycepin, scientists are still trying to find alternatives to avoid the co-
administration of an ADA-inhibitor. Aminoacyl derivatives of nucleotides are stable in 
neutral and alkaline conditions and might be used as effective prodrugs (Guo, 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Reaction catalysed by adenosine deaminase. 
The amino group at N7 of the purine base is deaminated to oxygen by the enzyme 
adenosine deaminase resulting in 3’ deoxyinosine and ammonium. 
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Cordycepin was chemically changed to N-alkyl-cordycepin, N-propionyl-cordycepin, N-
octanoyl cordycepin N-lauroyl-cordycepin and N-stearoyl-cordycepin, and orally 
administrated to mice (Wei et al., 2008). With this approach, the primary amine of adenine 
is protected from oxidation. Cordycepin levels measured in blood revealed that all 
derivatives can be transformed to cordycepin in vivo and that the measured half-time of 
cordycepin levels in blood highly increases (Wei et al., 2008).  
A different method to protect cordycepin from deamination is the development of a 
cordycepin-layered double hydroxides (LDHs) [Mg-Al-cordycepin] nanohybrid (Yang et 
al., 2006). The incorporation of organic guests into LDHs has received much attention 
recently because of the potential uses of the resulting inorganic-organic nanohybrid 
materials in different fields such as optics, catalysis, nanocomposite engineering and 
medical science (Khan and O’Hare, 2002). The [Mg-Al-cordycepin] nanohybrid is 
engulfed by cells by endocytosis. In the lysosome, the LDHs layers are dissolved slowly by 
the low pH-value and the interlayer biomolecule can be released inside the cell. The [Mg-
Al-cordycepin] nanohybrid was tested with human leukaemia U937 cells and found to 
inhibit the growth of these cells more efficiently than cordycepin addition alone (Yang et 
al., 2006). This result suggests that LDHs could be a promising nanocarrier for cordycepin 
delivery into the cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Chemical structure of coformycin and 2’ deoxycoformycin. 
2’ deoxycoformycin is used as pentostatin in cancer treatment. 
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Toxicity of cordycepin together with deoxycoformycin was studied in beagle dogs. 
Since the dog is an accepted species for evaluation of drugs intended for use in humans 
(Haggerty et al., 1992), data from dogs can be used to support the initiation of clinical 
trials of the drug. Doses of 10 to 20 mg/kg/day of cordycepin given once a day for 3 days 
in combination with deoxycoformycin were lethal; the maximum tolerated dose was 
8 mg/kg/day (Rodman et al., 1997). Lower cordycepin concentrations resulted in cell 
depletion in the bone marrow, glandular dilation and mucosal necrosis in the stomach, cell 
depletion and atrophy in the thymus, necrosis in the liver, salivary glands, intestine, and 
kidney and in the brain. The most severe toxic effects were noted for bone marrow and the 
gastrointestinal tract. These tissues appear to be the sites of dose-limiting toxicities 
(Rodman et al., 1997). 
 
 
1.5.1 Anticancer activity 
 
Cordycepin was the first antitumor antibiotic isolated. Antitumor antimetabolites typically 
are taken up by cells, metabolised, and subsequently enter cellular nucleotide pools where 
they exert their effect. Until recently, it was believed that the effectiveness of purine 
nucleosides and their analogues such as cordycepin in chemotherapeutic regiments was 
mainly based on their antiproliferative and cytotoxic effect. The antitumor activities of 
cordycepin in combination with deoxycoformycin were studied in mice infected with B16 
mouse melanoma cells. Administration of cordycepin (15 mg/kg body weight) 
significantly reduced the tumor lump without any loss of bodyweight or systemic actions 
(Yoshikawa et al., 2004). However, recent studies showed that cordycepin can also exhibit 
its anticancer activity via programmed cell death (Wu et al., 2007). The realisation that 
cancer is the result of an imbalance among cell cycle progression and cell death lead 
cancer research to be increasingly focused on cell cycle and cell death regulatory 
mechanisms (Foster, 2000; Solary et al., 2000) aiming to specifically induce apoptosis in 
cancer cells.  
 
 
 
 Introduction 
 25 
1.5.1.1 Radiosensitiser 
 
Potentially lethal damage (PLD) in X-ray irritated mammalian cells in culture can be fixed 
by a DNA repair mechanism increasing the fraction of surviving cells (Phillips and 
Tolmach, 1966). A number of studies have been carried out on factors and conditions 
which modify repair efficiencies especially for their implication in radiation therapy of 
tumors. Enhanced PLD capacity has been implicated as a major determinant in the radio 
resistance of malignant human tumors (Boothman et al., 1989). Cordycepin functions as a 
radiosensitiser in cultured mammalian cells (Robertson et al., 1978) and in particular, 
purine analogues such as cordycepin are very potent inhibitors of the DNA repair of PLD 
(Sugahara et al., 1984).  
In cultured Chinese hamster V79 cells, cordycepin (50 µM) increased the 
cytotoxicity after irradiation with γ-rays markedly (Yokoiyama et al., 1992). Cordycepin 
almost completely suppressed the PLD repair produced by γ-irradiation, possibly by 
interfering with the repair system (Robertson et al., 1977; Nakatsugawa et al., 1982). Since 
the repair of PLD resulted in radiation resistance in malignant cells, the inhibition of PLD 
repair may show promising results in radiation therapy preventing the secondary induction 
of tumors caused by radiation used in therapy. 
 
1.5.1.2 Activity against TdT+ cells 
 
Terminal deoxynucleotidyl transferase (TdT) polymerises a single-stranded 
deoxynucleotidyl sequence without the need of a template (Bollum, 1960). It is expressed 
in pre-T cells, thymocytes and early pre-B cells (Barton et al., 1976; Hoffbrand et al., 
1979) and is considered to play an important role during immunoglobulin and T cell 
receptor gene rearrangements, thereby increasing the diversity of immunoglobulin and T 
cell receptor molecules (Desiderato et al., 1984; Yancopoulos et al., 1986). Clinically, over 
90% of leukaemic cells in acute lymphocytic leukaemia and approximately 30% of 
leukaemic cells in the chronic myelogenous leukaemia exhibited elevated TdT activity. 
The TdT activity of such leukaemic cells is associated with a poor prognosis on 
chemotherapy and survival time (Benedetto et al., 1986), although the role of TdT in the 
outcome of leukaemia is not well defined. Newer studies revealed that cordycepin 
inhibited the activity of TdT very efficiently and thus has been identified as cytotoxic 
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against TdT+ cells in vitro in the presence of the ADA inhibitor deoxycoformycin, whereas 
TdT- cells were significantly less sensitive (Koc and McCaffrey, 1995; Koc et al., 1996). 
Based on these in vitro data, the combination of cordycepin and deoxycoformycin is 
undergoing Phase I clinical trials in several medical centers in the United States. The 
mechanism of the distinction of TdT+ and TdT- cells has not yet been identified. 
Cordycepin is phosphorylated and converted to mono-, di-, and triphosphates in both cell 
types to the same extent (Kodama et al., 2000) and the level of ADA activity in both cells 
are similarly low, as long as deoxycoformycin was present. This means that the 
cytotoxicity of cordycepin might be generated through inhibition of TdT. In vitro studies 
showed that cordycepin inhibited the enzymatic activity of human and calf thymus TdT 
(Tu and Cohen, 1980). The antileukaemic activity of cordycepin combined with 
deoxycoformycin required TdT positivity of the cells. However, further development of 
cordycepin as a potential antileukaemic agent for therapy of TdT+ leukaemia is required. 
 
1.5.1.3 Implications in apoptosis 
 
Apoptosis is a form of programmed cell death and was initially described by its 
morphological characteristics, including cell shrinkage, membrane blebbing, chromatin 
condensation and nuclear fragmentation (Kerr et al., 1972; Kerr et al., 1994). Mounting 
evidence indicates that the acquired ability to resist apoptosis is a hallmark of most, and 
perhaps all types of cancer. It is now clear that some oncogenic mutations disrupt 
apoptosis, leading to tumor initiation, progression or metastasis and it is well documented 
that most cytotoxic anticancer agents induce apoptosis, raising the intriguing possibility 
that defects in apoptotic programs contribute to treatment failure (Lowe and Lin, 2000). 
Recently, a relation among polyadenylation and apoptosis has been observed 
(Thomadaki et al., 2005). PAP II was found to be modulated and polyadenylation to be 
implicated in the process of apoptosis. PAP II changes during the apoptotic process 
induced by heat shock or nutrient deprivation, showing dephosphorylation, proteolysis and 
activity downregulation, which occur relatively early in the process of apoptosis 
(Atabasides et al., 1998). Along with the induction of apoptosis in different cell lines, the 
mRNA half-life of key proapoptotic or anti-apoptotic genes is regulated via 
polyadenylation, with kinetics and intensity differing according to the inducing agent and 
the cell line examined (Schiavone et al., 2000; Kim et al., 2001). Highly and sustaining 
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metabolising lymphocytes, as well as less differentiated cells, have higher levels of PAP II 
activity (Tsiapalis et al., 1998). Overexpression of PAP II mRNA has been demonstrated in 
chronic leukaemia (Sasaki et al., 1990), as well as in a number of different human tumors 
originating in breast and pancreas (Bodeker et al., 1998;, Scorilas et al., 1998 and 2000). 
High PAP II activity levels have been detected in cytosol of breast tumors of untreated 
patients, associated with the tumor-nodes-metastasis stage of the disease and node 
invasiveness (Schiavone et al., 2000). It has been suggested that PAP II may be considered 
as a new, independent, unfavourable prognostic factor for early recurrence and death in 
breast cancer patients. PAP may represent an aberrantly regulated factor in cancer cells, 
which supports the main characteristics of their malignant phenotype, such as enhanced 
proliferative activity and diminished cell turnover via apoptosis (Thomadaki et al., 2005).  
Exposure of the cervicial HeLa cells to cordycepin led to a continuous increase in 
PAP II activity and amount of protein, whereas in the breast cancer cell line MCF-7 
cordycepin led to a decrease in both PAP II activity and phosphorylated PAP isoforms 
(Thomadaki et al., 2005). The MCF-7 cells were arrested in the S phase and HeLa cells in 
the G2/M phase, which is in agreement with the observed PAP II modifications 
(Thomadaki et al., 2005). In these two epithelial cancer cell lines PAP II modifications 
follow cell cycle progression and apoptosis could not be induced by cordycepin.  
In studies on the human TdT+ Molt-4 leukaemia cell line and the Daudi lymphoma 
cell line, exposure of cordycepin led to growth inhibition and apoptosis induction in both 
cell types, probably through distinct pathways, because PAP II activity modifications as a 
response to cordycepin can only be observed in Molt-4 cells, not in Daudi cells 
(Thomadaki et al., 2007). The increase of PAP II activity and of the amount of isoforms in 
Molt-4 cells occured prior to any characteristic apoptotic or cytotoxic changes along the 
early reversible phase of cell commitment to apoptosis (Thomadaki et al., 2007). Different 
modulations of PAP II in these two cell lines may be a result of the additive effect of the 
changes in cell cycle and apoptotic pathway induced. 
In cells of the Head and Neck Squamous Cell Carcinoma (HNSCC), which is an 
oral cavity cancer, cordycepin significantly induces cell apoptosis in a time and dose 
dependent manner (Wu et al., 2007). These cells are arrested in the G2/M phase. 
Polyadenylation is very important at G1/S phase in order to produce the required mRNAs 
to further progress in cell cycle. Maybe mitosis can not finish and the cell will arrest at 
G2/M phase, because not all necessary proteins could be produced during G1/S phase (Wu 
et al., 2007).  
 Introduction 
 28 
Thus, cordycepin affects PAP II modification tumor cell specifically. The 
promising observation about the apoptotic effect of cordycepin in HNSCC cells may be a 
valuable approach in search and development for new anti-oral cancer drugs. 
 
 
1.5.1.4 Eryptosis induction 
 
Recently it has been unveiled that apoptosis is not only limitated to nucleated cells. Mature 
enucleated red blood cells (RBC) also share the capacity of self-destruction through 
apoptosis. Although the mechanism is poorly understood, mature RBCs can undergo a 
special type of apoptosis known as eryptosis without the involvement of mitochondria and 
nucleus (Lang et al., 2006). Cordycepin is able to induce eryptosis, as phosphatidylserine 
externalisation and cleavage of µ-calpain are significantly increased (Lui et al., 2007). An 
increase in intracellular concentration of [Ca2+]
 
seems to be a crucial factor for the 
eryptosis induction pathway mediated by cordycepin, as a depletion of the external source 
of Ca2+ results in a reduction of the cordycepin induced eryptosis. At higher cordycepin 
concentrations (>125 µM), haemolysis is also observed. This erythrotoxic effect of 
cordycepin implies that it might induce anaemia in cancer patients when it is used in 
chemotherapy.  
 
 
1.5.2 Antifungal activity 
 
The ascomycete Candida albicans has first been described in1839 and is a normal resident 
of the gastrointestinal tract of humans and other warm-blooded animals. It is also the most 
common human fungal pathogen. Although typically asymptomatic, C. albicans can 
proliferate even in healthy people to cause circumscribed infection of the skin, nails and 
mucous membranes. In patients with deficient immune systems (because of inherited 
disease, malignancy, concurrent infection, or medical intervention) this same yeast can 
behave as an aggressive pathogen, attacking virtually any organ system and leading to 
death in as many as 50% of cases of bloodstream infection (Eggimann et al., 2003). In the 
past decade, the frequency of diagnosed fungal infections has risen sharply due to several 
factors, including the increase in the number of immunosuppressed patients resulting from 
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the AIDS epidemic and treatments during and after organ and bone marrow transplants. 
Linked with the increase in fungal infections is a recent increase in the frequency with 
which these infections are resistant to standard antifungal therapy (White et al., 1998). 
Typical used drugs as treatment against C. albicans attack ergosterol biosynthesis or 
ergosterol containing membranes. Because it is diploid and lacks a complete sexual cycle, 
conventional genetic analysis is simply not possible. Thus, there is a clear need for a next 
generation of antifungal agents. 
Mice infected with C. albicans and treated with cordycepin in combination with 
deoxycoformycin survived significantly longer and exhibited significantly fewer yeast 
cells, although kidneys were not completely sterilised (Sugar and McCaffrey, 1998). 
Interestingly, this effect was unique for cordycepin, as 3’ deoxycytidine, 
3’ deoxyguanidine or 3’ deoxyuracil either alone or in combination with deoxycoformycin 
exhibited no effect on the survival of infected mice. The mechanism of action of 
cordycepin is not clear. However, identification of useful antifungal drugs with unique 
modes of action that differ from those of currently available antifungal drugs is desirable 
since fungi resistant to available agents would likely not be resistant to these newer drugs, 
and the possibility of combining compounds with differing modes of action may lead to 
more effective strategies for the treatment of invasive mycoses. Cordycepin may represent 
a new class of antifungal compounds offering new options for the treatment of fungal 
infections. 
 
 
1.5.3 Effect on intestinal bacteria  
 
Various micro-organisms are resident in the human intestinal tract as a highly complex 
ecosystem and contain a variety of enzymes that perform various types of conversions of 
bio molecules important for the metabolism in the intestine. Some of these bacteria 
participate in the normal physiological metabolism such as lactic acid producing bacteria, 
some contribute to the genesis of diseases by transforming ingested or endogenously 
formed compounds to harmful agents such as E. coli, Staphylococcus, Veillonella, 
Clostridium and some protect against diseases by generation of beneficial products 
(Finegold et al., 1975; Modler et al., 1990; Hoover, 1993). Gastrointestinal ecological 
investigations have demonstrated that there are some differences in intestinal bacteria 
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between cancer patients and healthy control people, between young and elderly people, as 
well as between breast and bottle-fed infants (Modler et al., 1990; Moore and Moore, 
1995). The microbiota of cancer patients and of elderly people is known to be mainly 
composed of Clostridium. The microbioty in healthy people remains relatively constant, 
but is known to be greatly influenced by physical, biological, chemical environmental or 
host factors (Modler et al., 1990; Hoover, 1993). 
Nine intestinal bacteria were cultured and exposed to cordycepin. The drug showed 
strong growth inhibition toward two species of Clostridium and E. coli, but stimulated 
growth of four Bifidobacterium strains and two Lactobacillus strains (Ahn et al., 2000). 
Daily intake of small amounts of cordycepin might therefore alter the growth and 
composition of the intestinal flora and modulate the genesis of potentially harmful agents.  
 
 
1.5.4 Anti-inflammation activity 
 
Interleukin-10 plays a pivotal role in the cytokine network. A large body of evidence 
supports the view that interleukin-10 shows a strong regulative effect on T-lymphocytes 
and antigen-presenting cells. The downregulative effect of interleukin-10 on the expression 
of MHC II antigens, co-stimulatory molecules and adhesion molecules on antigen-
presenting cells contributes to the inhibition of antigen presentation, resulting in the 
abrogation of proliferative responses and cytokine production of responding T cells or T 
cell clones (Willems et al., 1994; Schandene et al., 1994). Moreover, interleukin-10 
inhibits the secretion of proinflammatory cytokines as well and reduces the production of 
inflammatory mediators like nitric oxide, free radicals and prostaglandin (Moore et al., 
1993; Dokka et al., 2001). Hence, Interleukin-10 protects the host against excessive 
immunopathological and inflammatory processes. Deficiency of interleukin is associated 
with some diseases such as diabetes mellitus, uveitis and inflammatory bowel disease 
(Gunnet et al., 2002; Rizzo et al., 1998; Gasche et al., 2000). Although the role of 
interleukin-10 in health and disease still requires further understanding, preclinical tests 
have demonstrated that the administration of exogenous interleukin-10 can ameliorate 
some autoimmune and inflammatory diseases. 
Cordycepin was found to strongly increase interleukin-10 production by peripheral 
blood mononuclear cells in eleven healthy volunteers by enhancing the interleukin-10 
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mRNA expression (Zhou et al., 2002). In addition, it inhibited interleukin-2 production and 
T lymphocyte activation. Cordycepin may provide new immunoregulative mechanisms and 
may be beneficial for the treatment of autoimmune and inflammatory diseases (Zhou et al., 
2002). 
Activation of macrophages plays an important role in the initiation and propagation 
of inflammatory responses by the production of cytokines, nitric oxide and other 
inflammatory mediators. Overexpression of the inflammatory mediators in macrophages is 
involved in many diseases, such as rheumatoid arthritis (Tilg et al., 1992), atherosclerosis 
(Coker and Laurent, 1998), chronic hepatitis (Lind, 2003) and pulmonary fibrosis 
(Bertolini et al., 2001). Thus, the suppression of these mediators may be an effective 
therapeutic strategy for preventing inflammatory reaction and diseases. Stimulation of 
macrophages by lipopolysaccharide results in nitric oxide production and the expression of 
inducible nitric oxide synthetase (iNOS). Cordycepin inhibits nitric oxide production of 
induced macrophages has a negative impact on iNOS protein and mRNA levels in a dose-
dependent manner (Kim et al., 2006). The mechanism of cordycepin appears to involve the 
inhibition of phosphorylation of NF-κB, Akt and p38, all of which are involved in the 
production of iNOS and the activation of macrophages. In conclusion, cordycepin might be 
relevant for clinical use against inflammatory diseases. 
 
 
1.5.5 Inhibition of human platelet aggregation 
 
Platelet aggregation is absolutely essential for the formation of a haemostatic plug when 
normal blood vessels are injured. The interaction between platelets and collagen can also 
cause circulatory disorders, such as thrombosis, atherosclerosis and myocardial infraction 
(Schwartz et al., 1990). Inhibition of the platelet-collagen interaction might be a promising 
approach to the prevention of thrombosis. Thromboxane A2 formation plays an important 
role in the mechanism of collagen induced platelet aggregation (Cattaneo et al., 1991), and 
it also contributes to an increase in cytosolic free Ca2+ levels ([Ca2+]i) in collagen activated 
platelets. An increase in [Ca2+]i activates both the Ca2+/calmodulin-dependent 
phosphorylation of myosine light chain and the diacylglycerol-dependent phosphorylation 
of cytosolic protein to induce platelet aggregation (Kaibuchi et al., 1982). Drugs with an 
antiplatelet function generally elevate 3’,5’ cyclic adenosine monophosphate (cAMP), 
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which results in a decrease of [Ca2+]i levels (Cho et al., 2007a). Cordycepin has been 
associated with an inhibitory effect on adenylate cyclase activity, which would suggest a 
negative function of cordycepin in platelet activation (Londos and Wolff, 1977). 
Platelets activated by the thromboxane A2 analogue U46619 were stimulated with 
cordycepin leading in the dose-dependent inhibition of platelet aggregation (Cho et al., 
2006). [Ca2+]i significantly decreased (66%) in presence of U46619 and cordycepin, 
although it is still higher than the basal level. Nevertheless, cordycepin treatment 
completely blocked the downstream event of Ca2+-dependent phosphorylation giving 
evidence to the regulatory importance of [Ca2+]i. 
In collagen-induced platelets, cordycepin reduced significantly the production of 
thomboxane A2, although this effect was not related to inhibition of its metabolic enzymes 
cyclooxygenase-1 and thromboxane A2 synthetase (Cho et al., 2007b). Inhibition of 
thromboxane A2 production was leading to an inhibition of the activation of the 
downstream enzymes Ca2+/calmodulin-dependent protein kinase and Ca2+-dependent 
protein kinase C. Ca2+ influx through the plasma membrane and release from intracellular 
storage is normally induced by IP3, but the production of IP3 is not altered by cordycepin. 
Interestingly, cordycepin increased dose-dependently the level of cAMP and cGMP in the 
presence of collagen (Cho et al., 2007a; Cho, et al. 2007b), which are both strong 
endogenous negative regulators of platelet aggregation (Park et al., 2004). Cordycepin 
exerts an inhibitory effect on platelet aggregation which suggests that it may be developed 
as a novel therapeutic agent for thrombotic diseases such as cardiovascular disease. Other 
adenosine derivates are also considered as potent antiplatelet agents (Boyer et al., 2002; Xu 
et al., 2002). 
 
 
1.5.6 Antiviral activity 
 
Human immunodeficiency virus (HIV) is the causative agent for acquired 
immunodeficieny syndrome (AIDS) (Barré-Sinoussi et al., 1983). It is a lentivirus that 
primarily infects CD4+ lymphocytes and cells of the monocyte/macrophage lineage 
ultimately resulting in diverse immune perturbations and ensuing host susceptibility to 
severe and life-threatening opportunistic infections (Wong-Staal and Gallo, 1985). As in 
all retroviruses, an essential feature of HIV replication is reverse transcription of the plus-
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strand RNA genome into DNA, a process that requires reverse transcriptase (RT) 
(Baltimore, 1970). This enzyme is viral encoded and is found associated with genomic 
RNA in mature HIV virions (Veronese et al., 1985). The relative restriction of RT to 
retroviruses and viruses requiring a short reverse transcription step makes RT an important 
target for antiviral and particular antiretroviral therapeutic intervention. The step of reverse 
transcription is blocked by the 2’,5’ oligoadenylate (2-5A) system, which is part of the 
host’s natural antiviral response induced by interferons (Lengyel, 1982). Interferons 
increase 2’,5’ oligoadenylate synthetase gene expression resulting in increased synthesis of 
2-5A. The produced oligoadenylate activates a latent endoribonuclease (Rnase L) that 
cleaves viral and cellular RNA and thereby inhibits protein synthesis. 
The short half-life of authentic 2-5A in biological systems is a disadvantage in the 
control of viral replication (Doetsch et al., 1981). Modification of 2-5A at the 3’ hydroxyl 
groups provides various 2-5 A analogues with remarkably increased metabolic stability to 
cellular nucleases, while maintaining the ability to activate Rnase L (Nyilas et al., 1986). 
Consistent with its metabolic stability and biological activity the cordycepin 2-5 A 
analogues inhibit the reverse transcriptase more efficiently than the authentic 2-5 A 
(Montefiori et al., 1989). Cordycepin per se does not change the activity of reverse 
transcriptase nor does it show an antiviral activity in HIV-infected MT-2 cells, indicating 
that the cordycepin analogues of 2-5 A did not serve as a prodrug of cordycepin 
(Montefiori et al., 1989). From all tested analogues, Co-Co-Co and pCo-Co-Co are the 
most efficient inhibitors of reverse transcription, while other cellular DNA polymerases (α, 
β and γ) are insensitive (Müller et al., 1991).  
 
 
1.5.7 Activity against Leishmania and Trypanosoma species 
 
Leishmania and Trypanosoma species are parasitic protozoa of the order Kinetoplastida 
that cause Leishmaniasis and African sleeping sickness (Bloom, 1979). Both diseases are 
prevalent in various tropical regions of the globe and by infecting millions of people 
prominent causes of illness and death in endemic areas. Leishmaniasis or African sleeping 
sickness is initiated when sand flies or tsetse flies, respectively, inject the extracellular 
promastigote form of the parasite into the skin. The promastigotes are phagocytised by 
macrophages and transform into the amastigote stage, which is responsible for clinical 
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disease. Treatment and control of these important tropical diseases are compromised by the 
toxicity and expense of current drugs, the slow development of novel therapies and the 
increasing emerge of drug-resistant strains (Geary et al., 1986). 
The transport of nucleosides and nucleobases across the plasma membrane of 
parasitic protozoa has elicited considerable attention due to the central role of purine 
metabolism in these microorganisms. Unlike their vertebrate hosts, all parasitic protozoa 
examined are unable to synthesise purines de novo and, hence, rely completely on the 
salvage of these compounds from their hosts (Berens et al., 1995; Ullmann, 1984). The 
first step in these salvage pathways is the transport of the preformed purines across the 
surface membrane of the parasite, underscoring the importance of nucleoside and 
nucleobase permeases for parasite nutrition. Treatment, of course, tries to profit from this 
vulnerability. Drugs like Allopurinol are taken up by the parasite, metabolised by salvage 
enzymes allowing the end product to enter the nucleoside triphosphate pool of the parasite, 
whereas the corresponding interconversions do not occur efficiently in mammalian cells. 
Leishmania donovani possesses two distinct nucleoside transporters, which have Km values 
in the submicromolar range for adenosine and inosine, revealing that the parasite uptake 
systems have 100- to 1000-fold lower Km values than typical mammalian nucleoside 
transporters (Aronow et al., 1987). Related studies identified two distinct transport 
activities in African trypanosomes, which are driven by protonmotive force being able to 
concentrate adenosine inside the cells (Carter and Fairlamb, 1993; de Koning et al., 1998). 
On the contrary, mammalian cells have both facilitated diffusion carriers and 
Na+/adenosine co-transporters with much lower affinities (Thorn and Jarvis, 1996). These 
results underscore the efficiency with which the parasite transporters can compete with the 
host for essential purines and also the efficacy of agents for delivering cytotoxic purine 
analogues to the parasite. The current believe is, that adenosine is salvaged by a two-step 
process in Trypanosoma brucei where intracellular cleavage to adenine is followed by 
phosphoribosylation to AMP (El Kouni, 2003). 
The prodrug cordycepin would be efficiently conveyed by the parasite, converted 
into CoTP and could then inhibit growth of the parasite. In vitro assays with purified RNA 
polymerase III from Leishmania mexicana exhibit an inhibition of the enzymatic activity 
by CoTP (Nolan and Fehr, 1987). 
In a mouse model, administration of 2 mg/kg body weight of cordycepin in 
combination with ADA inhibitor deoxycoformycin completely eliminated parasites levels 
of T. brucei in the blood (Rottenberg et al., 2005). This auspicious treatment can also affect 
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the outcome of infection when administered after the parasite has penetrated into the brain 
parenchyma and can completely purge the mice from parasites.This data strongly supports 
further development and testing of nucleoside analogues as therapeutic agents for human 
African trypanosomiasis and Leishmania.  
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2 Transcription by RNA polymerase II 
 
The genome of eukaryotes is transcribed by three different highly conserved RNA 
polymerases. The ribosomal RNA (rRNA) is transcribed by RNA polymerase I, whereas 
RNA polymerase III transcribes several types of RNAs: the 5S rRNA, transfer RNAs 
(tRNAs) and other small RNAs. RNA polymerase II is the most versatile enzyme of the 
three and synthesises pre-messenger RNA (pre-mRNA) of protein-coding genes and most 
of the small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and other non-coding 
RNAs. 
 
 
2.1 RNA polymerase II transcription cycle 
 
In eukaryotes, the completion of messenger RNA (mRNA) synthesis is not simply the 
copying of the genetic information from the DNA template into an RNA transcript. Before 
the mRNA is ready to be transported out of the nucleus, it has to undergo three major 
processing steps to produce a mature and translatable mRNA. These three steps comprise 
the acquisition of the cap structure at the 5’ terminus, splicing out the introns within the 
body of the pre-mRNA and the generation of the 3’ end, which includes cleavage and the 
addition of a poly(A) tail. Therefore, the generation of mature mRNA by RNA Polymerase 
II (RNA Pol II) involves multiple processes, some occur sequentially and others in parallel. 
Transcription by RNA Pol II is a cyclic process composed of five primary phases: 
promoter binding and pre-initiation, initiation, promoter clearance, elongation and RNA 
transcript termination and release. Regulation of transcription can occur at each of these 
steps. Recent studies in yeast point to the existence of gene loops, in which a termination 
region of a transcriptionally active gene can be physically linked to its promoter site 
(O’Sullivan et al., 2004; Ansari and Hampsey, 2005). In such a case, termination can serve 
to facilitate transcriptional reinitiation. 
Transcription starts in the yeast S. cerevsisiae with the assembly of the pre-
initiation complex (PIC) at the promoter site of the DNA. The PIC consists besides RNA 
Pol II of the general transcription factors TFIID, TFIIB, TFIIE, TFIIF, TFIIH, the mediator 
complex and additional cofactors (Orphanides et al., 1996). The ATP-dependent process of 
melting of the double-stranded DNA into a singe-stranded bubble requires the action of the 
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general transcription factors TFIIE and TFIIH (Goodrich and Tjian, 1994; Holstege et al., 
1996). Generation of the open complex of DNA and PIC is a prerequisite for the process of 
transcription.  
Transcription initiation occurs upon addition of the two initiating nucleoside 
triphosphates (NTPs) complementary to the DNA sequence and the formation of the first 
phosphodiester bond. 
Before RNA Pol II enters the process of productive transcription elongation, it has 
to pass a stage known as promoter clearance. During this process, the PIC is partially 
disassembled. All general transcription factors except TFIIF remain at the promoter 
serving as a scaffold for a next round of PIC formation (Yudkovsky et al., 2000). 
Reinitiation of transcription therefore is a faster process relative to the initial round 
(Orphanides and Reinberg, 2000). 
The earliest stages of transcription are marked by instability of the transcription 
complex and a tendency to release the RNA. Appearance of stalled RNA Pol II-DNA 
complexes and short RNA products during promoter clearance indicates that immediately 
after transcription starts, a stable transcription elongation complex (TEC) has not formed. 
Biochemical studies have determined that RNA Pol II-TECs are unstable before the RNA-
DNA hybrid reaches 8 nt in length (Kireeva et al., 2000). Crystal structure of the yeast 
RNA Pol II-TEC containing a 14 nt RNA shows that the RNA-DNA hybrid within the 
transcription bubble is 9 nt long (Gnatt et al., 2001).  
During early elongation, the capping of the 5’ end of the nascent pre-mRNA is 
carried out. The first nucleotide of the RNA is converted to a diphosphate by the 5’ 
triphosphatase Cet1p (Tsukamoto et al., 1997) followed by the fusion with a GMP moiety 
catalysed by the guanylyltransferase Ceg1p (Itoh et al., 1984). Finally, the 
methyltransferase Abd1p methylates the GMP at N7 position completing the cap structure 
(Mao et al., 1995). 
During the process of transcription elongation, emerging introns are removed 
immediately. This event is called splicing and is a crucial and ubiquitous step in eukaryotic 
gene expression. It is carried out by the humongous splicosome complex which is 
composed of more than 200 different proteins and the RNA components U1, U2, U4, U5 
and U6, which are called small nuclear RNAs, or snRNAs (Nilsen, 2003). The splicosome 
forms on the intact precursor RNA after the 5’ splice site and branch site has been 
recognized by U1 and U2 snRNA, respectively. Within the assembled splicosome, intron 
excision occurs in two chemical steps: first the 5’ splice site cleavage and lariat formation 
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is carried out, then the 3’ splice site is cleaved and the exons are ligated. After the exon 
ligation, spliceosome disassembly frees its components for the de novo synthesis of further 
spliceosomes (Jurica and Moore, 2003). The excised RNA lanat is rapidly degraded. 
The final stage in the transcription process allows on one hand the release of the 
transcript from the site of transcription and on the other hand the release of RNA Pol II 
from the DNA template. This affords recycling of the RNA Pol II enzyme for a further 
round of transcription. Cleavage and polyadenylation of the mRNA precursor is essential 
for the transport of the mature mRNA out of the nucleus and its translation and stability 
(Ford et al., 1997; Wickens and Stephenson, 1984).  
 
 
2.2 CTD phosphoryation cycle 
 
With the step of promoter clearance, the beginning of cycling events within the 
transcription cycle starts: the phosphorylation of the highly conserved C-terminal domain 
(CTD) of Rpb1, the largest subunit of RNA Pol II (Allison et al., 1985) (figure 5). The tail-
like CTD protrudes from the catalytic core of RNA Pol II and is flexibly located at the exit 
groove of the pre-mRNA. The CTD is composed of heptapeptide repeats with the 
consensus sequence YSPTSPS. The number of the repeats varies species-dependently,  
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Phosphorylation of the CTD during the transcription cycle (Svejstrup, 
2004). 
The graph shows the phosphorylation levels at Ser 2 and Ser 5 of the CTD during the 
transcription cycle.  
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consists of 27 repeats in the yeast S. cerevisiae (Allison et al., 1985) and 52 in mammals  
(Cordon, 1990). These repeats can be heavily modified by reversible phosphorylation at 
serine 2 (Ser 2) and serine 5  (Ser 5) (Christmann and Dahmus, 1981), allowing four 
possible phosphorylation states: unphosphorylated, phosphorylated at Ser 2, 
phosphorylated at Ser 5, and phosphorylated at both sites, Ser 2 and Ser 5.  
In contrast to its simple repeated sequence, the function of the CTD is very 
complex and it is involved in all steps of mRNA formation (Dahmus, 1995). RNA Pol II 
phosphorylated at Ser 5 associates with the transcription step of initation and early 
elongation and it is reduced towards the 3’ region. In contrast, the amount of 
phosphorylated Ser 2 increases towards the 3’ end during elongation and marks a 
polymerase at late elongation or termination (Komarnitsky et al., 2000; Cho et al., 2001). 
At the preinitiation step, the CTD remains unphosphorylated (figure 5).  
In S. cerevisiae, the Kin28p subunit of the general transcription factor TFIIH bound 
to the cyclin CDK7 phosphorylates the CTD at Ser 5 (Feaver et al., 1994; Rodriguez et al., 
2000), whereas the cyclin-dependent kinases Bur1p/Bur2p and Ctk1p/Cdk9p hold a kinase 
activity for Ser 2 phosphorylation (Keogh et al., 2003; Cho et al., 2001) . Fcp1p is thought 
to play a major role in the recycling of RNA Pol II by dephosphorylating Ser 2 (Hausmann 
and Shuman, 2002). The second identified CTD-phosphatase is the Ser 5 phosphatase 
Ssu72p, which is also part of the cleavage and polyadenylation factor (Krishnamurthy et 
al., 2004). The action of CTD kinases and phosphatases are necessary for RNA Pol II to 
trigger the next step of the transcription cycle. Therefore, this balanced action of CTD 
kinases and phosphatases is highly regulated. With such an important role in transcription, 
it is not surprising that the CTD is essential for viability (Allison et al., 1988). The CTD is 
a key element in guiding the polymerase through the transcription cycle and in coupling 
the transcription process to mRNA processing events. Thus, the CTD plays an active role 
in all transcription processes, both by recruiting the RNA-processing factors to the nascent 
transcript and by directly activating them (Prelich, 2002). The detection of CTD-binding 
domains for several capping (Cho et al., 1997), splicing (Yuryev et al., 1996), and 3’ end 
processing factors (Barilla et al., 2001) suggests that the CTD serves as an assembly 
platform for processing factors. Moreover, most of the mRNA processing steps occur 
cotranscriptionally and many events during the synthesis of a mature mRNA are co-
regulated (figure 6) (Maniatis and Reed, 2002; Orphanides and Reinberg, 2002).  
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Figure 6 Linking pre-mRNA processing to the RNA Pol II transcription cycle 
(Orphanides and Reinberg, 2002). 
In the traditional view of gene expression, each step has been referred to an individual 
event, and the completion of it triggers the next step in the row. In contrast to that, the 
contemporary view shows gene expression as a subdivision of continuous processes, which 
are physically and functionally connected. The CTD plays a pivotal role in coordinating 
the transcription and processing events. 
 
 
2.3 Chromatin modification and transcription  
 
In eukaryotic cells, DNA is assembled into chromatin, a highly compacted nucleoprotein 
complex. The basic unit of chromatin, the nucleosome, is an octamer of core histones (two 
of each H2A, H2B, H3 and H4) wrapped around 147 bp of DNA. Chromatin provides 
DNA compaction and thereby adds another level of complexity to the regulation of the 
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processes requiring protein access to DNA. Chromatin remodeling is dynamic, and 
chromatin structure is altering so that transcription machinery has access to previously 
condensed DNA. Chromatin remodeling complexes use ATP to mechanically rearrange 
nucleosomes. There are 7 major chromatin-remodeling complexes in yeast: SWI/SNF, 
RSC, INO80, CHD1, Isw1a, Isw1b, and Isw2, each are containing a related ATPase 
catalytic subunit (Uffenbeck and Krebs, 2006). The mechanisms by which these complexes 
rearrange nucleosomes are various, enabling both general transcriptional regulation and 
promoter-specific regulation. It has also been demonstrated that chromatin remodelers are 
able to regulate transcription at the level of elongation (Morillon et al. 2003), and perform 
regulatory functions via novel remodeling activities, such as histone exchange and (or) 
histone variant deposition (Krogan et al., 2003; Kobor et al., 2004; Mizuguchi et al., 2004). 
Histones are posttanslationally and covalently modified at the protruding and 
therefore highly accessible N-terminal tails by a wide variety of enzymes. These 
modifications include acetylation, methylation, ubiquitination and phosphorylation. 
Histone modification is another mechanism used by cells to control access to DNA in 
chromatin. Depending on the type of modification, changes in electronegativity can occur, 
which can alter the DNA–histone binding affinity and stabilising or destabilisng the 
chromatin structure. Histone modification also generates binding surfaces for other factors, 
such as chromatin remodelers, repressors, or transcription factors (Spencer and Davie, 
1999). The large number of possible histone modification allows highly specific and 
complex signaling mechanisms and some particular histone modification can be associated 
to general transcriptonal effects. For example, the acetylation via histone acetyltransferases 
(HATs) is associated with active transcription (Struhl, 1998), while deacetylation through 
histone deacetylase (HDAC) complexes normally results in gene repression (Kadosh and 
Struhl, 1998). Lysine acetylation affects chromatin by imparting a negative charge and 
neutralizing the interaction between the histone tail and the phosphate backbone of DNA 
and creates a novel binding site that is bound by factors containing bromodomains. Histone 
acetylation is typically enriched at transcriptionally active genes, because it destabilises the 
chromatin structure (Svejstrup, 2007).  
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2.4 Transcription termination 
 
Transcription termination is critical for the overall maintenance and integrity of the 
transcriptome and it plays an important role in the regulation of gene expression. 
RNA Pol II is able to terminate polyadenylation-dependently as for the mRNA and as well 
polyadenylation-independently for snRNA, snoRNA and cryptic unstable transcripts 
(CUTs).  
 
2.4.1 Polyadenylation-dependent termination 
 
Termination is functionally connected with cleavage and polyadenylation of the nascent 
transcript (Zaret and Sherman, 1982). In the two-step pre-mRNA 3’ processing reaction, 
transcription of the poly(A) signal triggers the endonucleolytic cleavage of the nascent 
transcript generating an upstream cleavage product, which is immediately polyadenylated  
 
 
 
Figure 7 Models for transcription termination by RNA Pol II (Rosonina et al., 2006). 
A) Antiterminator or allosteric model. Termination is achieved either by the release of 
anti-termination factors or by binding termination factors triggering a conformational 
change of RNA Pol II to a less processive state. B) Endonucleolytic cleavage of the nascent 
RNA transcript provides a free 5’ end which serves as an entry point of the exonuclease 
Rat1p. When Rap1p reaches the RNA Pol II complex, it induces termination and RNA Pol 
II dissociates from the DNA template. 
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(Colgan and Manley, 1997). The remaining downstream cleavage product having an 
uncapped 5’ end is highly unstable and is rapidly degraded (Manley et al., 1982).  
Two models exist addressing the mechanistic basis for the connection between 
termination on one hand and cleavage and polyadenylation on the other: the “torpedo” and 
the “allosteric” or “antiterminator” model (figure 7) (Rosonina et al., 2006). In the latter 
model, transcription termination is caused by the destabilisation and/or a conformational 
change of the RNA Pol II elongation complex after transcribing the poly(A) site. Release 
of antitermination factors or recruitment of termination factors triggers dissociation from 
the DNA template (Logan et al., 1987). The torpedo model postulates that endonucleolytic 
cleavage at the poly(A) site creates an entry site for the 5’ → 3’ exonuclease Rat1p, which 
degrades the RNA downstream of the cleavage site. The exonuclease continues degrading 
the transcript until it reaches the RNA Pol II elongation complex and destabilises it by 
inducing an arrest and promotes termination (Connelly and Manley, 1988). Although both 
models rely on recognition of the poly(A) site, the fundamental difference is that only the 
torpedo model depends on the successful endonucleolytic cleavage of the nascent RNA to 
create an entry site for Rat1p. 
A hybrid model for coupling termination with 3’ end processing has been proposed, 
where aspects of both models are combined, since neither the exonuclease Rat1 nor the 
binding of cleavage and polyadenylation factors alone were sufficient to cause a poly(A) 
site dependent termination (Luo et al., 2006). According to the hybrid model, the 
association of Rat1p and CPF on the CTD of the RNA Pol II elongation complex results in 
an allosteric change in the polymerase which favours termination and endonucleolytic 
cleavage is stimulated by associated 3’ end processing factors. 
 
2.4.2 Elements of polyadenylation-dependent termination 
 
Termination of RNA Pol II transcription is initiated by the cotranscriptional recognition of 
cis-acting sequences in the 3’ end of the nascent transcript by a multi-component complex 
carrying out cleavage and polyadenylaton. 
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2.4.2.1 Cis-acting elements 
 
The cis-acting elements, sequences on the RNA precursor, determine the site of cleavage 
and polyadenylation. The signals for 3’ end formation in yeast are less well conserved than 
the poly(A) site signals in higher eukaryotes (Wahle and Kuhn, 1997). However, there are 
common elements in the untranslated region (UTR) of genes, which guide the site of 
cleavage and polyadenylation (see figure 8 on page 37) 
The efficiency element is found at variable distances upstream of the cleavage site 
and often contains alternating AU dinucleotides or U-rich stretches. Computer analysis has 
shown that more than half of approximately 1000 examined nuclear genes in yeast contain 
the sequence UAUAUA in the 3’ UTR (Graber et al., 1999). The U residues at the first and 
the fifth positions have been identified as the most critical nucleotides in this sequence 
(Guo and Sherman, 1995). 
The positioning element is located approximately 20 nucleotides upstream of the 
cleavage and polyadenylation site. It consists of an A-rich stretch and sequences as 
AAUAAA or AAAAA have been identified as most efficient (Guo and Sherman, 1995). 
The positioning element also contributes to 3’ end processing and poly(A) site selection 
(Abe et al., 1990; Hyman et al., 1991; Irniger et al., 1992). The U-rich elements are found 
immediately upstream or downstream of the poly(A) site (Graber et al., 1999). They 
contribute to poly(A) site recognition and enhance processivity of 3’ end formation (Dichtl 
and Keller, 2001). The poly(A) site preferentially is a Pyrimidine(A)n, and might itself act 
as a polyadenylation signal (Heidmann et al., 1992).  
 
2.4.2.2 Factors involved in 3’ end processing 
 
Proteins that are sufficient to perform 3’ end formation in vitro have been identified (Chen 
and Moore, 1992). For the cleavage reaction, the cleavage and polyadenylation factor IA 
(CF IA), cleavage and polyadenylation factor IB (CF IB), and the cleavage factor II (CF II) 
are sufficient, while specific poly(A) addition requires in addition the polyadenylation 
factor (PF I) and the poly(A) binding protein (Pab1). It was shown that CF II and PF I form 
a functional unit in vivo (Ohnacker et al., 2000) and therefore this factor has been renamed 
as cleavage and polyadenylation factor (CPF) (figure 8).  
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Cleavage and polyadenylation factor IA (CF IA) 
CF I was originally detected as an activity needed for cleavage and polyadenylation 
reaction in vitro (Chen and Moore, 1992) and further purification identified two 
components, CF IA and CF IB (Kessler et al., 1996). CF IA consists of four proteins: 
Rna14p, Rna15p, Pcf11p and Clp1p. Yeast strains harbouring temperature-sensitive 
mutations in the essential genes RNA14 or RNA15 show a dramatic poly(A) tail shortening 
(Minvielle-Sebastia et al., 1991). These mutations are synthetically lethal with mutations in 
the PAP1 (poly(A) polymerase) gene (Minvielle-Sebastia et al., 1994). Extracts from 
RNA14-or RNA15-mutant strains are defective in cleavage and polyadenylation (Minvielle-
Sebastia et al., 1994) indicating that they are involved in both steps of 3’ end processing. 
The same malfunction has also been reported for extracts of strains carrying temperature-
sensitive mutations in PCF11 gene (Amrani et al., 1997). Pcf11p contains a CTD 
interaction domain binding the Ser 2 phosphorylated CTD and couples 3′ end processing to 
transcription (Barilla et al., 2001; Noble et al., 2005). The Clp1p component interacts with 
Pcf11p (Gross and Moore, 2001) and Ysh1p of CF II (Kyburz et al., 2003). Crystal 
structure of Clp1-ATP with the Clp1-binding site of Pcf11p was unable to explain the 
function of ATP binding and/or its hydrolysis by Clp1p in the process of 3’ end formation 
(Noble et al., 2007). 
 
Cleavage and polyadenylation factor IB (CF IB) 
CF IB is a single polypeptide encoded by the NAB4/HRP1 gene (Kessler et al., 1997). 
Nab4p is an essential heterogeneous nuclear ribonucleoparticle (hnRNP) that can shuttle in 
and out of the nucleus (Kessler et al., 1997). It is unclear, if Nab4p is involved in the 
cleavage reaction itself or if it is only required for regulating cleavage site utilisation 
(Minvielle-Sebastia et al., 1998). In vitro cleavage reactions lacking NAB4 produced an 
increase in the usage of cryptic cleavage sites leading to the hypothesis that Nab4p is 
involved in the discrimination between correct and cryptic cleavage sites (Minvielle-
Sebastia et al., 1998). In addition to its role in 3′ pre-mRNA processing, Nab4p has been 
implicated in mRNA export and nonsense-mediated decay (Gonzalez et al., 2000). 
 
Cleavage and polyadenylation factor (CFP) 
CPF contains all subunits of CF II and PF I and in addition the proteins Ref2p, Pti1p, 
Swd1p, Glc7p, Ssu72p and Syc1p. These six proteins are combined in a further 
subcomplex of CFP named associated with Pta1 (APT), because it was observed by 
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tagging different subunits of CPF that not all proteins pulled down the entire CFP complex 
(Nedea et al., 2003). Ref2p is a non-essential RNA binding protein that is important for the 
efficient cleavage of pre-mRNAs with weak poly(A) sites (Russnak et al., 1995). 
Furthermore, it has been implicated in poly(A)length control and snoRNA 3’ end 
maturation (Dheur et al., 2003; Magnus et al., 2004). 
Glc7p is the catalytic subunit of type 1 protein phosphatase (Feng et al., 1991) and 
is involved in the regulation of many different physiological processes, e.g. sporulation, 
glycogen metabolism and mitosis. It plays an essential role in snoRNA transcriptional 
termination and for that the roles of two other APT components, Swd2p and Ref2p, are to 
keep Glc7p associated with the complex (Nedea et al., 2008). Depletion of Glc7p causes 
shortened poly(A) tails in vivo and in vitro and Glc7p is not essential for cleavage at the 
poly(A) site, but for poly(A) addition (He and Moore, 2005). 
The CTD phosphatase Ssu72p (Krishnamurthy et al., 2004) is an essential protein 
and was initially identified based on genetic interaction with the general transcription 
factor TFIIB (Sun and Hampsey, 1996). It interacts physically with TFIIB (Wu et al., 
1999), the Rpb2 subunit of RNA Pol II (Dichtl et al., 2002a), TFIID (Sanders et al., 2002) 
and TFIIH (Ganem et al., 2003). This would suggest a role for Ssu72p in transcription 
initiation, however as component of CFP, defective forms of Ssu72p affect cleavage (He et 
al., 2003) and termination (Steinmetz and Brow, 2003) but it is dispensable for 
polyadenylation.  
Swd2p is an essential protein. It is a subunit of CPF as well as of the COMPASS-
complex, which methylates K4-H3 (Roguev et al., 2001). Swd2p is required for global 
histone methylation on K4-H3, for RNA Pol II termination on specific genes, but not for 
3’ end processing (Dichtl et al., 2004; Cheng et al., 2004). 
 
Cleavage factor II (CF II) 
CF II consists of four essential proteins: Cft1p/Yhh1p, Cft2p/Ydh1p, Brr5p/Ysh1p and 
Pta1p. Yhh1p and Ydh1p are both RNA binding proteins that are involved in poly(A) site 
recognition (Dichtl et al., 2002b; Kyburz et al., 2003). Both proteins interact with 
phosphorylated CTD of RNA Pol II, and they may therefore mediate the binding of CFP to 
the CTD, which is important for the coupling of transcription and 3’ end formation 
(Bentley, 2002). YHH1 mutant strains show a defect in RNA Pol II termination. Ysh1p 
belongs to a large family of metallo-hydrolytic enzymes that have the ability to cleave 
nucleic acids (Callebaut et al., 2002) and it is thought that Ysh1p might be the 
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endonuclease that cleaves the pre-mRNA at the poly(A) site (Chanfreau et al., 1996; Jenny 
et al., 1996). Pta1p is reported to be involved in poly(A) addition but not in cleavage 
(Preker et al., 1997), but another study found its implication in both steps (Zhao et al., 
1999). Glc7p depleted extracts revealed a defect in poly(A) addition and in the 
accumulation of phosphorylated Pta1p, leading to the suggestion that the activity of Pap1p 
might be regulated, directly or indirectly, by phosphorylation of Pta1p (He and Moore, 
2005).  
 
Polyadenylation factor I (PF I) 
PF I was initially identified as an activity, which supported poly(A) addition but not 
cleavage. It contains the proteins Yth1p, Fip1p, Pap1p, Mpe1p and Pfs2p, which are all 
essential. Yth1p is implicated in both, cleavage and polyadenylation (Barabino et al., 
2000). The protein bears five zink fingers having the ability to bind RNA (Barabino et al., 
1997). Moreover Yth1p might play an important role for transition from cleavage to 
polyadenylation (Tacahashi et al., 2003). Fip1p interacts with Pap1p (Preker et al., 1995). 
The interaction between Fip1p and Rna14p (Preker et al., 1995) is thought to link the two 
large subcomplexes within the 3′ end processing machinery: CFI, which binds the 
upstream A-rich motif in the pre-mRNA (Gross and Moore, 2001), and CPF, which 
contains the poly(A) polymerase and Ysh1p, the nuclease responsible for pre-mRNA 
cleavage. The protein Fip1p is largely disordered in the absence of Pap1p, and this suggest 
that only a portion of Fip1p folds upon binding the polymerase (Meinke et al., 2008). 
Phosphorylated CF II might weaken the binding of Fip1p to Pap1p, which could have an 
influence on polyadenylation efficiency (He and Moore, 2005). 
Pap1p catalyzes the addition of a polyadenosine tail to pre-mRNAs and was the 
first purified factor of the 3’ end machinery. The yeast and mammalian Pap1p proteins are 
47% identical within the first 400 amino acids thought to comprise the nucleotidyl 
transferase activity (Martin and Keller, 1996). Yeast Pap1p is not required for cleavage in 
vitro, however, temperature-sensitive mutants show a change in poly(A) site usage in 
ACT1 transcript (Mandart and Parker, 1995). The crystal structure of Pap1p has been 
solved alone and in complex with cordycepin (Martin et al., 2000; Bard et al., 2000).  
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Figure 8 Diagram showing the cis- and trans-acting elements required for 
transcription termination and 3’ end processing in yeast (Proudfoot, 2004) 
Abbreviations used in this scheme: EE efficiency element; PE positioning element; UUE 
upstream U-rich; DUE downstream U-rich element. The array displays the poly(A) site. 
 
2.4.3 Polyadenylation independent termination 
 
Transcription termination of snRNA and snoRNA depends on a protein complex called 
Nrd1p-complex containing the RNA binding proteins Nrd1p and Nab3p and some 
additional co-factors (Steinmetz et al., 2001). Like components of the polyadenylation-
dependent termination, the Nrd1p-compex interacts directly with RNA Pol II through a 
CTD-interaction domain on Nrd1p. Two common RNA sequence motifs are recognised by 
the Nrd1p-complex and play a significant role in defining polyadenylation-independent 
termination: the sequence GUA[AG] corresponds to the Nrd1p-binding site and Nab3p 
binds specifically to the UCCU motif (Carroll et al., 2004). Efficient termination of snRNA 
and snoRNA transcription requires the cis-element which is recognised by Nrd1p and 
Nab3p, the putative RNA helicase Sen1p and an intact CTD of RNA Pol II (Steinmetz et 
al., 2001). The primary snRNA and snoRNA transcripts contain extended 3’ ends that are 
trimmed by the nuclear RNA exosome. This complex with 3’→5’ exonucleolytic activity 
is able to degrade unstructured stretches of RNA and trimming proceeds until the complex 
encounters specific protein bound RNA elements at the 3’ end of the mature snRNA and 
snoRNA (Allmang et al., 1999; van Hoof et al., 2000). The activity of the exosome is 
stimulated by the TRAMP complex (LaCava et al., 2005), consisting of a recently 
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identified poly(A) polymerase Trf4p (or Trf5p) (Vanacova et al., 2005; Wyers et al., 2005), 
Mtr4p, a putative RNA helicase previously implicated in the activation of the nuclear 
exosome (de la Cruz et al., 1998) and Air1p/Air2p. TRAMP-mediated polyadenylation of 
RNA destabilised the RNA by marking it for degradation by the nuclear exosome 
(Egecioglu et al., 2006). The Nrd1p-complex copurifies with both the nuclear exosome and 
TRAMP (Vasiljeva and Buratowski, 2006). Interestingly, Nrd1p has been shown to bind 
strongly Ser 5 phosphorylated CTD in vitro and chromatin immunoprecipitation 
experiments revealed that Nrd1p is recruited to RNA Pol II at the 5’ end of the gene 
(Vasiljeva, et al., 2008). 
The importance of coupling transcription termination and proper 3’ end formation 
has been illustrated by the discovery of the from intergenic DNA regions abundantly 
transcribed but scarcely detectable cryptic unstable transcripts (CUTs) (Wyers et al., 2005). 
These transcripts are hardly detectable in wild-type strains, but can be visualised by 
disrupting either TRF4 the gene encoding the poly(A) polymerase subunit of the TRAMP 
complex or RRP6, a nonessential subunit of the nuclear exosome (Mitchell and Tollervey, 
2000). RNA Pol II termination of CUT transcripts also involves the Nrd1p-complex. 
However, CUTs are rapidly degraded by polyadenylation by the TRAMP complex and 
subsequent action of the exosome. Because of the lack of any protective element, they are 
completely degraded by the nuclear exosome. This mechanism identifies the implication of 
the TRAMP complex together with the nuclear exosome in transcription quality control. 
CUT transcription has been shown to interfere with promoters of coding regions and hence 
regulates gene expression. The expression of IMD2, SER3 and PHO5 are regulated by 
transcription of a CUT. IMD2 encodes an enzyme important for GTP biosynthesis and 
IMD2 mRNA levels correlate inversely with GTP levels (Exinger and Lacroute, 1992). 
When GTP levels are high, transcription starts from G-start sites (TATA box proximal) 
resulting in the synthesis of noncoding transcripts that prevent initiation for IMD2 
production. Low GTP levels allows the usage of the A start site (TATA box distal) and the 
production of IMD2 mRNA (Kuehner and Brow, 2008). SER3 encodes a serine 
biosynthetic enzyme and its expression is regulated by the CUT SRG1, which covers the 
promoter of SER3 (Martens et al., 2004). SRG1 transcription is induced by high serine 
levels resulting in repression of SER3; in lack of serine, SRG1 transcription is dramatically 
reduced allowing SER3 expression (Martens et al., 2005). In the case of PHO5, the 
noncoding antisense transcript is transcribed at low levels and functions in PHO5 
activation and not repression (Uhler et al., 2007). 
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RNA Pol II has the choice between different transcription termination modes and 
the polymerase has to be directed to proper termination by cis-acting elements and the 
pooling of necessary factors (figure 9). 
 
 
 
 
 
Figure 9 Transcription termination and 3’ end processing of three different RNA 
Pol II derived transcripts (Lykke-Andersen and Jensen, 2007). 
 
 
 
2.5 Export of mRNA 
 
The transport of RNA molecules from the nucleus to the cytoplasm is fundamental for 
gene expression. Different RNA species produced in the nucleus are exported through the 
nuclear pore complexes via different RNA export pathways (Köhler and Hurt, 2007). Only 
correctly processed mRNAs are allowed to be exported to the cytoplasm, providing 
evidence that mRNA maturation and export are linked to each other (Lei and Silver, 2002). 
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The nascent mRNA is cotranscriptionally coated with proteins and assembled into a 
messenger ribonucleoprotein (mRNP) by the THO/TREX complex. The THO complex 
consists of the subunits Tho2p, Hpr1p, Mft1p and Thp2p and forms a robust subcomplex 
of TREX, which additionally harbours Yra1p, Sub2p and Tex1p (Strässer et al., 2002). The 
TREX complex physically links proteins that function either in mRNA export or 
transcription: the THO complex functions in transcription elongation (Chávez et al., 2000), 
while the subunits Yra1p and Sub2p are required for mRNA export (Strässer et al., 2002), 
and importantly, all four components of the THO complex interact genetically with both 
YRA1 and SUB2. Mutants of TREX show an accumulation of poly(A) RNA in the nucleus 
indicating that also THO mutants have a role in mRNA export. TREX accompanies the 
elongating RNA Pol II and the THO subcomplex interacts with the chromatin, whereas 
Sub2p and Yra1p associate with the nascent RNA transcript (Abruzzi et al., 2005). In turn, 
Yra1p recruits the export receptors Mex67p-Mtr2p, which do not bind the GTPas Ran 
directly, but interact with nucleoporins and shuttle between nucleus and cytoplasm 
(Zenklusen and Stutz, 2001) (figure 10). 
The nuclear exosome has been implicated in the degradation of nuclear pre-mRNA, 
unadenylated and 3’ unprocessed pre-mRNAs as well as mRNPs assembled with mutant 
TREX complex (Zenklusen et al., 2002; Bousquet-Antonelli et al., 2000; Hilleren et al., 
2001). The exosome is therefore not only a major player in the nuclear mRNA surveillance 
mechanism that degrades mRNAs with aberrant 3’ ends but is also responsible for the 
degradation of defective mRNPs. How aberrant mRNPs are identified is unknown. 
Sac3p was identified as an mRNA export factor having genetic interaction with 
subunits of the TREX complex and being able to physically recruit the Mex67-Mtr2 export 
receptor (Fischer et al., 2002; Lei et al., 2003). Sac3p forms together with Thp1p, Sus1p 
and Cdc31p a complex called Sac3-Thp1-Sus1-Cdc31-complex or TREX-2 (Fischer et al., 
2004). This complex is associated with the inner side of the nuclear pore complex via the 
nucleoporins Nup1p and Nup60p (Fischer et al., 2002). Interestingly, Sub1p is also part of 
the SAGA complex, a large transcription-initiator that catalysis histone acetylation and 
deubiquitylation (Shukla et al., 2006; Köhler et al., 2006) suggesting that Sub2p functions 
in coupling of SAGA-dependent gene expression with mRNA export via its tether to the 
inner side of the nuclear pore complex (Rodriguez-Navarro et al., 2004) (figure 10).  
The model of gene gating was proposed by Günther Blobel and it says that every 
expressed gene is physically connected to a particular nuclear pore complex in the nuclear 
membrane (Blobel, 1985). Several recent studies have shown that a number of genes are 
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dynamically targeted to the nuclear envelope upon activation and this positioning appears 
to facilitate transcription and subsequent nuclear mRNA export (Taddei et al., 2006; Cabal 
et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Gene gating and mRNA export (Köhler and Hurt, 2007). 
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3 Poly(A) polymerase 
 
In eukaryotes, polyadenylation of pre-mRNA plays an essential role in the initiation step of 
protein synthesis, as well as in the export and stability of mRNAs. Poly(A) polymerase 
(PAP) is classified as a template-independent polymerase, a category shared only by 
terminal deoxynucleotidyl transferase. Although it employs the same catalytic mechanism 
as other nucleic acid polymerases, poly(A) polymerase is significantly different in that it 
does not utilise a template strand to select and position the incoming nucleotide.  
An activity which added adenosine residues to the 3' ends of RNAs was discovered 
in the early 1960s, and at the time it was a reaction of unknown significance. All 
eukaryotic genomes code for one or several canonical nuclear PAPs. Yeast has one 
(Lingner et al., 1991) and higher eukaryotes have two or three copies. In mammals, there 
exist different forms: PAP I, PAP II, PAP IV, TRAP, neo-PAP and Star-PAP. There has 
been considerable evolutionary conservation of the amino acid sequence of the N-terminal 
catalytic domain, with extensive similarities from yeast to human, as yeast and the first 
400 nt of mammalian PAP have around 47% identity (Ohnacker et al., 1996).  
 
 
3.1 Yeast poly(A) polymerase 
 
3.1.1 Canonical poly(A) polymerase 
 
Canonical poly(A) polymerases in eukaryotes are responsible for the addition of poly(A) 
tails during the processing of the 3' ends of messenger RNA precursors in the nucleus. 
Yeast Pap1p retains polymerase activity when separated from the holoenzyme assembly 
and can processively add long stretches of adenosine nucleotides to an RNA primer in 
vitro. Yeast Pap1p was crystallised in combination with two CoTPs, one occupies the 
position of the incoming base, prior to its addition to the mRNA chain, and the other is 
believed to occupy the position of the 3' end of the mRNA primer (Bard et al., 2000). 
Pap1p is composed of three domains that encircle the active site, like it has been observed 
for other nucleic acid polymerases. In contrast to the incoming CoTP, the mononucleotide 
primer shows extensive interactions with Pap1p (Bard et al., 2000). Since the enzyme has 
no contact to the incoming adenosine, no hypothesis for a strict ATP selection can be 
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made. The C-terminal domain of Pap1p holding an RNA binding domain binds the RNA 
primer/product. 
The association in CPF enhances Pap1p processivity; there is no requirement to 
induce processivity as in the case of the mammalian PAP (Preker et al., 1997). Fip1p is the 
only protein shown to interact with Pap1p (Helmling et al., 2001). Fip1p has also been 
shown to affect the in vitro activity of poly(A) polymerase as it inhibits polyadenylation 
activity of Pap1p. A poly(A)-binding protein is needed to stop the polyadenylation process. 
First, the major cytoplasmic poly(A)-binding protein Pab1p has been suggested to regulate 
polyadenylation (Amrani et al., 1997). Then it was thought, that Pap1p recruits and 
activates the poly(A) nucleases Pan2-Pan3 (Brown and Sachs, 1998), which would imply 
that a deadenylation step is required for poly(A) tail length control. It has also been 
proposed that Nab2p is implicated in poly(A) tail lengh regulation (Hector et al., 2002). 
However, in vitro polyadenylation assays, either Pab1p or Nab2p produced the corret 
poly(A) length of 70 As in the absence of PAN, which was localised to the cytoplasm 
(Dheur et al., 2005). It seems that in yeast, the process for poly(A) length control is the 
same as in mammalian cells an does not involve a deadenylation process. 
 
3.1.2 Uncanonical poly(A) polymerases 
 
In yeast, Trf4p and Trf5p have been identified as poly(A) polymerase localised to the 
nucleus (Vanacova et al., 2005; LaCava et al., 2005). Trf4p and Trf5 are part of the 
TRAMP complex in vivo. The poly(A) tails made by the TRAMP complex primarily serve 
to initiate RNA degradation (see chapter 2.4.3). Trf4p needs the TRAMP subunit Air1p or 
Air2 for in vitro polyadenylation activity (Vanacova et al., 2005).  
 
 
3.2 Mammalian poly(A) polymerase 
 
3.2.1 PAP 
 
PAPα was fist identified (Raabe et al., 1991; Wahle et al. 1991) and has also been 
extensively characterised. The structure of the mammalian PAPα in complex with CoTP 
has been determined by X-ray crystallography (Martin et al., 2000; Martin et al., 2004). 
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The crystal structure of the bovine PAP is very similar to the yeast structure, but 
catalytically important residues of the bovine PAP make specific contacts to the adenine 
base and discriminate against guanine, cytosine and uracil. PAP strongly discriminates 
against nucleotides other than ATP (Wahle, 1991; Martin and Keller, 1998) although 
discrimination against GTP is not as stringent as against pyrimidines. Additionaly, the 
RNA binding domain of bovine PAP was shown to overlap with the nuclear localization 
signal and three aspartates essential for catalysis could be identified. The three aspartates 
ligate two of the three active site metals. One of these metals also contacts the adenine ring 
(Martin et al., 2000).  
In vitro, the interaction of PAP with the CPSF subunits CSPF160 and hFip1p 
stimulate PAP by tethering it to the RNA for which it has intrinsically a low affinity 
(Kaufmann et al., 2004; Kerwitz et al., 2003). The poly(A)-binding protein nuclear 1 
(PABPN1) interacts with the first synthesised 11 adenosine residues and further increases 
the affinity of mPAP for the RNA. This activates processive mode of the enzyme (Kerwitz 
et al., 2003). After approximately 250 A residues have been polymerised in a poly(A) tail, 
PAP switches back to a distributive mode (Wahle, 1995). The mechanism responsible for 
this poly(A) tail length control is not fully understood. 
In vertebrates, multiple forms of PAP mRNA are synthesized from a single gene by 
alternative splicing (figure 11). The longest mRNA forms encode PAPs I and II, which are 
distinguished from each other by their C-terminal sequences (Raabe et al., 1991), whereas 
competition between splicing and polyadenylation of the mRNA precursor produces short 
forms of mRNA encoding PAP III, V, and VI (Zhao and Manley, 1996). Of these five 
PAPs, PAP II is the predominant form in most cells, and contains three functional 
domains: a catalytic domain, an RNA-binding domain and a large domain rich in serine 
and threonine at the C-terminus (Martin and Keller, 1996; Martin et al., 1999). PAP I and 
II also possess two nuclear localization signals, NLS1 and NLS2, which are both required 
for the efficient transport of the enzymes into the nucleus (Raabe et al., 1994). Functional 
analysis has shown that the RNA binding domain (RBD) and polymerase module (PM) are 
essential but not sufficient for catalytic activity. The regulatory Ser/Thr-rich domain 
provides several consensus and nonconsensus phosphorylation sites (Colgan et al., 1996 
and 1998). It is not required for in vitro activity and yeast is lacking this domain. The three 
truncated forms of PAPs III, V, and VI, which terminate in the middle of the protein-
coding region of PAP I and II, lack NLS 1 and 2, and Ser/Thr-rich domain. The introns 9, 
10 and 12 contain all an AAUAAA hexanucleotide (Zhao and Manley, 1996). Although  
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Figure 11 Structures of the alternatively spliced forms of PAP. (Zhao and Manley, 
1996) 
The numbered open boxes display the exons, and splicing is indicated by angled lines 
between exons. The RNA binding domain (RBD) is located in exons 3, 4 and 5, the 
polymerase module (PM) in exons 5, 6 and 7, NLS1 in exon 16, NLS2 in exon 19 and 
Ser/Thr-rich region (S/T) is located from exon 16 to 22. 
 
 
the mRNAs for PAP III, V, and VI are indeed detectable in cells, the proteins translated are 
below the limit of detection, and the recombinant proteins have no polyadenylation activity  
(Thuresson et al., 1994; Zhao and Manley, 1996). Thus, the functions of these three PAP 
are unknown.  
During cell cycle, PAP has been shown to carry different modification patterns. 
Mitosis/meiosis-promoting factor (MPF) is a heterodimeric cyclin-dependent kinase 
consisting of p34cdc2 and cyclin B and phosphorylates a wide range of targets, acting as a 
‘master regulator’ of mitosis (King et al., 1994). PAP is also phosphorylated by MPF at 
totally seven consensus sites (Colgan et al., 1996) and non-consensus sites (Colgan et al., 
1998). Direct phosphorylation assays in vitro revealed that phosphorylated PAP showed a 
significant reduction in activity, which could be reversed by phosphatase addition. 
Phosphorylation of all seven phosphorylation sites results in an nearly total repression of 
activity, while partial phosphorylation has no detectable effect. This modification has been 
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demonstrated for PAP I and PAP II. Yeast Pap1p lacks the C-terminal Ser/Thr rich domain 
which might suggest that cell cycle regulation of PAP activity might be restricted to 
metazoa. 
 
3.2.2 TRAP 
 
TRAP was identified as a testis-specific poly(A) polymerase in mice, that is localized to 
the cytoplasm of germ cells (Kashiwabara et al., 2000). TRAP gene is a single copy gene 
on the genome and is therefore not splicing variant derived from the PAP gene. The fact 
that TRAP is expressed in spermatogenic cells, could imply that additional poly(A) 
extensions of existing mRNAs might be added by TRAP in the cytoplasm of these cells, 
maybe as a step of post-transcriptional regulation. However, the function of TRAP is still 
not fully understood. 
 
3.2.3 Neo-PAP 
 
Neo-PAP was identified as a form of PAP by molecular cloning from a human tumor cell 
cDNA library (Topalian et al., 2001). Due to its identification and overexpression in 
human neoplasms, this molecule was named neo-poly(A) polymerase (neo-PAP). 
Intriguingly, the intron-exon organization of the PAP and neo-PAP genes is almost 
identical, suggesting that they arose by gene duplication and subsequent recombination. 
Neo-PAP is indistinguishable in its biochemical functions in vitro from PAP. However, 
significant sequence dissimilarities in the C-terminal domain of neo-PAP and PAP as well 
as apparent differences in the phosphorylation of these two molecules suggest that each 
may be influenced by distinct regulatory controls. Neo-PAP is not phosphorylated 
throughout cell cycle although it provides consensus phosphorylation sites. Neo-PAP may 
therefore be an important RNA processing enzyme that is regulated by a mechanism 
distinct from that utilized by PAP. 
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3.2.4 Star PAP 
 
Star PAP (nuclear speckle targeted PIPKI regulated poly(A) polymerase) was identified as 
a type I phosphatidylinositol 4-phosphate 5 kinase (PIPKI) interacting protein (Mellman et 
al., 2008). PIPKI localises to nuclear speckles and Star-PAP colocalises with PIPKI. It is 
unique among known PAPs, because it contains a catalytic domain splitted by a praline-
rich region. In addition, it contains a zinc-finger and only one NLS. Poly(A) polymerase 
activity of Star-PAP is stimulated in vitro by the presence of phosphatidylinositol-4,5-
biphosphate (Ptdlns-4,5P2) that is generated by PIPKI (Heck et al., 2007). Othe 
rphosphoinosities did not affect Star-PAP activity, and no phosphoinositide had an effect 
on PAP I. Star-PAP was associated with HO-1 mRNA and was required for efficient 3’ 
processing. HO-1 is an important cytoprotective enzyme for reactive oxygen induced stress 
response (Duckers et al., 2001). It was speculated that antioxidant response might induce 
the assembly of a Star-PAP complex together with PIPKI. PIPKI would produce Ptdlns-
4,5P2 that controls processivity of Star-PAP. 
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VI Results 
 
1 Molecular effects of cordycepin in Saccharomyces cerevisiae 
 
Cordycepin as an adenosine analogue without the 3’ OH group is thought to inhibit the 
process of polyadenylation in eukaryotic cells by preventing the addition of further 
adenosines after it’s incorporation into the poly(A) tail (Butler et al., 1990), especially at 
lower concentrations (Zeevi et al., 1981). This compound is also widely used in 
experiments as a polyadenylation inhibitor in vitro as well as in vivo (Ioannidis et al., 1999; 
Costanzo et al., 2001; Gershon et al., 2006). The aim of this project is to characterise the 
molecular effects of cordycepin particular the effect RNA metabolism in the yeast 
Saccharomyces cerevisiae. 
 
In early studies, it was suggested that S. cerevisiae is resistant to cordycepin (Anderson and 
Roth, 1974). Later, it was found that S. cerevisiae cultivated in thiamine-free medium is 
sensitive to cordycepin and that the presence of thiamine increases growth resistance for 
the drug (Iwashima et al. 1992). Iwashima and co-workers found two mutant strains, which 
are resistant to the inhibitory action of cordycepin: CD-R1 was found to be deficient in a 
common transport system for thiamine and therefore cordycepin might not been taken up 
by the cells. The CD-R2 mutant had no defect in the thiamine import system, but the 
incorporation of cordycepin into RNA was markedly lower suggesting that the conversion 
of cordycepin into a more active form is impaired in this mutant. Later, a lesion in 
adenosine kinase was identified in the mutant strain CD-R2 (Iwashima et al., 1995). 
According to that, cordycepin might be taken up by the cells via the thiamine 
transport system, as the yeast S. cerevisiae does not take up exogenous adenosine and also 
can not use it as a purine source (Mäser et al., 1999). Cordycepin is then converted to 
cordycepin monophospate (CoMP) by the enzyme adenosine kinase (ADO1) (Lecoq et al., 
2001), which has a major role in recycling adenosine produced from S-adenosyl-
methionine (AdoMet) by the methyl cycle (Barrado et al., 2003). ADO1 is not an essential 
gene, because in the absence of ADO1, AMP can still be produced using the purine de 
novo biosynthesis system or xanthine as a source. CoMP is transformed into the active 
form CoTP by the enzyme adenylate kinase (ADK1) (Konrad, 1988). Adk1p is not 
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essential, probably because of the existence of a second adenylate kinase, Adk2p, normally 
localised to the mitochondria (Cooper and Friedberg, 1992). 
 
 
1.1 Mutant strains of factors involved in 3’ end formation are 
cordycepin sensitive 
 
Since cordycepin acts as a chain terminator of transcription elongation and 
polyadenylation, its presence should lead to a higher growth impact on strains carrying 
mutations affecting 3’ end formation. Mutation and cordycepin could exhibit a synergistic 
effect. This was tested with a drop test, where dilutions of yeast cultures were dropped on 
plates either containing or lacking cordycepin (figure 12). The addition of 40 µg/ml 
cordycepin does only cause a very slight growth defect in wild-type strains, but several  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Mutation of factors involved in 3’ end formation causes a growth inhibition 
in presence of cordycepin.  
Ten-fold dilutions of yeast strains indicated at the left were dropped on SD plates 
containing or lacking cordycepin [40 µg/ml] and incubated at 25 °C for 3 days. Cleavage 
and polyadenylation factor (CPF) and cleavage and polyadenylation factor IA (CP IA), the 
phosphoryated CTD and transcription termination are illustrated on the right. 
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mutant strains showed a severe growth phenotype in presence of cordycepin. Mutants of 
RNA14 and RNA15 were initially identified as cordycepin (Bloch et al., 1978) and both 
encode for factors of the cleavage and polyadenylation factor (CF IA). The mutant strains 
rna14-1 and rna15-1 show defects in cleavage and polyadenylation demonstrating their 
role in 3’ end formation. Both mutant strains showed a strong sensitivity against the drug 
cordycepin, as growth is strongly inhibited in presence of cordycepin compared to that on 
normal media. Mutation of YSH1, which is thought to be the endonuclease, that cleaves the 
nascent RNA transcript (Chanfreau et al., 1996), displayed as well strong cordycepin 
sensitivity. A nonessential factor involved of this machinery is Ref2p, which also shows a 
clear growth inhibition in presence of the adenosine analogue. As well factors affecting the 
phosphorylation status of the CTD were highly sensitive to cordycepin. Ssu72p exhibits a 
phosphatase activity for Ser 5, Kin28p is the Ser 5 kinase and CTK1 holds a kinase activity 
for Ser 2. Mutations affecting either the process of transcription (rpb1-1) or transcription 
termination (rat1-1) were also sensitive to cordycepin.  
 
 
1.2 Mutation of PAP1 leads to cordycepin resistance 
 
Most interestingly, mutation in the PAP1 gene revealed cordycepin resistance. This 
observation was highly unexpected, since Pap1p is the enzyme synthesising the poly(A) 
tail on the pre-mRNA. This is exactly the process, which is thought to be affected by 
cordycepin. Different temperature-sensitive mutant alleles of PAP1 were tested and all 
seemed to be resistant to cordycepin (figure 13). Interestingly, the mutant strains pap1-2, 
pap1-5 and pap1-7 appeared to grow even slightly better at semi-permissive temperature 
(33 °C) in presence of cordycepin than without. 
 
 
 
 
 
Figure 13 PAP1 temperature sensitive mutant strains are resistant to cordycepin. 
Ten-fold serial dilutions of the yeast strain indicated on the left were dropped on SD plates 
containing or lacking cordycepin [40 µg/ml]. The plates were incubated at the indicated 
temperatures for 3 days.  
wild-type
pap1-2
pap1-5
pap1-7
30 °C 33 °C 37 °C
cordycepin µg/ml 40 400 0 0
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1.3 Effect of cordycepin on poly(A) tails 
 
Since cordycepin is thought to have an affect on polyadenylation, poly(A) tail length 
distribution was analysed in wild-type cells in presence of cordycepin. Wild-type cells 
shifted to 40 µg/ml cordycepin showed a decrease in the poly(A) tails levels after 60 
minutes (figure 14 A). The poly(A) tail signal was even fainter after 120 minutes. Poly(A) 
tails seems to decrease in presence of cordycepin. When wild-type cells were grown for 6 
hours at different cordycepin concentrations, the signal for the poly(A) tails was as well 
decreasing (figure 14 B). The addition of 20 – 60 µg/ml cordycepin resulted in a slight 
decrease of poly(A) levels, 80 µg/ml cordycepin led to a pronounced decrease of poly(A) 
tails. However, the length distribution of the poly(A) tails did not change upon cordycepin 
addition.  
 
 
Figure 14 Poly(A) tail length distribution analysis.  
Poly(A) tail length distribution assay of wild-type cells. Total RNA was extracted and 
labelled with Pap1p and radioactive cordycepin. The RNA was digested with RNase A and 
T1 and the remaining poly(A)RNA was separated on a 15% polyacrylamid gel. The 
position and size in number of nucleotides is indicated on the left. A) Wild-type cells were 
shifted to 40 µg/ml cordycepin and cells were harvested at the indicated time points. B) 
Cells were cultured at the indicated cordycepin concentration and harvested after 6 hours. 
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1.4 Cordycepin affects poly(A) site selection 
 
RNA levels were examined in wild-type strains after a shift to cordycepin (figure 15). A 
decrease in mRNA levels of CYH2, ADH1, ACT1 and ASC1 was observed, with a 
pronounced drop between 60 min and 120 min. A reduction of RNA levels has as well 
been observed for transcriptional inhibitors such as 6-Azauracil (Lennon et al., 1998) or  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 RNA levels after the addition of either 20 or 40 µg/ml cordycepin.  
Northern blot of total RNA extracted from wild-type cells at the indicated time after the 
shift to media containing cordycepin at the displayed concentration. The membrane was 
hybridised with random-primed labelled probes against the different mRNA species and 
with labelled primers against 18 S rRNA and U3. The asterix marks extended RNAs. 
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cells carrying a temperature sensitive mutation in RPB1 (Herrick et al., 1990). The levels 
of PGK1 mRNA were only slightly affected by cordycepin, because PGK1 is a very stable 
mRNA with a half-time of more than 90 minutes (Wang et al., 2002). The observed level 
of the decrease might be related to the respective mRNA stability. The RNA levels of 18S 
rRNA and U3 were as well not affected by cordycepin. The same effect was observed with 
a drug concentration of 40 µg/ml. CYH2, ASC1 and ACT1 pre-mRNA contain introns, but 
only the pre-mRNA of CYH2 can be detected on a Northern blot. Furthermore, additional 
longer CYH2 transcripts could as well be observed. To test, whether the extended CYH2 
RNAs still contain the intron, the membrane was hybridised with a probe against the intron 
sequence of CYH2 (figure 16). The extended RNAs were detectable with an intron-probe 
indicating that these RNAs were unspliced read-through products. 
Extended RNAs were also observed for ACT1 and ASC1 transcripts, although the 
enlarged RNAs were similar in length leading to the suggestion, that different poly(A) sites 
may be used to generate these extended transcripts. To analyse the distribution of the 
3’ ends of the ASC1 and ACT1 transcripts at different time points after the shift to 
cordycepin, the RNAs were analysed on an acrylamide Northern gel after cleavage with 
RNase H and an oligonucleotide near the 3’ end of the open reading frame. In the wild-
type strain, the ACT1 mRNA has five 3’ ends (Manhart and Parker, 1995) labelled I to V 
on the scheme of the 3’ end of ACT1 (figure 17 A). Under normal growth conditions, site I 
 
 
Figure 16 RNA levels for CYH2 mRNA and pre-mRNA. 
Northern blot of total RNA extracted from wild-type cells at the indicated timepoints after 
the shift to media containing cordycepin at the displayed concentration. The membrane 
was hybridised with random-primed labelled probes against A) CYH2 mRNA and B) 
CYH2 intron. The asterix marks extended RNAs.  
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Figure 17 Cordycepin alters the relative levels of different 3’ ends of the ACT1 and 
ASC1 mRNA. 
A) Total RNA extracted from wild-type cells was digested with RNase H at the 3’ end of 
the open reading frame, separated by a 8 % denaturing polyacrylamidgel and blotted to a 
nitrocellulose membrane. The membrane was hybridised with random-primed labelled 
probes against the 3’ UTR to analyse the relative usage of the different poly(A) sites. A 
scheme of the observed poly(A) sites is shown at the top and the quantification of the 
relative usage of the most distal site is shown on the right. B) The same analysis for ASC1. 
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is used the most and almost 60% of the ACT1 transcripts are cleaved at site I (Manhart and 
Parker, 1995), whereas site V is used only to 11%. However, the relative usage of the 
different poly(A) sites changed dramatically in the presence of cordycepin. The same five 
poly(A) sites were detectable, but the relative usage of site V changed from 6% to almost 
40% after 120 minutes after the cordycepin shift. 
Similar results were also seen with the ASC1 mRNA. However, before the addition 
of cordycepin four poly(A) sites were detectable labelled I to IV (figure 17 B). The relative 
usage of the most distal poly(A) site IV is 25%. This proportion changed to almost 100% 
after 120 minutes after cordycepin addition. These results suggest that cordycepin leads to 
an alteration in the specificity of the site of polyadenylation. Two possible explanations 
could interpret that cordycepin led to the production of different levels of the multiple 3’ 
ends of ACT1 and ASC1 mRNAs. On the one hand, cordycepin may affect the relative 
stabilisation of the different transcripts by either destabilising the shorter transcripts or by 
stabilising the longer mRNAs. On the other hand, cordycepin could interfere with the 
poly(A) site recognition mechanism by altering the actual efficiencies of the different 
polyadenylation sites. 
 
 
1.5 Concentration dependent effect of cordycepin 
 
The RNA levels of different RNA species were analysed in wild-type cells at different time 
points after a shift to different concentrations of cordycepin. Levels of 18 S rRNA and 
tRNA3LEU were not affected by cordycepin, not even at the highest used concentration of 
96 µg/ml (figure 18). In the case of mRNAs, the decrease of the respective mRNA signal 
was generally more prominent at the highest concentration. The decrease is again mRNA 
dependent, as the decrease in ADH1 and ACT1 mRNA levels was more dramatic than for 
the stable PGK1 mRNA, which seemed to be resistant to the presence cordycepin for at 
least 120 minutes. 
However, the extended RNAs of CYH2 and the poly(A) site shift of ACT1 and 
ASC1 mRNAs seemed to be produced most efficiently at a cordycepin concentration of 
16 µg/ml. This is most apparent in the case of ASC1 by comparing the signal at 120 
minutes after the shift to cordycepin at different concentrations. 16 µg/ml of cordycepin 
caused an almost complete change in the poly(A) site usage to the most distal site. At a 
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concentration of 32 µg/ml the relative usage of site IV is reduced and at 96 µg/ml the 
lower band seemed to be as intense and the upper band. These results suggest, that 
cordycepin has a concentration dependent effect. At lower concentrations, the drug might 
 
 
Figure 18 Cordycepin effects mRNA in a concentration dependent manner. 
Northern blot of total RNA extracted from wild-type cells at the indicated time after the 
shift to cordycepin at the indicated concentration. The membrane was hybridized with 
random-primed labelled probes against the different mRNA species and with labelled 
primers against 18S rRNA and tRNA3LEU.  
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interfere with the mechanism of polyadenylation site recognition leading to an increase in 
the use of the more distal poly(A) site. At higher concentration the primary effect of 
cordycepin might be the interference with the process of transcription per se leading to a 
drop of total mRNA levels. 18S rRNA and tRNA3LEU levels were not changed even after 
the addition of hight concentration of the drug.  
 
 
1.6 Mutations in PAP1 suppress cordycepin induced changes in 
poly(A) site usage  
 
The CF IA subunits RNA14 and RNA15 are involved in polyadenylation site recognition, as 
mutations in both genes alter poly(A) site usage in favour for the most distal 
polyadenylation site (Mardart and Parker, 1995). A similar poly(A) site shift  has been 
reported for the pap1-1 mutant strain. Since mutations in these three genes cause a poly(A) 
site shift, the distribution of the 3’ ends of ACT1 was analysed in presence of cordycepin. 
An alteration in the distribution of the polyadenylation site usage was observed in the 
rna14-1 mutant strains after the addition of cordycepin at 30 °C and as well at 33 °C 
(figure 19). However, all tested PAP1 mutant strains do not show any change in the 
poly(A) site usage in presence of cordycepin at permissive, semi-permissive or restrictive 
temperature. Cordycepin is therefore able to act differently in mutant strains with altered 
poly(A) site distribution. This result could indicate that cordycepin resistance correlates 
with the suppression of a poly(A) site shift on ACT1 mRNA (see below).  
 
 
1.7 Microarray analysis of wild-type and pap1-1 in absence and 
presence of cordycepin 
 
Cordycepin caused an alteration in the polyadenylation site usage in ACT1 and ASC1 
mRNA in wild-type cells, but not in the cordycepin resistant PAP1 mutant strains. How 
cordycepin changes polyadenylation site usage is unclear, as well as the mechanism by 
which the resistant PAP1 mutants suppresses the actions of cordycepin. To get further 
insight into the primary effects of cordycepin and the mechanism by which cordycepin 
could interfere with poly(A) site recognition, gene expression levels was analysed by 
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microarray. In such a gene expression profiling experiment, the levels of thousands of 
transcripts can be simultaneously monitored to study the effects of treatments such as the 
addition of cordycepin. With this tool genes can be identified whose expression is changed 
in response to cordycepin. This might provide significant insight into the biological mode 
of action of cordycepin.  
The outline of this experiment was to compare RNA levels of wild-type strain 
S288C and the temperature sensitive mutant strains pap1-1 in presence and absence of 
cordycepin. Both strains were cultivated at 25 °C and shifted to 40 µg/ml cordycepin for 
60 minutes; the pap1-1 mutant strains was furthermore shifted to restrictive temperature 
without cordycepin to analyse whether the loss of PAP1 and the addition of the PAP1 
 
 
Figure 19 Cordycepin suppresses poly(A) site shift in PAP1 mutant strains. 
Northern blot of total RNA extracted from indicated strains at the indicated time after the 
shift to [40 µg/ml] cordycepin at the indicated temperature. The membrane was hybridised 
with random-primed labelled probes against ACT1 mRNA.  
 Results 
 70 
inhibitor cordycepin indeed initiate the same response in the cell. All cultures were grown 
in triplicates and all four  conditions were analysed relative to the untreated wild-type to 
directly compare all four conditions. Total RNA was extracted and reverse transcribed into 
cDNA using an oligo(dT) primer and a random nonamer primer. For the reverse 
transcription reaction, aminoallyl dUTP was provided as a component of the 
deoxynucleotide stock. Incorporated aminoallyl dUTP was coupled with the N-
hydroxysuccinimid linked flourophorr Cye3 or Cye5. The fluoroscent targets were pooled 
and hybridised under stringent conditions to the oligo array. Laser excitation of the 
incorporated targets yielded an emission with a characteristic spectrum, which was 
measured by a scanning confocal laser microscope (figure 20). The resulting monochrome 
images were imported into software (GenePix) in which the images were pseudo-coloured 
and merged. Data from each single hybridisation dot was expressed as the log2 scale of the 
normalised ratio of Cye3/Cye5. According to this, a log2 value of 0 stands for equality in 
the respective gene expression and positive numbers indicate a relative increase in the 
 
 
Figure 20 Graphical representation of the different steps of a two-colour microarray 
experiment (modified from Duggan et al., 1999). 
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respective RNA abundance and negative numbers represent a decrease relative to the 
reference. For this experiment, the limit for increased and decreased RNA levels was set at 
a log2 value of 1 of -1 respectively; meaning when the respective RNA levels were at least 
two-fold increased or decreased.  
 
1.7.1 Effect of cordycepin in the wild-type strain 
 
The data of two individual experiments were collected, combined and the average for each 
data point was calculated. This average number was used for further analysis. Cordycepin 
caused in the wild-type strain an increase fold in 222 RNAs, and a decrease in 72 RNAs. 
This is a surprising result since one could assume that cordycepin as a inhibitor of 
polyadenylation might cause a more general decrease of RNA levels. All identified 
increased or decreased RNAs were categorised with the Gene Ontology (GO) terminology 
(figure 21). The cellular compartment with the highest number of proteins generated of the 
increased RNA section were the nucleus (80 proteins), followed by the cytoplasm 
(39 proteins), mitochondrion (24 proteins), cytosol (8 proteins) and the endoplasmatic 
reticulum (7 proteins), however, most proteins (93) could no be localised to a specific 
compartment. The cellular functions allotted with the highest number of proteins were: 
catalytic function (45 proteins), transport (11 proteins) and transcriptional regulation 
(5 proteins). The majority of proteins (129) however, could not be assigned to a specific 
cellular function. The three most prevalent biological processes were a cellular process 
(98 proteins), metabolic process (54 proteins) and transport (23 proteins), but for most 
proteins (102), the biological process was not known. 
The decreased RNA section was examined the same way and most of the respective 
proteins localise to the nucleus (37 proteins), followed by the cytoplasm (25 proteins), the 
mitochondrion (13 proteins), the cytosol (11 proteins) and for 37 proteins the cellular 
localisation is not known. 27 proteins hold a catalytic activity, 7 proteins a transporter 
activity and 31 could not be assigned to a specific cellular function. Cordycepin affected 
RNAs involved in all kind of cellular compartments, and similarly affected different 
biological processes and molecular functions. But none of the gene ontology terms was 
significantly overrepresented in the increased or the decreased RNA cluster. Cordycepin 
seemed to exhibit a more uniform cellular effect since no biological pathway was activated 
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Figure 21 Cordycepin seems to stabilise RNA transcripts derived from hORFs. 
Increased and decreased RNA in wild-type strains after cordycepin addition were analysed 
according to the annotated compartment, function and process of the respective protein. 
The numbers reflect the amount of RNAs annotated to the specific term. 
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or inactivated in response to the presence of the drug, which makes it difficult to get 
further evidence in the characterisation of the mode of action of this compound. 
An interesting observation was that the analysis of the 222 increased RNAs 
revealed that the greatest section of these RNAs could not be annotated to any 
compartment, function or process (figure 21). The amount of RNA transcripts of unknown 
function seemed to accumulate in presence of cordycepin. 44.1% of the increased RNA 
transcripts were annotated to the term hypothetical ORF (hORF), whereas only 27.4% of 
the decreased RNA fraction and 22.6% of the number of RNAs obtained after processing 
the raw data were hORFs. Generally, hORFs describe open reading frames of unknown 
function or genes for which only extremely limited information about their function has 
been obtained. In many cases, the ORFs have been predicted from complete genomes 
using gene-finding programmes and the genomic sequence of hORFs does usually not 
comprise any homology to other genes. These ORFs are transcribed, but are non-coding 
(Kowalczuk et al., 1999). The number of hORFs almost doubled in presence of 
cordycepin. 
Recently, cryptic unstable transcripts (CUTs) have been characterised as short (300-
600 nt) noncoding RNA transcripts that correspond to inter- and intragenic regions of the 
genome (Wyers et al., 2005). 10% of intergenic transcripts in S. cerevisiae may represent 
CUTs. They are highly unstable and therefore hardly detectable in wild-type cells. CUTs 
can be visualised by disrupting TRF4, the poly(A) polymerase subunit of the TRAMP 
complex or RRP6, the nonessential subunit of the nuclear exosome. To analyse whether 
cordycepin might have an effect on the stabilisation of CUTs, Northern blot analysis was 
carried out. In wild-type cells, the CUT NEL025c was not detectable (figure 22). In the two 
gene deletion strains ∆TRF4 and ∆RRP6, the CUT was detected as a smeary band. It was 
reported that the RNA transcript of NEL025c extends from a defined 5’ end to multiple and 
closely spaced 3’ end which are polyadenylated by Trf4p or Trf5p (Wyers et al., 2005). 
The destabilising effect of polyadenylation can be carried out by Trf4p or Trf5p, 
explaining the stronger signal of NEL025c in the ∆RRP6 mutant. In presence of 
cordycepin, the NEL025c transcripts were extended and a signal of significant longer 
transcripts was observed. These extended transcripts may arise from the same two possible 
mechanisms as proposed for the extended transcripts observed in ACT1, ASC1 and CYH2 
mRNA: Cordycepin could either interfere with poly(A) site selection with the tendency to 
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use the more distal poly(A) sites more often or cordycepin could have a stabilising effect 
on the elongated transcripts. 
 
1.7.2 The effect of cordycepin in the pap1-1 mutant strain 
 
In this microarray analysis, RNA extracted from wild-type cells was directly compared 
with the temperature-sensitive mutant pap1-1 cultured at permissive temperature. This 
experiment was carried out to compare the effect of the mutant form of Pap1p with the 
effect of cordycepin in wild-type cells. Since cordycepin is thought to act as a 
polyadenylation inhibitor, both conditions are thought to affect the same process and might 
show a similar gene expression pattern. Since PAP1 mutants showed resistance to 
cordycepin the microarray data might give insight into the cellular effect of the pap1-1 
mutation. The analysis of the microarray data revealed that 323 RNAs were increased and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Cordycepin stabilises the CUT NEL025c. 
Northern blot of wild-type, ∆TRF4 and ∆RRP6 strains which were shifted to 20 µg/ml 
cordycepin for 60 minutes. Total RNA was extracted and a Northern blot was performed. 
The membrane was hybridised with random-prime labelled probes against the CUT 
NEL025c. The asterisks mark the elongated CUT transcripts. 18S rRNA served as control. 
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Figure 23 Pap1-1 mutation seems to enrich RNA transcripts assigned to the 
mitochondrion.  
Increased and decreased RNA in wild-type strains after cordycepin addition were analysed 
according to the annotated compartment, function and process of the respective protein. 
The numbers reflect the amount of RNAs annotated to the specific term. 
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144 RNAs were decreased more than two-fold in the pap1-1 mutant compared to the wild-
type S228C.  
 The RNAs were grouped according to their compartment and function (figure 23) 
and interestingly, 122 of the 323 increased RNAs were assigned to the mitochondrion. And 
even more interestingly, RNAs involved in the process of ATP synthesis and oxidative 
phosphorylation were highly enriched in the increased RNA fraction (table 4).  
 
 Gene ontology term p-value 
wt/pap1-1 
p-value 
wt/pap1-1 + Co 
component mitochondrial membrane part 9.16 E -28 1.75 E -23 
 
mitochondrial respiratory chain 1.73 E -26 2.45 E -21 
 
mitochondrion 3.69 E -22 2.13 E -16 
 
proton-transporting ATP synthase complex 8.97 E -15 7.52 E -16 
 
proton-transporting two-sector ATPase complex 1.01 E -09 3.14 E -10 
function hydrogen ion transmembrane transporter activity 1.84 E -24 3.04 E -20 
 
monovalent cation transmembrane transporter 5.75 E -23 6.55 E -19 
 
oxidoreductase activity 6.21 E -23 2.79 E -20 
 
cation transmembrane transporter activity 1.07 E -14 1.61 E -11 
 
ion transmembrane transporter activity 1.08 E -14 9.78 E -11 
 
hydrogen ion transporting ATP synthase activity 2.39 E -10 8.98 E -10 
process oxidative phosphorylation 1.43 E -40 1.19 E -38 
 
generation of precursor metabolites and energy 2.69 E -35 1.42 E -33 
 
electron transport chain 3.17 E -25 2.99 E -20 
 
respiratory electron transport chain 3.17 E -25 2.99 E -20 
 
ATP synthesis coupled electron transport 3.17 E -25 2.99 E -20 
 
oxidation reduction 3.17 E -25 2.99 E -20 
 
phosphorylation 4.22 E -19 3.25 E -17 
 
ATP biosynthetic process 2.52 E -14 2.13 E -15 
 
purine nucleoside triphosphate biosynthetic  2.55 E -13 2.99 E -14 
 
proton transport 1.80 E -12 2.68 E -13 
 
hydrogen transport 1.80 E -12 2.68 E -13 
 
ribonucleoside triphosphate biosynthetic process 1.80 E -12 2.68 E -13 
 
Table 4 PAP1 mutation leads to an increase of RNAs involved in ATP synthesis. 
Enriched gene ontology terms of increased RNAs in pap1-1 cultured at permissive 
temperature with the respective p-value. 
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This observation may indicate that a less effective Pap1p reflects a low ATP status and 
might therefore stimulate the cell to increase of ATP synthesis. 
If pap1-1 mutants were cordycepin resistant because of elevated ATP synthesis, the 
addition of ATP to the media might suppress the resistance. However, yeast does not have 
an adenosine transporter (Mäser et al., 1999). Therefore, pap1-1 and pap1-2 mutants were 
dropped on plates containing cordycepin plus additional adenine. Elevated adenine could 
suppress the cordycepin sensitivity in the wild-type strain (Figure 24). But no effect on the 
resistant growth of the PAP1 mutants was observed, independently of the temperature at 
which they were incubated (except that pap1-1 didn’t grow at 33 °C). In summary, the 
effect of cordycepin on growth could be diminished by the addition of adenine in wild-type 
cells, but had no effect on PAP1 mutants.  
RNA levels of pap1-1 cells shifted to cordycepin for 60 minutes were directly compared to 
wild-type RNA levels. This gene expression pattern could then be compared to the data 
from pap1-1 mutants, gaining further insight into the effect of cordycepin. The microarray 
analysis revealed 361 increased and 126 decreased RNAs relative to the wild-type. These 
increased and decreased RNAs were found to be highly similar to those observed in the 
pap1-1 cell without cordycepin (table 4). Therefore, cordycepin has no effect in this 
mutant strain.  
 
Figure 24 Supplementation of adenine suppresses cordycepin sensitivity of wild-type 
cells. 
Ten-fold dilutions of yeast strains as indicated on the left were dropped on SD plates 
containing the indicated supplements and incubated at the displayed temperature for 3 
days.  
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1.7.3 Effect of PAP1 shutoff 
 
In this microarray analysis, RNA extracted from wild-type cells was compared with the 
temperature-sensitive mutant pap1-1 shifted to restrictive temperature for 60 minutes. The 
analysis of the microarray data revealed that 580 RNAs were increased and 870 RNAs 
were decreased more than two-fold. In the decreased RNA fraction, the component of the 
ribosome and the process of translation was highly enriched (table 5). No other process or 
function was significantly enriched in the decreased or increased RNA pool. However, the 
shutoff with pap1-1 requires a temperature shift, which has been shown to cause even in a 
wild-type strain a rapid decrease in mRNA levels (Herruer et al., 1988; Li et al., 1999). 
This decrease appears to be due to a rapid and transient arrest of general transcription in 
yeast cells resulting in an overall decrease in mRNA levels (Warner, 1999). Levels of 
ribosomal protein transcripts are affected most prominently (Wang et al., 2002). In 
addition to having short inherent half-lives, these transcripts comprise roughly 50% of the 
mRNA of actively growing yeast (Li et al., 1999). In summary, the data of this array must 
be compared to data obtained from a wild-type strain shifted to 37 °C, otherwise the effect 
of the transcriptional decay of ribosomal RNA might be too prominent to detect any other 
change in RNA levels. 
 
 gene ontology term p-value 
compartment cytosolic ribosome 2.03 E -84 
 
ribosomal subunit 2.66 E -56 
 
ribosome 3.06 E -52 
 
large ribosomal subunit  1.29 E -46 
 
small ribosomal subunit 9.16 E -35 
 
ribonucleoprotein complex 1.07 E -26 
function structural constituent of ribosome 3.53 E -58 
 
structural molecule activity 8.67 E -41 
process cellular biosynthetic process 4.98 E -25 
 
translation 2.12 E -16 
 
Table 5 Shutoff of PAP1 leads to a decrease of RNAs encoding ribosomal compounds.  
Enriched gene ontology terms of decreased RNA in pap1-1 after 60 minutes at restrictive 
temperature with the respective p-value. 
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2 Systematic and genome-wide screening for factors involved 
in transcription and associated pre-mRNA processing with 
the adenosine analogue cordycepin 
 
Although the core machinery for pre-mRNA 3’ end formation and transcriptional 
termination has been well characterised (Proudfoot, 2004), it seems likely that additional 
proteins may act at the interface between transcription and processing. Gene deletions that 
render cells hypersensitive or resistant to a specific drug can lead to the identification of 
pathways that buffer the cell against the toxic effects of the drug and might thereby also 
provide clues about its mode of action (Lum et al., 2004; Parsons et al., 2004). To identify 
such proteins the yeast knock out collection was screened for growth phenotypes in the 
presence of the RNA chain terminator cordycepin. The yeast gene deletion library consists 
of 4825 strains which contain each a deletion in a non-essential gene. Two different 
screening approaches were carried out: a simple drop test and a functional profiling screen.  
 
 
2.1 Drop test screen with cordycepin 
 
In the simple drop test, a small liquid culture of each gene deletion strain was dropped on 
synthetic complete plates containing or lacking cordycepin. Growth of individual strains 
was analysed after incubation at 30 °C for three days (figure 25). All strains from the gene 
deletion library were initially screened by a single drop test with a cordycepin 
concentration of 20 µg/ml. The identified strains were then re-examined on plates 
containing 20 µg/ml or 40 µg/ml with a drop test were three ten-fold dilutions of the initial 
culture were used. With the drop test, 155 cordycepin sensitive strains and 9 resistant 
strains were identified. Resistant growth on a plate is very difficult to identify by eye, 
which might be the reason for the low number of identified resistant strains (table 6). 
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2.2 Functional profiling 
 
The second approach was a chemical profiling screen. The yeast gene deletion library was 
constructed by the homologous recombination of each non-essential gene locus with an 
individual kanMX deletion cassette conferring G418 resistance (figure 26) (Giaever et al., 
2002). The kanMX marker contains two distinct 20 nucleotide sequences (UPTAG and 
DNTAG) that serve as molecular bar codes to uniquely identify each mutant. These 
individual tags are flanked by two 17-19 nucleotide sequences (blue), which are identical 
for all constructed gene deletion strains. This allows the pooling of all gene deletion strains 
and their simultaneous analysis. The pool of mutants can be subjected to selection, for 
example in the presence of cordycepin. Mutants that are sensitive to cordycepin will grow 
slower and will be underrepresented in the culture applied to selection compared to the 
non-treated control. On the other hand, mutants which are resistant to cordycepin will grow 
faster and will be overrepresented in the cordycepin containing culture compared to the 
reference. After isolation of genomic DNA, the individual bar codes from each culture can 
be amplified by PCR and labelled by using differently tagged nucleotides. The labelled 
probes are pooled and hybridised on an oligonucleotide array. The growth of each strain in 
presence of selective pressure can thereby be directly compared to its reference growth.  
 
 
 
 
Figure 25 Cordycepin responsive strains. 
Ten-fold serial dilutions of the yeast strain indicated on the left were dropped on SD plates 
containing the indicated cordycepin concentrations. The plates were incubated at 30 °C 
for 3 days.  
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The big advantage of this screening approach is that the fitness of each gene deletion strain 
can be quantitatively scored and already small changes in growth can be detected. 
However, gene deletions, which cause a strongly reduced growth will be strongly diluted 
in the culture and no signal can be obtained from these strains (around 300 – 400 strains). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 Principle of the functional profiling (Ooi et al., 2006). 
A) The kanMX deletion cassette (not in scale) integrated in each gene deletion strain. It 
contains the kanMX marker (pink) and two unique barcodes (red; UPTAG and DNTAG), 
which are flanked by two universal priming sites (blue). The genomic sequence 
surrounding the integrated cassette is shown in yellow. B) Schematic outline of the 
functional profiling assay. Gene deletion strains are pooled and analysed in parallel. After 
a competitive growth, genomic DNA is extracted and the unique barcodes are amplified 
using differently labelled universal primers. Hybridisation to an oligo array reveals the 
relative abundance of each gene deletion strain in the two cultures. 
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Optimal results are obtained with this method with an applied selective pressure 
that causes a growth inhibition of 5 – 10% on wild-type cells (Alain Jaquier, personal 
communication). To find the respective cordycepin concentration growth analysis was 
performed. Wild-type strain was subjected to different cordycepin concentrations and 
growth of the cultures was monitored by measuring the OD600 every hour (figure 27). The 
cultures were kept in exponential growth phase and diluted when reaching an OD600 of 0.5. 
From the resulting growth curves it was deduced that 20 µg/ml cordycepin caused an 
inhibition of wild-type growth of around 10%.  
The yeast gene deletion cell pool used for this experiment was obtained from Alain 
Jaquier from the Institute Pasteur in Paris. The cultures were grown in duplicates, and yeast 
strain pools were collected after 12 and 18 generations. The labelling of the probes and the 
microarray hybridisations were carried out in the lab of Alain Jaquier. The microarray data 
from the functional profiling were defined as the log2 value of the ratio 
+Cordycepin/reference. All gene deletion strains with a value of 1 or higher were 
considered cordycepin resistant. 
 
 
 
 
Figure 27 Growth curve of wild-type yeast subjected to different cordycepin 
concentrations. 
The graph represents the growth behaviour of wild-type strains at 30 °C subjected to 
different cordycepin concentrations. The strains were grown in exponential growth and 
diluted if they reached an OD of 0.5. The OD was measured every hour and the growth 
determined as the log(ODt/ODto). 
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The gene deletion strains with a value of -1 or smaller were defined as cordycepin 
sensitive. After 12 generations, 132 strains were identified as sensitive to cordycepin and 
73 as resistant. After 18 generations, 281 strains were sensitive and 215 strains were 
resistant (table 6). The numbers of identified strains more than doubled from generation 12 
to generation 18, indicating that also slight growth changes were identified. However, 
initially we focused for further analysis mostly on the data generated after 12 generations. 
Almost all strains that were identified as cordycepin sensitive or resistant after 12 
generations appeared as well after 18 generations. 
 
 
 sensitive overlap resistant overlap 
drop test 155 34 9 3 
functional profiling 
12 generations 132 34 73 3 
functional profiling 
18 generations 281 34 215 3 
 
Table 6 Identified cordycepin sensitive and resistant gene deletion strains. 
Overlap describes the number of gene deletion strains that were identified in the drop test 
and the function profiling screening approach. 
 
 
2.3 Analysis of the screening results 
 
Parsons and co-workers presented a functional profiling analysis in S. cerevisiae using 82 
compounds and natural product extracts (Parsons et al., 2006). Combining all obtained 
chemical-genetic profiles, they identified a set of 121 genes whose corresponding deletion 
mutant displayed statistically significant multi drug sensitivity. These multi drug sensitive 
genes include genes whose deletion leads to an increased membrane permeability, for 
example ERG5 encoding a drug-efflux pump or PDR1, which encodes for a transcription 
factor that regulates gene involved in multi drug resistance (Parsons et al., 2006). 173 gene 
deletion strains were identified as multi drug resistant. Most of these strains have a deletion 
in a gene encoding for a ribosomal protein and were generally growing slowly, which 
 Results 
 84 
apparently resulted in the observed multi drug resistance phenotype. Genes whose deletion 
provokes a multi drug resistance or sensitivity were removed from the identified 
cordycepin sensitive of resistant mutants resulting in decreased numbers in the list 
(table 7). 
 
 sensitive overlap resistant overlap 
drop test 143 30 8 3 
functional profiling 
12 generations 123 30 55 3 
functional profiling 
18 generations 262 30 182 3 
 
Table 7 Identified cordycepin responsive gene deletion strains after the removal of 
multi drug sensitive and multi drug resistant strains. 
 
 
From tables 4 and 5 it is quite obvious that the overlap of the two screen results is 
rather small. Apparently, the environment of the yeast cells plays a tremendous role for the 
output of a screen. For the drop test screen, the yeast cells were grown on plates for 3 days, 
allowing the cells to exit exponential growth phase. In contrast, the yeast cells were grown 
in a liquid culture and kept in exponential growth phase for the functional profiling screen. 
Furthermore, the yeast gene deletion strains were pooled and cultured in a competitive 
manner. These circumstances could influence the result of a screening procedure. 
Moreover, many strains that were identified in the drop test but not in the functional 
profiling screen were lost because of the general slow growth of the mutant. 
The genes whose deletion causes cordycepin sensitivity or resistance were analysed 
according to their gene ontology (GO) terms in the category compartment, function and 
process (figure 28). Cordycepin seems to affect all cellular compartments and molecular 
processes, as the identified genes were not restricted to the compartment of the nucleus or 
the process of transcription. One could argue such a central process as transcription and 
mRNA formation might provoke global effects. The relative abundance of the respective 
GO terms was very similar for the genes resulting from the drop test and for those from the 
functional profiling. The additional genes identified in the functional profiling after 18 
generations were not uniformly distributed with regard to the GO term in the case for  
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Figure 28 Cordycepin sensitive and resistant gene deletion strains grouped by gene 
ontology terms. 
The most abundant gene ontology terms for component, function and process are shown.  
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cordycepin sensitive gene deletions. Genes localised to the cytoplasm, membrane and 
mitochondria having an unknown function were significantly enriched. For the genes 
whose deletion causes cordycepin resistance, these additional genes were distributed more 
uniformly.  
Some significantly enriched GO terms associated with cordycepin sensitivity are 
symbolised by a few examples in table 8. In both screens, genes that belong to a chromatin 
remodeler and which are involved in the process of the chromosomal architecture were 
highly enriched, especially subunits of the SWR1 complex. This complex mediates the 
ATP-dependent exchange of histone H2A for the H2A variant HZT1 leading to 
transcriptional regulation of selected genes by chromatin remodelling (Mizugushi et al., 
2004). Interestingly, the gene deletion strain (∆HTZ1) lacking this histone variant was as 
well identified as cordycepin sensitive. 
The term ‘RNA biosynthetic process’ is enriched in the sensitive part of the drop 
test only, and these genes function in different stages of transcription: SPT3, a subunit of 
the transcriptional activator complex SAGA, SPT4, a transcriptional elongation factor, the 
SWD1 subunit of the COMPASS complex, and RAI1, interacting with Rat1p and involved 
in transcription termination. This result may indicate that a screen using the adenosine 
analogue cordycepin can identify factors involved in transcription and associated pre-
mRNA processing. 
A third group of genes, which appeared only in the functional profiling screen, 
could be localised to peroxisomes and are involved in peroxisome biogenesis or transport 
into peroxisomes. The peroxisomes are small organelles participating in the metabolism of 
fatty acids and most interestingly, also in the catabolism of purines (Wanders and 
Waterham, 2006). Genes necessary for proxisome biogenesis are termed PEX genes (Kiel 
et al., 2006). Some of these PEX genes deletion strains displayed a strong sensitivity 
towards cordycepin. It might be that CoTP is also degraded in the peroxisomes. However, 
when genes important for peroxisome integrity and biogenesis were deleted, the process of 
purine catabolism could be carried out less efficiently. This might also lead to a less 
efficient CoTP degradation and a subsequent higher CoTP concentration in the cell. To test 
whether strains lacking PEX genes were also cordycepin sensitive in the drop test, some 
strains lacking a PEX gene were dropped on plates lacking or containing cordycepin 
(figure 29). The tested strains all exhibited reduced growth in presence of cordycepin, 
indicating that peroxisomes might be involved in the suppression of cordycepin toxicity. 
  87 
Component GO term p-value genes 
drop test chromatin remodeling 
complex 
2.42E-10 
 
SWC3 SWD1 HPC2 SWC5 SWR1 RSC1 SNF6 HIR3 BRE2 VPS71 ARP5 YAF9 HTZ1 HIR2 
ARP8 SNF2 
 
vacuolar proton-transporting 
ATPase complex 
1.89E-07 
 
VMA2 TFP1 VMA8 PPA1 VMA6 VMA4 TFP3 VMA13 
 
FP 12 peroxisome 8.09E-08 PEX22 PEX19 PEX5 PEX10 PEX3 PEX14 PEX4 PEX2 PEX1 PEX13 PEX12  
 
chromatin remodeling 
complex 
1.03E-06 
 
SWC3 LDB7 HPC2 SWC5 SWR1 VPS72 HIR3 BRE2 ARP6 VPS71 HTZ1 HIR2 
 
SWR1 complex 8.90E-07 SWC3 SWC5 SWR1 VPS72 ARP6 VPS71 
FP 18 mitochondrial inner 
membrane 
1.51E-13 
 
COR1 CBS1 CBS2 COQ4 COX20 BCS1 SHE9 QCR7 RIP1 PET117 PET122 QCR6 COX18 
SHY1 PET54 COX6 MDM31 YIA6 PET191 ATP7 PAM17 COX1 
 
peroxisome 
 
3.72E-07 
 
PEX22 PEX19 PEX5 PEX10 PEX3 PEX14 PEX8 PEX4 PEX2 PEX1 PEX13 PEX12 MLS1 
PEX17 PEX6 PEX15 PEX25 
 
mitochondrion 
 
3.32E-06 
 
SWC3 CYC3 GCV3 COR1 COQ1 RTC2 PDB1 YBR238C MRPL37 MRPL27 YCP4 IMG2 
CBS1 CBS2 COQ4 COX20 MRP1 BCS1 SHE9 QCR7 RIP1 CIN8  
 
SWR1 complex 1.85E-06 SWC3 SWC5 SWR1 VPS72 ARP6 VPS71 YAF9 
Process    
drop test maintenance of chromatin 
architecture 1.97E-11 
SWC3 SWD1 SPT7 HPC2 SWC5 BRE1 UME6 SUM1 SWR1 SPT3 ADA2 RAD6 RSC1 SPT4 
SNF6 HIR3 BRE2 VPS71 ARP5 YAF9 HTZ1 HST1 SPT20 HIR2 ARP8 NPT1 RFM1 SNF2 
LGE1 
 
RNA biosynthetic process 
 
4.93E-07 
 
SWD1 HPC2 BRE1 REG1 REF2 UME6 SUM1 SPT3 RPB9 SNF4 RAI1 RSC1 SPT4 GTR2 
BUD32 SNF6 STB5 CST6 GON7 HIR3 BRE2 SPT8 YAF9 SIN4 PHO80 HTZ1 HST1 THP1 
HIR2 NPT1 RFM1 SNF2 PHO85 
FP 12 peroxisomal transport 2.05E-14 PEX22 PEX19 PEX5 PEX10 PEX3 PEX14 PEX4 PEX2 PEX1 PEX13 PEX12 PEX6 PEX15 
 
histone exchange 5.86E-06 SWC3 SWC5 SWR1 VPS72 ARP6 VPS71 
FP 18 peroxisomal transport 9.01E-17 
 
PEX22 PEX19 PEX5 PEX10 PEX3 PEX14 PEX8 PEX4 DJP1 PEX2 PEX1 PEX13 PEX12 
PEX17 PEX6 PEX15 PEX25 
 
histone exchange 2.04E-05 SWC3 SWC5 SWR1 VPS72 ARP6 VPS71 YAF9 
 
mitochondrial respiratory 
chain complex assembly 
2.74E-06 
 
COX20 QCR7 PET117 SHY1 CBP4 PET191 COX17 COX19 COX12 
 
 
Table 8 Significantly enriched GO terms with the respective p-value of the identified genes whose deletion causes cordycepin 
sensitivity. 
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After 18 generations, genes localising to the mitochondria involved in cellular 
respiration and in the respiratory chain complex IV assembly were also identified as 
significantly enriched. The sensitivity caused by the deletion of these genes may only 
slightly hinder growth, since they were not enriched after 12 generations. This is very 
interesting, since mitochondria are the main sites of cellular ATP synthesis. This may 
imply that these strains have less a higher CoTP to ATP ratio possibly increasing the 
chance for an enzyme to choose CoTP instead of ATP as a reaction partner. This could 
lead to the observed cordycepin sensitivity of these strains. Additionally the drop test 
showed significantly enriched genes of the vacuolar ATPase complex and vacuolar 
proteins involved in the pH regulation. The lack of these vacuolar genes could also have an 
impact on relative ATP levels or relative ATP abundance, which might be the cause for the 
observed cordycepin sensitivity. 
Since both screening approaches were carried out to identify new factors involved 
in 3’ end formation the results from both screenings were combined and further 
experiments were focussed on genes localising to the nucleus or having an unknown 
function. Figure 30 summarises the selected genes and their function. In this selection, the 
consensus of the two screening results is also relatively small and. However, subunits of 
the chromatin remodeler SWR1 or SWI/SNF complex, genes involved in chromatin 
modification (SAGA complex, SET1 complex), general transcription factors and 
repressors, and genes having a function in mRNA processing and export can be found in 
 
 
 
Figure 29 PEX mutants are cordycepin sensitive.  
Ten-fold serial dilutions of the yeast strain indicated on the left were dropped on SD plates 
containing 40 µg/ml cordycepin. The plates were incubated at 30 °C for 3 days.  
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Figure 30 Selected genes, whose deletion causes cordycepin sensitivity, sorted according their function.  
The colour reflects the respective screening method, drop test only (yellow), functional profiling only (green) and both (red). 
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this selection. Also the term cell cycle and signal transduction appears and some genes 
with an unknown function. Moreover, it is unclear whether all hypothetical genes encode 
for proteins.  
In the drop test, strains lacking genes involved in RNA turnover were identified as 
cordycepin resistant (figure 31). At concentrations up to 120 µg/ml cordycepin no growth 
phenotype was observed in these strains, although wild-type cells growth was strongly 
reduced. Pop2p mediates 3' to 5' mRNA deadenylation, Ski3p forms a complex with the 
putative RNA helicase Ski2p and this complex plays a central role in the cytoplasmic 
degradation of mRNA mediated by the exosome (Wang et al., 2005). XRN1 encodes for a 
cellular 5’ to 3’ exonuclease that degrades the mRNAs after deadenylation and decapping. 
Loss of these genes leads to a stabilisation of mRNA and this apparently can suppress 
cordycepin toxicity. Ado1p is the adenosine kinase in yeast which converts adenosine to 
AMP. This gene is not essential in yeast, since AMP can still be produced form de novo 
purine biosynthesis. But cordycepin probably can not be converted into CoTP anymore, 
and therefore it can not cause termination of RNA synthesis.  
In the results from the functional profiling, the term ribosome and translation is 
enriched in the list of those genes, whose deletion causes cordycepin resistance. Strains 
lacking a gene involved in ribosomal stability or integrity are cordycepin resistant.  
 
 
 
Figure 31 mRNA stabilisation suppresses cordycepin toxicity.  
Ten-fold serial dilutions of the yeast strain indicated on the left were dropped on SD plates 
containing the indicated cordycepin concentration. The plates were incubated at 30 °C for 
3 days.  
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However, many multidrug resistance genes encode for ribosomal proteins, therefore it 
could be that the deletion of ribosomal proteins in general causes a resistance to many 
conditions or drugs. Therefore, the ribosomal genes were not further analysed. 
 
 
2.4 Poly(A) tail analysis 
 
To test whether some of the identified genes function in 3’ end formation, the 
poly(A) tail distribution was analysed in most of the cordycepin sensitive mutants (Martin 
and Keller, 1998). The poly(A) tails in yeast wild-type cells show a homogeneous 
distribution from approximately 10 to 70 added As. 
Many mutant strains revealed the same poly(A) length distribution, but in some 
mutants poly(A) tails were altered (figure 32), indicating that the deleted gene might have 
a function in polyadenylation and 3’ end processing. For a few mutant strains, the reason 
for the altered poly(A) tail structure is known, as for ∆XRN1. Strains lacking the 
cytoplasmic mRNA exonuclease accumulate mRNA with a truncated poly(A) tail resulting 
from deadenylation as the first step in mRNA turn over (Muhlrad et al., 1995). For most 
mutant strains with altered poly(A) distribution, the reason for it is not clear. In ∆THP1 
and ∆SAC3 strains an accumulation of short poly(A) and additionally extended poly(A) 
tails were observed. Yeast lacking THP1 or SAC3 has been shown to accumulate 
polyadenylated RNA in the nucleus (Fischer et al., 2002), however, what causes the 
accumulation of short poly(A) tails is unclear. The most intriguing poly(A) phenotype 
observed, the lack of any poly(A) tail signal in ∆PHO80 and ∆PHO85, was further 
analysed and is the principal subject of chapter three. 
 
 
2.5 Synthetic lethality test 
 
To further concentrate on genes harbouring a possible function in 3’ end formation, some 
selected genes were tested for a possible genetic interaction with RNA14 in a synthetic 
lethal test. RNA14 is an essential gene and is involved in cleavage and polyadenylation 
(Mandart, 1998). Synthetic lethality describes any combination of two separately non-
lethal mutations that leads to inviability (figure 33). A synthetic growth defect indicates a  
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Figure 32 Poly(A) tail length distribution is altered in many cordycepin responsive 
mutant cells. 
Poly(A) tail length distribution assay of cordycepin sensitive mutants  after growth at 30°C 
for 6 hours. Total RNA was extracted and labelled with Pap1p and radioactive cordycepin. 
The RNA was digested with RNase A and T1 and the remaining poly(A) tails  were 
separated on a 15% polyacrylamid gel. The position and size in number of nucleotides of 
the marker bands are indicated on the left. 
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combination of two separate non-lethal mutations and confers a growth defect more severe 
than that of either single mutation. The interpretation is that a synthetic growth defect 
reflects an important genetic interaction, whereas synthetic lethality reflects an essential 
interaction. 
In the temperature sensitive mutant rna14-1 carrying a URA3 plasmid containing 
the wild-type RNA14 gene, genes identified in the screen were deleted. Challenging these 
cells with 5-flouroorotic acid forces them to loose the plasmid, thus, exhibiting the double 
mutation. Many of the tested genes were indeed synthetic lethal in combination with 
rna14-1 (figure 34). APQ12 is involved in nucleoplasmatic transport of mRNA and 
∆APQ12 mutants show a defect in mRNA export (Baker et al., 2004). THP1 forms a 
complex with SAC3, which showed a growth defect in combination with rna14-1 and is 
involved in the coupling of mRNA 3’ end formation and export. HTZ1 is a histone H2A 
analogue, which is incorporated into chromatin by the SWR1 chromatin remodelling 
complex, whose SWR1 subunit exhibited a growth defect in combination with RNA14. The 
SNF6 and SNF2 subunits of the SWI/SNF complex exhibited as well a genetic interaction 
with RNA14. The two hypothetical transcripts YDL172c and YDL173w exhibited both a 
strong sensitivity against cordycepin and appeared in both screens. These two genes 
overlap almost completely. ISR1 encodes for a protein kinase of unknown function but is 
synthetic lethal with rna14-1. ISR1 displayed a physical overlap with the 3’ UTR of YTH1, 
an essential factor of the 3’ end machinery. Disrupting ISR1 might lead to a less efficient 
YTH1 mRNA production, which could be responsible for the observed cordycepin 
sensitivity. Apparently, a gene deletion can also indirectly cause sensitive growth in 
presence of cordycepin. This example nicely illustrates that using cordycepin for screening 
the gene deletion library indeed revealed mutants having a defect in 3’ end formation. 
 
 
 
Figure 33 Principle of synthetic lethality. 
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Figure 34 Synthetic lethality test with rna14-1. 
Ten-fold serial dilutions of the yeast strain indicated on the left were dropped on SD plates 
containing 1 mg/mg 5’ fluoroorotic acid (5-FOA) as indicated. The plates were incubated 
at 30 °C for 3 days.  
 
 
effect genes 
synthetic lethality APQ12, ECM30, HTZ1, ISR1, PHO80, RPB9, SNF6, THP1, RAI1, YDL172c, YDL173w 
growth defect AKR1, BUB1, CST6, RMD7, SNF1, SNF2, SPT8, SWR1, SAC3 
normal growth GTR1, MUD2, PEP5 
 
Table 9 Summary of tested genetic interactions with rna14-1. 
Tested genetic interactions with rna14-1 were listed according to the growth phenotype of 
the double mutant. 
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 From the tested 23 genes, eleven genes were synthetic lethal, nine genes showed a 
genetic interaction, but only three genes exhibited no genetic interaction with RNA14, 
suggesting that most of the identified genes might have a synergistic function with respect 
to RNA14 (table 9). 
 
 
2.6 Elongated RNA transcripts in cordycepin sensitive mutants 
 
Several cordycepin sensitive gene deletion strains were selected and tested for the presence 
of elongated transcripts as had been observed in wild-type cells shifted to cordycepin. 
Therefore, Northern blot analysis was performed with eleven gene deletion strains before 
and after the addition of cordycepin to the culture. CYH2 hybridisation revealed that none 
of the tested mutant strains exhibited extended CYH2 transcripts, only upon cordycepin 
addition longer RNA transcripts were observed (figure 35). Poly(A) site usage was 
analysed in ACT1 and ASC1 mRNA. Ref2p is the only not essential protein of the core  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 Cordycepin sensitive mutants display an alteration in the poly(A) site usage 
of ACT1 and ASC1 mRNA and elongated CYH2 transcripts in presence of cordycepin. 
Northern blot of total RNA extracted from wild-type and mutant strains cultured in 
presence of absence of cordycepin [20 µg/ml]. The membrane was hybridized with 
random-primed labelled probes against ACT1, ASC1 and CYH2 mRNA. The asterisks 
mark elongated CYH2 transcripts. 
 Results 
 96 
3’ end machinery and therefore ∆REF2 mutants showed a preferred usage of more distal 
poly(A) sites than wild-type cells without the addition of cordycepin. All tested mutants 
seemed to have a normal poly(A) site usage in the absence of cordycepin, which was 
altered when cordycepin was added. 
Since cordycepin also led to elongated transcripts of the CUT NEL025c in the 
∆TRF4 and ∆RRP6 mutant strains, this transcript was also analysed for the selected mutant 
strains (figure 36). Although wild-type cells do not accumulate the NEL025c transcript in 
presence of cordycepin, Northern blot analysis revealed that in the ∆HTZ1 and ∆SWR1 a 
smear of a signal was observed in presence of cordycepin, similar to that observed in the 
∆TRF4 mutant. However, further analysis of a possible accumulation of elongated 
NEL025c and possibly also of other CUTs in these two mutant strains is necessary to draw 
a final conclusion.  
 
 
 
 
Figure 36 Cordycepin might lead to an accumulation of the CUT NEL025c in some 
cordycepin sensitive mutants 
Northern blot of total RNA extracted from wild-type and mutant strains cultured in 
presence of absence of cordycepin [20 µg/ml]. The membrane was hybridized with 
random-primed labelled probes against the CUT NEL025c. The asterisks mark elongated 
NEL025c transcripts. 18S rRNA served as control. 
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2.7 Poly(A) site shift in cordycepin resistant mutants 
 
Since cordycepin affects poly(A) site usage of ACT1 and ASC1 mRNAs in wild-type 
strains, it was tested, whether cordycepin resistance also implies a suppression of the 
observed poly(A) site shift. Six cordycepin resistant mutants were cultured and shifted to 
medium containing cordycepin. ∆ADO1 acted as a control, since cordycepin can not be 
converted into the active CoTP in this mutant strain and therefore a difference in the 
poly(A) site usage of ACT1 should not be detectable. As shown in figure 37, ∆ADO1 
displayed no altered poly(A) site usage of the ACT1 mRNA nor a general decrease in the 
ACT1 mRNA level. This indicates, that the conversion to CoTP is necessary to cause a 
change in poly(A) site usage. The five tested cordycepin resistant mutant strains showed a 
decrease in the ACT1 mRNA signal and in addition a shift of the poly(A) site usage in the 
ACT1 mRNA. This indicates that cordycepin resistance does not correlate with the 
observed polyadenylation site shift. 
 
 
 
 
 
Figure 37 Cordycepin resistance does not correlate with suppression of cordycepin-
induced poly(A) site shift. 
Northern blot of total RNA extracted from cordycepin resistant mutant strains at the 
indicated time after the shift to cordycepin [20 µg/ml]. The membrane was hybridized with 
random-primed labelled probes against ACT1 mRNA. 
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2.8 Partial suppression of cordycepin toxicity by supplementation of 
adenine 
 
In the cordycepin resistant pap1-1 mutant an increased expression of genes involved in 
ATP synthesis was detected. This suggested that elevated ATP levels might reduce 
cordycepin toxicity. To test this hypothesis, four selected cordycepin sensitive mutant 
strains were dropped on plates containing cordycepin additional adenine. ∆REF2 and 
∆ISR1 strains acted as controls as both of these mutants were directly or indirectly 
associated to 3’ end formation. For all four cordycepin sensitive mutant strains, the 
addition of adenine could only slightly suppress cordycepin toxicity (figure 38), although 
growth was still clearly reduced compared to growth on minimal media.  
 
 
 
 
Figure 38 Partial suppression of cordycepin toxicity by the addition of adenine. 
Ten-fold dilutions of wild-type and mutant yeast strains were dropped on SD plates 
containing the indicated supplements and incubated for 3 days.  
 
 
2.9 pap1-2 mutation suppresses cordycepin sensitivity 
 
The pap1-1 mutant strain is resistant to cordycepin, which might be caused by increased 
ATP synthesis. This opens the question whether a Pap1 mutation in a cordycepin sensitive 
gene deletion strain could have an influence on the growth inhibition of these mutants in 
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presence of cordycepin. Therefore, APQ12, SAC3 and THP1 genes were deleted in the 
pap1-2 temperature sensitive mutant strain and growth was tested in a drop test. Pap1-2 
doublemutants displayed a restored growth phenotype in presence of cordycepin (figure 
39), whereas the three single gene deletion mutants exhibited strongly inhibited growth in 
presence of the drug. This means that pap1-2 mutation is able to suppress cordycepin 
sensitivity in gene deletion strains that are sensitive to cordycepin. Since the pap1-2 
mutation was able to restore growth in presence of cordycepin in these mutant strains in 
might also suppress the altered cordycepin-induced polyadenylation site usage. Northern 
blot analysis of ∆APQ12 pap1-2 and ∆SAC3 pap1-2 double mutants revealed that the most 
proximal polyadenylation site is used almost uniquely (figure 40). Apparently, the pap1-2 
mutation suppresses not only the growth phenotype of these mutant strains, but also 
restores the cordycepin-induced variation of polyadenylation sites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 pap1-2 mutation suppresses growth inhibition in presence of cordycepin in 
cordycepin sensitive gene deletion strains.  
Ten-fold dilutions of single mutants and pap1-2 double mutants were dropped on SD plates 
with or without 40 µg/ml cordycepin and incubated for 3 days at 30 °C.  
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Figure 40 Cordycepin-induced alteration in the poly(A) site usage is suppressed by 
pap1-2 mutation. 
Northern blot of total RNA extracted from single and double mutant strains at the 
indicated times after the shift to cordycepin [20 µg/ml]. The membrane was hybridized 
with random-primed labelled probes against ACT1 mRNA. 
 
 
2.10 Analysis of transcription termination  
 
In the previous chapter we provide evidence that cordycepin affects poly(A) site 
recognition. Therefore, the possible involvement of genes, whose deletion causes 
cordycepin sensitivity, in termination was addressed by transcriptional run-on analysis 
(TRO) (Birse et al., 1998). TRO was performed with a plasmid borne CYC1 gene that was 
under the control of a minimal CUP1 promoter (pCUP-CYC1, figure 41).Distribution of 
run-on transcripts over single-stranded DNA probes (1–6 in figure 41) was analysed in 
wild-type and selected cordycepin sensitive mutant cells. Correct termination results in 
run-on signals over probes 1– 3 but not over probes 4–6 (Birse et al., 1998). Slot 
hybridisations showed that transcription termination was efficient in wild-type cells. The 
38 bp deletion in the CYC1 3’ UTR in the CYC1-512 mutant causes a defect in termination 
and polyadenylation and the signals in probe 4 – 6 were strongly increased (Birse et al., 
1998; Zaret and Sherman, 1982). The TRO results for all tested cordycepin sensitive 
mutants did not indicated a deficiency in termination of the pCUP-CYC1 gene (figure 41). 
RNA Pol II requires certain factors for a proper termination. Some of these factors are 
recruited to RNA Pol II already at the promoter. Therefore, the promoter might influence 
termination. TRO analysis was performed also with the GAL-CYC1 construct. However, 
the four tested gene deletion mutants did not display any termination defect (figure 42).  
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Figure 41 Cordycepin sensitive gene deletion strains are not deficient in transcription 
termination. 
A) Representation of the pCUP-CYC1 gene that was analysed by transcriptional run-on 
(TRO). M13 probes (1–6) complementary to regions of the CYC1 gene (indicated in 
nucleotides relative to the transcription start site) and the poly(A) site are indicated. 
B) Slot blot hybridizations obtained following TRO indicated strains. 1– 6 represent CYC1 
probes as described in (A), M13 (M) and ACT1 (A) probes served as controls. 
C) Quantification of run-on data. Values obtained by PhosphorImager scanning were 
corrected by subtraction of the M13 background signal and normalized to the value of 
probe 1, which was fixed at 100%. 
 
 
 
 
 
 
 
 
Figure 42 Transcriptional run-on with a GAL-CYC1 construct 
Left: Slot blot hybridizations obtained following TRO indicated strains. 1– 6 represent 
CYC1 probes, M13 (M) and ACT1 (A) probes served as controls. Right: Quantification of 
run-on data. Values obtained by PhosphorImager scanning were corrected by subtraction 
of the M13 background signal and normalized to the value of probe 1, which was fixed at 
100%. 
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Since elongated CYH2 transcripts could be detected in Northern blots of wild-type 
cells after cordycepin addition (see part 3), TRO analysis was performed in wild-type cells 
after a shift to cordycepin containing media (figure 43). 30 and 60 minutes after 
cordycepin addition, no defect in transcription termination could be observed on the GAL-
CYC1 gene, although at these time points the extended CYH2 transcripts appeared. 
Cordycepin addition might therefore not lead to a general increase in read through 
transcripts and therefore to a less efficient termination. The appearance of the observed 
RNA transcripts of CYH2 in the Northern blot might reflect a gene specific termination 
defect, which could not be resolved with TRO analysis on GAL-CYC1 gene. Cordycepin 
addition was also tested in the cordycepin resistant pap1-2 mutant and as expected, no 
transcription termination defect could be observed. 
 
Figure 43 Cordycepin has no effect on transcription termination in wild-type and 
pap1-1 mutant strains. 
Slot blot hybridizations and quantification obtained following TRO of wild-type and pap1-
2. The cells were shifted to 40 µg/ml cordycepin. At indicated time points the cells were 
harvested and TRO was performed. 
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3 Cordycepin-hypersensitive growth links elevated 
polyphosphate levels to inhibition of poly(A) polymerase in 
Saccharomyces cerevisiae 
 
 
 
This chapter describes a project emerged from a collaboration with Florian Freimoser and 
Thomas Werner from the Insitute of plant science at the ETH of Zürich and the results 
have been published in Nucleic Acids Research 2008, Vol 36, Nr 2, 353 – 363. 
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VII Discussion 
 
 
Cordycepin is an adenosine analogue that has the ability to enter cellular nucleotide pools 
after its conversion into cordycepin triphosphate and its incorporation into RNA leads to 
termination of RNA synthesis. Importantly, CoTP is a biological active compound and its 
function as an antitumor antibiotic has been identified many years ago (Jagger et al., 1961). 
In case of the yeast RNA polymerases, presented kinetic parameters suggest that the 
inhibitory effect of cordycepin is higher on RNA Pol II than on poly(A) polymerase 
(Horowitz et al., 1976). However, the adenosine analogue revealed potent inhibitory 
activity on poly(A) polymerases of mammals (Müller et al., 1977), vaccina virus (Shuman 
and Moss, 1987) and of yeast (Hooker et al., 2001). Because cordycepin has been shown to 
act as a strong inhibitor of the enzyme terminal deoxynucleotidyl transferase (Müller et al., 
1977) it is currently undergoing clinical trial phase I in the Unites States for treatment of 
TdT+ leukaemia patients.  
 
The molecular effects of cordycepin in Saccharomyces cerevisiae 
 
The addition of cordycepin to yeast media exhibited several distinct effects on RNA 
metabolism. The drug produced a decrease in steady-state mRNA levels of several genes 
as expected for a chain terminator. The observed decrease seemed to correlate with the 
stability of the mRNA. PGK1 has a half-live of over 90 minutes and PGK1 mRNA levels 
remained stable for 120 minutes in presence of cordycepin. Furthermore, we detected 
extended RNA transcripts of CYH2, ACT1 and ASC1 mRNA. In the case of ACT1 and 
ASC1 mRNA, cordycepin changed the relative usage of the polyadenylation site in favour 
of the most distal poly(A) site. Mutant strains of factors of the 3’ end machinery such as 
RNA14, RNA15 and YTH1 have been associated to a similar shift in poly(A) site usage 
(Mandart and Parker, 1995; Dichtl et al., 2002b). Most interestingly, also pap1-1 exhibit a 
shift of poly(A) site usage (Mandart and Parker, 1995), which is unexpected because 
polyadenylation site selection precedes the process of poly(A) addition. We hypothesise 
that the binding of CoTP on Pap1p reduced effectiveness of the enzyme leading to the 
same phenotype as observed in the pap1-1 mutant. 
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Strikingly, elongated transcripts of CYH2 were detected, which were longer than 
1 kb and unprocessed as they still contained the intron sequence. This effect of cordycepin 
was especially evident at lower concentrations (16 – 40 µg/ml) however at higher 
concentration (98 µg/ml) the decrease in mRNA levels was more prominent. The reason 
for the elongated CYH2 transcripts could be a read-through of RNA Pol II induced by 
cordycepin by interfering with polyadenylation site recognition. Unspliced read-through 
transcripts are normally degraded through RNA surveillance mechanisms (see above) 
(Bousquet-Antonelli et al., 2000; LaCava et al., 2005). Using transcriptional run-on 
analysis, a defect of transcription termination in presence of cordycepin could not be 
detected in wild-type cells, which suggests that cordycepin does not cause a deficiency in 
transcription termination in general.  
Consistent with our observations, cordycepin does not seem to affect only mRNA 
synthesis as a RNA chain terminator. It has been demonstrated before, that cordycepin is 
not a typical chemical inhibitor of transcription (Grigull et al., 2004). The authors found, 
that the gene expression profile obtained by cordycepin did not correlate well with those 
from transcriptional inhibitors such as 6-azauracil, 1,10-phenanthroline or the temperature-
sensitive mutant strain rpb1-1.  
 
Cordycepin as an inhibitor of RNA surveillance? 
 
Gene expression profiles of wild-type cells revealed that more RNAs were increased more 
than twofold (222) in presence of the drug than decreased more than twofold (72). No gene 
ontology term was found to be significantly enriched in these RNA groups. Interestingly, 
44% of the 222 increased RNAs were hORFs, which means that the fraction of hORFs 
almost doubled in comparison with the decreased RNA group (27.4%) or the RNAs 
obtained after processing the raw data (22.6%). The CUT NEL025c was stabilised in 
∆TRF4 and ∆RRP6 mutants in presence of cordycepin and elongated NEL025c transcripts 
could be detected. CUTs are short, 300 – 600 nt, noncoding RNAs transcripts produced by 
RNA Pol II. They may represent 10% of intergenic transcripts in S. cerevisiae (Wyers et 
al., 2005). CUTs are polyadenylated through the TRAMP complex subunits Trf4p and 
Trf5p, which targets them for degradation by the nuclear exosome (Wyers et al., 2005). 
What could be the role of cordycepin in the CUT degradation pathway? CoTP might be 
incorporated into the destabilising poly(A) tail by the poly(A) polymerases Trf4p and 
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Trf5p resulting in a RNA chain termination and in shorter poly(A) tails. Since the poly(A) 
tail synthesised by the TRAMP complex is accelerating RNA decay, a shorter poly(A) tail 
might lead to a less efficient degradation by the nuclear exosome. Another possibility is 
that the incorporated CoMP at the 3’ end of the poly(A) tail might block entry of the 
nuclear exosome. Maybe the combination of shorter poly(A) tails and a CoMP at the 
3’ end of the poly(A) tail led to the observed stabilisation of the CUT NEL025c. However, 
this effect is mild, since no stabilisation of NEL025c was observed in wild-type cells. But 
cordycepin enhanced the stabilisation of the CUT in a ∆TRF4 or ∆RRP6 deletion strain. 
CUTs have been implicated in the regulation of expression of neighbouring genes. For 
example, IMD2 and SER3 expression are regulated by transcription of a CUT (Kuehner 
and Brow, 2008; Martens et al., 2005). Thus, the stabilisation of CUT might have an effect 
on the expression of adjacent genes. Moreover, less efficient RNA surveillance could also 
lead to the detection of the extended CYH2 transcripts in presence of cordycepin. These 
elongated transcripts are intron containing and not properly processed. They might be the 
product of a read-through by RNA Pol II and would probably be rapidly degraded by the 
TRAMP/exosome degradation pathway. It seems possible therefore, that in presence of the 
adenosine analogue, the degradation of these transcripts might be less efficient leading to 
stabilised CYH2 transcripts that are detectable in Northern blot analysis.  
 
Genome-wide identification of cordycepin targets 
 
Determining the mode of action of a compound is a central issue in molecular medicine. 
Yeast is one of the simplest eukaryotic organisms. The single cell organism has a short life 
cycle of 90 minutes and is inexpensive to grow and maintain. Its haploid genome has a 
small size and is of relatively low complexity. Yeast has become a prominent model for 
human diseases and pathways, since at last 31% of the proteins encoded in the yeast 
genome have a human orthologue and nearly 50% of human disease genes exhibit yeast 
orthologes (Foury, 1997). An almost complete collection of gene deletion mutants of 
S. cerevisiae is available (Winzeler et al., 1999). These collections permit a comprehensive 
genome-wide view of drug action. New genomic technologies have been implemented in 
the yeast model organism: functional profiling (Giaever et al., 2002), gene expression 
profiling of drug action (Marton et al., 1998) or synthetic lethal screens (Tong et al., 2004). 
In a functional profiling study in yeast, the mode of action of 78 compounds was analysed 
and a novel target for the antitumor agent 5-fluorouracil was uncovered (Lum et al., 2004). 
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This new function has been confirmed by conventional molecular biological methods 
(Fang et al., 2004), providing proof of this principle for analyzing the modes of action of 
clinically relevant compounds. In a more recent study, more than 400 chemical compounds 
and diverse environmental stresses (Hillenmeyer et al., 2008) 
The yeast gene deletion library was screened for sensitive or resistant growth 
phenotype in presence of cordycepin to gain further insight into the molecular effects of 
this drug and to identify new factors that are involved in RNA metabolism. The screening 
was performed by two different approaches. The first screen was a simple drop test, in 
which diluted yeast cultures were spotting on plates and growth of each yeast strain in 
presence and absence of cordycepin was analysed. As a second approach functional 
profiling was performed. This method allows the culturing of all yeast gene deletion strains 
in a competitive environment and relative fitness of each strain is visualised by microarray 
analysis. A big advantage of screening by functional profiling is its comprehensive 
genome-wide view of drug action and its fast and cheap screening procedure. This method 
is very sensitive and the relative fitness of each strain is represented quantitatively. 
Approximately 350 gene deletion strains are lost in this procedure because they are 
overgrown due to their extremely slow growth. A drop test screen is much more elaborate 
and is less sensitive, since growth of the mutant strains is compared by eye. Interestingly, 
our results revealed that the screening procedure and the culturing condition seemed to 
have a great impact on the outcome of the screen as the overlap of the two screens was 
surprisingly small (8.9%). Large-scale chemical genomic assays were usually carried out 
by functional profiling analysis (Lum et al., 2004; Parsons et al., 2006; Hillenmeyer et al., 
2008). However, their result might be biased since possible targets might be only 
recognisable by a different screening approach like for example a drop test. 
Different classes of cordycepin targets have been identified. One class included 
genes involved in CoTP synthesis. The ADO1 deletion strain revealed a resistance against 
the drug (Iwashima et al., 1992). Ado1p converts adenosine into adenosine monophosphate 
(Lecoq et al., 2001) and is therefore necessary to convert the pro-drug cordycepin into the 
toxic compound CoTP. The resistance of the ∆ADO1 strain demonstrates that this 
conversion is absolutely essential for the mode of action of cordycepin. ADK1 converts 
CoMP to CoTP (Konrad et al., 1988) and its deletion strain was also cordycepin resistant, 
although the cell contains other enzymes with a adenylate kinase activity (Cooper and 
Friedberg, 1992). 
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Furthermore, genes that may change ATP/CoTP ratio were identified. The absence 
of genes associated with peroxisome biogenesis (PEX genes) resulted in cordycepin 
sensitivity. Peroxisomes are small organelles with diverse functions: α- and β-oxidation of 
fatty acids, biosynthesis of ether phospholipids, oxidation and in mammals they are 
implicated as well in purine catabolism (Wanders and Waterham, 2006). Although it has 
not been demonstrated, that yeast peroxisomes are implicated in purine catabolism, we 
hypothesise that cordycepin might as well be degraded in peroxisomes. Disrupting the 
organelle structure and integrity might decrease the degradation efficiency resulting in a 
higher cordycepin concentration in the cell. Deletion strains of genes which encode for 
mitochondrial proteins were mostly only moderately sensitive to cordycepin. The core 
activity of mitochondria is the supply of energy by ATP synthesis. Deleting genes involved 
in ATP synthesis might result in a less efficient ATP synthesis changing the cellular 
ATP/CoTP ratio. The increased probability for an enzyme to interact with CoTP instead of 
ATP might lead to the observed growth inhibition of the respective deletion strain in 
presence of cordycepin. 
In the group of genes whose deletion causes a resistant growth in presence of 
cordycepin, genes involved in mRNA turnover and ribosome biogenesis and translation 
were identified. Stabilising mRNAs by inhibiting degradation suppresses the toxicity of 
cordycepin and the respective gene deletion strains were resistant to the adenosine 
analogue even at much higher concentrations. The fact that mRNA stabilisation leads to 
cordycepin resistance provides further evidence that reduced RNA synthesis is the primary 
reason for cordycepin toxicity. 
Interestingly, gene deletion strains of subunits of the SWR1 chromatin remodelling 
complex exhibited strong sensitivity to cordycepin. This complex deposits the histone H2A 
variant Htz1p into chromatin (Krogan et al., 2003). Consistently, the growth of ∆HTZ1 was 
also highly inhibited by cordycepin. Chromatin remodelling occurs through two different 
classes of molecular processes. The first class remodels chromatin by post-translational 
modification of the protruding histones tails, such as acetylation, methylation, 
phosphorylation, ubiquitylation, and sumoylation (Rando et al., 2003). The second class is 
ATP-dependent and is catalyzed by chromatin remodelling complexes. By changing the 
DNA–histone interactions ATPases can slide, eject, insert or restructure histone octamers 
(Saha et al., 2006). Htz1p has been shown to have a destabilizing effect on 
intranucleosomal interactions and as well on internucleosomal interactions (Abbott et al., 
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2001). Genome-wide studies have demonstrated that Htz1p deposition happens at the vast 
majority at promoter regions (Guillemette et al., 2005). Destabilised nucleosome 
complexes could facilitate the binding of the RNA polymerase complex to the DNA. Such 
a function of Htz1p would be consistent with its primary location at promoter regions. 
HTZ1 is not an essential gene, and ∆HTZ1 does not show a general transcription defect 
(Guillemette et al., 2005). However, pull-down experiments demonstrated an association of 
Htz1p and RNA Pol II (Guillemette et al., 2005). It has been shown that the histone H2A 
analogue is required for full activation of GAL1 and GAL10 genes (Guillemette et al., 
2005). Moreover, the cell cycle genes CLN2 and CLB5 require Htz1p at their promoter for 
their timely and complete transcriptional activation (Meneghini et al., 2003). 
Most interestingly, we found in ∆SWR1 and ∆HTZ1 strains that the level and the 
length of the CUT NEL025c was increased in presence of cordycepin. This could mean 
that these two mutant strains either have an increased transcription rate of CUTs or that 
CUTs are more stable in these strains. Since Htz1p has been linked to promoters of 
actively transcribed genes (Millar et al., 2006) is unlikely, that these mutant strains have 
elevated CUT transcription rates. Htz1p incorporation into promoter regions facilitates 
transcription from the promoter, but might also hinder transcription of the respective CUT. 
Such a mechanism might explain our observation of increased NEL025c levels in ∆SWR1 
and ∆HTZ1 strains. A provocative idea would be that Htz1p might be involved in the 
recruitment of the TRAMP complex and the exosome for efficient CUT degradation. A 
lack of Htz1p incorporation in the nucleosome might have a mild stabilising effect on 
CUTs, which can be enhanced by cordycepin. 
Since we were mostly interested in new factors implicated at the interface of 
transcription and pre-mRNA processing, the further functional analysis was focussed 
mostly on genes coding for proteins with a nuclear localisation. Several candidates were 
further tested by a synthetic lethality test with rna14-1. From 23 tested genetic interactions, 
eleven were synthetic lethal, nine generated doublemutants had a severe growth defect and 
only three genes did not exhibit a genetic interaction with RNA14. The effect of cordycepin 
could be duplicated by mutation in a 3’ end factor, which further underscores that genes 
identified in our cordycepin screening might indeed function in 3’ end processing. 
Northern blot analysis revealed that mRNA levels of ACT1 were affected in several mutant 
strains. Poly(A) tail length distribution analysis of most of those gene deletion strains 
showed that almost half of the examined strains showed an altered poly(A) tail distribution. 
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However, little is known about cellular pathways regulating poly(A) tail length. Many gene 
deletion strains exhibited an accumulation of short poly(A) tails indicating that the 
respective deleted gene might be implicated in 3’ end processing. Analysis of termination 
by transcriptional run-on experiments was carried out with 15 cordycepin sensitive gene 
deletion strains. All 15 genes showed genetic interaction with RNA14, implicating that they 
might have a role in 3’ end formation. However, none of the tested strains showed a defect 
in transcriptional termination that could be visualised by run-on technique. Further 
characterisation of the identified mutants may provide new insight into the mechanism of 
RNA synthesis. 
 
Polyphosphate as a potential inhibitor of Pap1p activity 
 
Most interestingly, our work identified poly P as potent inhibitor of Pap1p. Poly P is a 
chain of tens or many hundreds of phosphate residues linked by high-energy 
phosphoanhydride bonds and it is present in all species tested to date, from each of the 
three kingdoms of life (Kornberg et al., 1999). Poly P has numerous and varied biological 
functions depending on its location (species, cell, or subcellular compartment): substitution 
for ATP in kinase reactions, reservoir of Pi, chelation of metals (e.g. Mn2+, Mg2+, Ca2+), 
buffer against alkali, mRNA processing and degradation, environmental remediation of 
phosphate, and regulatory roles in the physiological adjustments to growth, development, 
stress, and deprivation (Kornberg et al., 1999). It promotes ribosomal protein degradation 
by binding and activating the Lon protease in E. coli delivering amino acids needed to 
respond to starvation (Kuroda et al., 2001). In mammalian cells, the TOR kinase is 
activated by poly P under conditions of nutritional starvation (Wang et al., 2003). 
We found that in ∆PHO80 and ∆PHO85 mutant strain polyphosphate accumulated 
and co-purified with the RNA. In the poly(A) tail labelling assay, polyphosphate inhibited 
the activity of Pap1p in vitro. A possible inhibitory connection of polyphosphate on 
poly(A) polymerase in vivo was indicated by the synergistic effect of the accumulated 
polyphosphate and cordycepin on Pap1p, which might be the reason for the strong 
sensitivity of these deletion strains to this drug. The observed synthetic lethality of 
∆PHO80 with RNA14 underscored the hypothesis that polyphosphate might have a role in 
regulating Pap1p in vivo. We showed that polyphosphate bound Pap1p directly and we 
assume that it interacts with the DNA binding domain of Pap1p since it has a high 
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chemical similarity to the backbone of the DNA molecule. In yeast, cellular poly P levels 
can reach a concentration of 120 mM, but the majority is localised to the vacuole, but it has 
also been detected in the nucleus (Kornberg et al., 1999; Indge, 1986). Poly P levels in 
yeast are strongly dependent on growth phase and accumulate during diauxic shift induced 
by glucose depletion from the media (Werner et al., 2005). During this process, a complete 
rearrangement of gene expression takes place (Radonjic et al., 2005). Downregulation of 
expressed genes might be a result of the inhibition of polyadenylation by poly P. However, 
poly P level measurements in the nucleus are difficult.  
A different phosphate molecule has been associated with the regulation of the 
recently identified Star-PAP in mammalian cells (Mellman et al., 2008). The activity of 
Star-PAP is highly increased in presence of phosphatidylinositol-4,5-biphosphate (Ptdlns-
4,5P2). Star-Pap has been shown to interact with the Ptdlns-4,5P2 producing enzyme 
PIPKI, which allows the speculation that the associated PIPKI regulates the activity of 
Star-PAP by Ptdlns-4,5P2 production. Polyphosphate might control the activity of yeast 
Pap1p in a similar mechanism, although the enzyme polyphosphate kinase has not been 
identified in yeast. 
 
Mutation in PAP1 triggers ATP synthesis 
 
Paradoxically, mutations within PAP1 caused resistance towards cordycepin. Several 
alleles were tested and all revealed cordycepin resistance and suppression of the extended 
RNA transcripts. This effect was unique to PAP1 mutants. PAP1 mutation also suppressed 
cordycepin toxicity in cordycepin sensitive mutants and doublemutants had no detectable 
poly(A) site shift. Gene expression profile of pap1-1 revealed two important findings: 
Firstly, the process of ATP synthesis is upregulated in this mutant compared to wild-type 
strain. Secondly, cordycepin had little effect on the gene expression pattern in pap1-1, 
indicating that cordycepin is not effective in this mutant. Since CoTP competes with ATP 
in enzymatic reactions, we conclude that the ratio ATP/CoTP determines cordycepin 
toxicity. 
Another interesting question arising from this observation is why ATP synthesis is 
induced in strains carrying a mutation in PAP1. Pap1p requires ATP for the synthesis of 
poly(A) tails. One possibility could be that Pap1p acts as a sensor for ATP levels in the 
cells. A change in Pap1p processivity by a mutation in PAP1 could resemble a low ATP 
level situation that triggers ATP synthesis. Further experiments will be needed to answer 
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the mechanism of the proposed ATP synthesis activation signal. Fip1p is the only 
interaction partner of Pap1p in the PF I complex and has been shown to regulate Pap1p 
activity (Helmling et al., 2001). Fip1p is an essential protein and it plays a central role in 
regulating polyadenylation. Fip1p might be a candidate being implicated in the ATP 
synthesis signal mechanism. 
 
Final remarks 
 
Cordycepin is a nucleoside analogue has been implicated in various activities in 
mammalian cells. The activity against the parasites Leishmania and Trypanosoma (Berens 
et al., 1995; Rottenberg et al., 2005) but as well the anti-fungal activity against C. albicans 
(Eggimann et al., 2003) appear to be promising for a possible use of cordycepin for the 
treatment of these diseases. Since understanding the mechanism of the mode of action of a 
drug is essential for its therapeutic usage, the results presented in this thesis open new 
views on the molecular effects of cordycepin. Furthermore, our analysis may represent new 
starting points for the characterisation of genes involved in RNA synthesis.  
 
 Material and Methods 
 125 
VIII Material and Methods 
 
4 Growth and handling of S. cerevisiae  
 
Wild-type BY4741 (Mat a; his3∆1; leu2∆0; met15∆0; ura3∆0) and isogenic mutant strains 
were obtained from EUROSCARF (Winzeler et al., 1999). Other used strains are listed in 
table 4.1. Doublemutants were generated by disrupting the open reading frame of the 
respective gene with the kanMX or NatR cassette by homologous recombination in rna14-1 
(containing RNA14 on a URA3 plasmid) or pap1-2 (containing PAP1 on a URA3 plasmid). 
Yeast strains were cultured in either full-medium or synthetic complete (SC) medium. 
Full-medium contained 1% yeast extract (Brunschwig), 2% Bacto-Peptone (Brunschwig) 
and 2% glucose (YPD). Liquid synthetic complete media contained 0.67% yeast nitrogen 
base (MP Biomedicals), 0.06% complete synthetic mix (lacking histidine, uracil or 
tryptophan) and either 2% glucose (SD) or 2% galactose (SGal). Plates contained 10% agar 
(Brunschwig). SD was supplemented with cordycepin purchased from Sigma at the 
indicated concentration or 5’ fluoroorotic acid (1 mg/ml) from Zymo Research (Orange, 
CA, USA).  
 
strain genotype reference 
kin28-ts3 Mat a; leu2; trp1; ura3; ade2; ade3; lys2; kin28-ts3 Valay et al., 1995 
pap1-1 Mat a; ade1/ade2; lys2; gal? ; Ura3-52; pap1-1 Patel and Butler, 1992 
pap1-2 Mat α; pap1::LEU2; pA-pap1-2-TRP1; ura3-1; his3-11 Walter Keller lab 
pap1-5 Mat α; pap1::LEU2; pA-pap1-5-TRP1; ura3-1; his3-11 Walter Keller lab 
pap1-7 Mat α; pap1::LEU2; pA-pap1-7-TRP1; ura3-1; his3-11 Walter Keller lab 
rat1-1 Mat a; ura3-52; leu2∆1; his∆200; rat1-1 Amberg et al., 1992 
rna14-1 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; 
rna14-1 
Minvielle-Sebastia et al., 
1994 
rna15-1 Mat α; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; 
rna15-1 Walter Keller lab 
rpb1-1 Mat a; ura3-52; rpb1-1 Nonet et al., 1987 
S288C Mat a; SUC2; gal2; mal; mel; flo1; flo8-1; hap1; ho; bio1; bio6 
Mortimer and Johnston, 
1986 
ssu72-2 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; 
ssu72-2 Walter Keller lab 
ysh1-3 Mat a; ura3-1; trp1-1; ade2-1; leu2-3; 112; his3-11; 15; TRP1::ysh1 [ysh1-3-HIS3-CEN] Walter Keller lab 
Table 4.1 Strains used in this study. 
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5 Primers 
 
primer 5’ → 3’ sequence purpose 
KanB rev CTGCAGCGAGGAGCCGTAAT strain verification 
KanC forw TGATTTTGATGACGAGCGTAAT strain verification 
NatR rev GTGAAGGACCCATCCAGTGCCT strain verification 
Akr1 A forw CGTTATCATTGTTAGAACTTTGGCT strain verification 
Apq12 A forw GCCACAGACAGCTATCTCTATGAAT strain verification 
Apq12 B rev GGAATCTTTTGACCAGACTAATGAA strain verification 
Bub1 A forw CGTTTGACTTCACGTCCATGG strain verification 
Cst6 A forw CAATGACAATGACAATGAAGGC strain verification 
Ecm30 A forw CTTCAGGGGGTTTTTCCTTGCT strain verification 
Gtr1 A forw CCGAGTCGTTTGAAGTCATCTC strain verification 
Htz1 A forw GCTCCGTGCACGAAAACAACAA strain verification 
Isr1 A forw GTAATATGCCCATCAAAACTCATC strain verification 
Mud2 A forw TTATTTGCACTAATAATGCCAG strain verification 
Mud2 B rev ATTCTCCCTGTTATATGATCTTCCC strain verification 
Pep5 A forw CAGGATGTGTTACGATGCAGACA strain verification 
Pho2 A forw TATGGAGTTAAAGTGTGGGATTGT strain verification 
Pho4 A forw TACGGTGTGTATGTGTATGTCTGTG strain verification 
Pho4 B rev CGCTTGTTCAAATACGGACTACTAT strain verification 
Pho5 B rev ATAGTCGCCAGGGAAAGAGTAGTAT strain verification 
Pho80 A forw AAACAATCAGTCTCCATACTCATCC strain verification 
Pho80 B rev TCTCCAGTATATTCAATTCGTGACA strain verification 
Pho81 A forw AGTTTTTGAGAGTCCCTTCAAGTTT strain verification 
Pho81 B rev GGAAACAACAGTAGCAAGGTAAAAA strain verification 
Pho84 A forw GCGTATTACTCATTAATTAACCGACC strain verification 
Pho84 B rev TTGACCAATAACAGTACCAACAGAA strain verification 
Pho85 A forw AATGAAATTTTTAACAATGCAGAGC strain verification 
Pho85 B rev AGTTTAGTTATAGCCCTCTTGGTGT strain verification 
Pho86 A forw CAATAATGGAAATCCAGATGGTG strain verification 
Pho86 B rev TTATCGGACTTTCTACCCTCTTTCT strain verification 
Pho87 A forw AAGGTTTAAGATTGTGCATAGGAAA strain verification 
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primer 5’ → 3’ sequence purpose 
Pho87 B rev ATCATCTACTTTCAATTTCTCGTCG strain verification 
Rai1 A forw CTCAGCTGCTTGTATAGCCTA strain verification 
Rai1 B rev ATTTCCGTGCTATTCCTCTAAAAGT strain verification 
Rmd7 A forw GGGGATGAGATGGTTGCTCTT strain verification 
Rpb9 A forw CGGGCTGCTTGTCCTGTTCCTT strain verification 
Sac1 A forw TTTAGTAACCTGTAGACCTTCA strain verification 
Sac3 A forw CTTTATCCACTAGCCCTTTTTCTTC strain verification 
Sit4 A forw GAGCATTGAAGAGCTACAGACG strain verification 
Snf1 A forw GGCCAAGACATAGCTTTGGGCTT strain verification 
Snf2 A forw CAAATTGATTGACGAAACGGGG strain verification 
Snf6 A forw GCGGCTGGACCATACAGGTTCT strain verification 
Spt8 A forw CGGCTATGAAAAAAATGGCAGAG strain verification 
Spt8 B rev GAATGCTTCTGCAGGATAGTTAGAG strain verification 
Swr1 A forw TTGAAGAAAGAGTGCAAAGGGA strain verification 
Thp1 A forw CTGGAATATGAGCAGACAATAGTAT strain verification 
Thp1 B ref TATCAACATTTCTATGTGAGGAGCA strain verification 
Vtc4 A forw ACGTAACCCATCATAGGAAATTGTA strain verification 
Vtc4 B rev TGCAAAATGTGTAAACCTTGTCTAA strain verification 
YDL172c A forw GTGGTGACTGTAGAAGAGGGCAAT strain verification 
YDL172c B rev ACATAATTTCTCCAAAGTCAAGCAG strain verification 
YDL173w A forw GGCTCCAAGAGACAGCGACCGT strain verification 
YDL173w B rev GTTTGCTACTGTCTTTGAATTGGAT strain verification 
Yke2 A forw CTGTAGTGCGATGATATCTTGGT strain verification 
Akr1 150 bp forw CCCTCAATATGAACGATCTATA kanMX gene deletion 
cassette 
Akr1 150 bp rev CCACCTCATGAGCTTTCCTAAT kanMX gene deletion 
cassette 
Apq12 150 bp forw TGTTCTTGTCTTTCTCTCTCCT kanMX gene deletion 
cassette 
Apq12 150 bp rev AAATCAAGTCACAATTGTAATG kanMX gene deletion 
cassette 
Bub1 150 bp forw CGATACGCGCTAGGAAGTAAA kanMX gene deletion 
cassette 
Bub1 150 bp rev CCATAAGTGACAGATGTCAAGA kanMX gene deletion 
cassette 
Cst6 150 bp forw GAGGTTATCGTGTATACGTATC kanMX gene deletion 
cassette 
Cst6 150 bp rev CGGCAGAAAAGAAAGGATGCAG kanMX gene deletion 
cassette 
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primer 5’ → 3’ sequence purpose 
Ecm30 150 bp forw GGTGTTTTTTCTTTCGGGTAAA kanMX gene deletion 
cassette 
Ecm30 150 bp ref GAAGATTTTTACTTTTCTTCAA kanMX gene deletion 
cassette 
Gtr1 150 bp forw GCCTCTTCTTTATCACTCTCGC kanMX gene deletion 
cassette 
Gtr1 150 bp rev GCTTTTTCCTCCCATTGTCCTAT kanMX gene deletion 
cassette 
Htz1 150 bp forw CAGCTCTATTTAACAGCTGAAC kanMX gene deletion 
cassette 
Htz1 150 bp rev ACGGCTACTGCGCTATCGTT kanMX gene deletion 
cassette 
Isr1 150 bp forw GCGCTGCTAATAGATTCTTGCCT kanMX gene deletion 
cassette 
Isr1 150 bp rev GGATGAAGAAAAGGAAAGGCG kanMX gene deletion 
cassette 
Mud2 150 bp forw TACGCTGTAGAATGGATCACTT kanMX gene deletion 
cassette 
Mud2 150 bp ref TTTTCCAGATCGCAAGTTAGTA kanMX gene deletion 
cassette 
Pep5 150 bp forw GTGGTGTACGGATTATGTGTAACTG kanMX gene deletion 
cassette 
Pep5 150 bp rev CGGTTGCCACATTAATAATTTT kanMX gene deletion 
cassette 
Pho4 150 bp forw AAGTGCGATTTTCTCGTTTTCT kanMX gene deletion 
cassette 
Pho4 150 bp rev CTTCTGTTAATGTGAGTGCGTGT kanMX gene deletion 
cassette 
Rai1 150 bp forw GAGTAAGCATTCGGGTAAATTG kanMX gene deletion 
cassette 
Rai1 150 bp rev CGAGTTTCGGATCATACAGGG kanMX gene deletion 
cassette 
Rmd7 150 bp forw GCGCGTTTGCTGGGACAAAAGA kanMX gene deletion 
cassette 
Rmd7 150 bp rev CTCCAATTCAGTTCTATACATGC kanMX gene deletion 
cassette 
Rpb9 150 bp forw TTAGTTTGAGTTGTTTTATTGG kanMX gene deletion 
cassette 
Rpb9 150 bp ref CGGTGCTAAGATCAGGATTTTT kanMX gene deletion 
cassette 
Sac1 150 bp forw TGCTGCACTACTGCTTACCCAC kanMX gene deletion 
cassette 
Sac1 150 bp rev CATGAAAGATAAAGTAAAAAAG kanMX gene deletion 
cassette 
Sac3 150 bp forw CAGAGAGCGTAGTGATGCATA kanMX gene deletion 
cassette 
Sac3 150 bp rev CCCTGGCTTCACTTTTTGCACA kanMX gene deletion 
cassette 
Sit4 150 bp forw AATAGGTTATTGCATACTATCA kanMX gene deletion 
cassette 
Sit4 150 bp rev AATTTTTTATTTGGTCATTTTG kanMX gene deletion 
cassette 
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primer 5’ → 3’ sequence purpose 
Snf1 150 bp forw CCAAACAGTCATTCAGGAAGTA kanMX gene deletion 
cassette 
Snf1 150 bp rev CCGAAGAAATAATGCCAATAAAA kanMX gene deletion 
cassette 
Snf2 150 bp forw GTGACGTACGTGGACCTTTTGT kanMX gene deletion 
cassette 
Snf2 150 bp rev GATATTAAACATCCCAACTCGG kanMX gene deletion 
cassette 
Snf6 150 bp forw GGAAAAGATGGGAGAGAAAAAA kanMX gene deletion 
cassette 
Snf6 150 bp rev GCTGCACAAATCCACTATGTCA kanMX gene deletion 
cassette 
Spt8 150 bp forw CTTCCAGAATGCCCTTTCAGGA kanMX gene deletion 
cassette 
Spt8 150 bp rev GCCTTTGTCTGCCCGGACCCTG kanMX gene deletion 
cassette 
Swr1 150 bp forw AAAAGGATAGATTTTGAGCTTT kanMX gene deletion 
cassette 
Swr1 150 bp rev AACAATGCCATGGTGAGTACAT kanMX gene deletion 
cassette 
Thp1 150 bp forw GTCGTTGACTTTCTCTCCCTTT kanMX gene deletion 
cassette 
Thp1 150 bp rev TGTTACTCCCTTTTTTCCTCCT kanMX gene deletion 
cassette 
YDL172c 150 bp forw GGTGGTATCGTTCAACGTGATT kanMX gene deletion 
cassette 
YDL172c 150 bp rev CGTTTTGCAATTGGTAGAGGT kanMX gene deletion 
cassette 
YDL173w 150 bp 
forw CCAGACGAGTTCCTTTATAACGT 
kanMX gene deletion 
cassette 
YDL173w 150 bp rev GGTGGTATCGTTCAACGTGATT kanMX gene deletion 
cassette 
Yke 2 150 bp forw GAAGTCTGAAATTTTGATGCGA kanMX gene deletion 
cassette 
Yke 2 150 bp rev TTTAGGACAGTGAAATGCGTAGG kanMX gene deletion 
cassette 
∆Pho80-NatR forw 
TCTGCAAGCTATCATAAGACGAGGATA 
TCCTTTGGAGACTCATAGAAATCCACT 
ACGATTTAGGTGACAC 
NatR gene deletion cassette 
∆Pho80-NatR rev 
TTTAATTTTGCTCAATCATGATTGCTTT 
CATAATACCCCACGAAAAATCAAATAC 
GACTCACTATAGGGAG 
NatR gene deletion cassette 
Cyh2 forw AGCACAGAGGTCACGTCTCA PCR probe for hybridisation 
Cyh2 ref ATTCAACAACACCACCAGCA PCR probe for hybridisation 
Cyh2 intron forw ATGTAGTTCCATTTGGAAGAGG PCR probe for hybridisation 
Cyh2 intron ref AACAAAAGAAACGTGGTAACTC PCR probe for hybridisation 
Act1 forw TCTTCCCATCTATCGTCGGT PCR probe for hybridisation 
Act1 ref AGTTTGGTCAATACCGGCAG PCR probe for hybridisation 
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primer 5’ → 3’ sequence purpose 
Asc1 forw TTGACTGGTGACGACCAAAA PCR probe for hybridisation 
Asc1 rev AGCAGACCAAGCCAAAGAAA PCR probe for hybridisation 
Adh1 forw GTCACACTGACTTGCACGC PCR probe for hybridisation 
Adh1 rev TGTCAGCTCTGTTACCGACG PCR probe for hybridisation 
Pgk1 forw TCCCATTGGACGGTAAGAAG PCR probe for hybridisation 
Pgk1 rev GTGTTGGCATCAGCAGAGAA PCR probe for hybridisation 
Nel025 forw CTGTTGACATTGCAGACAAT PCR probe for hybridisation 
Nel025 rev GTGGTTAGAAGATTAATGTGAT PCR probe for hybridisation 
U3/snR17a forw AGGACATTTCTATAGGAATCG PCR probe for hybridisation 
U3/snR17a ref AAAGAAGTACATAGGATGGGTC PCR probe for hybridisation 
tRNA3LEU GAACTCTTGCATCTTACGATAFC hybridisation 
18S rRNA ACGAAAAATCAAATAC hybridisation 
Act1 RNase H ACATAACGATGTTACCGTATAATTC RNase H digest of ACT1 
Asc1 RNase H AAGAGAAAACTTCATCTTGGGCAGA RNase H digest of ASC1 
 
Table 4.2 Primers that were used in this study. 
 
 
6 Drop test 
 
The strains were grown over night in 200 µl of the respective media and temperature and 
three ten-fold serial dilutions were made. 4 µl of each dilution were spotted on different 
yeast plates and incubated for 3 days at the respective temperature.  
 
 
7 Growth curve 
 
The wild-type strain BY4741 was cultured in SD media at 30°C in a water bath overnight 
and diluted in the morning to an OD600 of 0.05 (50 ml cultures) in pre-warmed cordycepin 
containing (0, 10, 20, 40 µg/ml) SD media and incubated again at 30°C. The OD600 was 
measured every hour and cultures were diluted to an OD600 of 0.05 when they reached an 
OD600 of 0.4 - 0.5. The OD600 was graphically displayed against the time. The percentage 
of inhibition was calculated with the added trend line equation.  
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8 Functional profiling 
 
43 cell pools obtained from Alain Jacquier (Institute Pasteur, Paris) were pooled and 
mixed. 100 ml SD was inoculated by the cell pool and this pre-culture was incubated 
overnight at 30°C in a water bath. When the pre-culture reached an OD600 of 1, the culture 
was diluted to an OD600 of 0.05 in SD and SD containing 20 µg/ml cordycepin in duplicate. 
The OD600 was measured every hour and growth was monitored in a graph. After 12 and 
18 generations, 10 ml of cell culture was harvested by centrifugation (5 minutes, 3500 rpm, 
4°C) and shortly washed with ice-cold water. The cell pellet was frozen in liquid nitrogen 
and stored at - 80°C. Genomic DNA extraction was performed as described below. 
Labelling of the probes, hybridisation to arrays and analysis of the data was done by 
Florence Decourty and Alain Jacquier in Paris (Decourty et al., 2008). 
 
 
9 Transformation of yeast cells  
 
Yeast transformation was carried out as described by Schiestl and Gietz (1989). 50 ml of 
yeast were grown in YPD to an OD600of 0.5 to 0.8 or in SD to an OD600 of 0.3 to 0.5 and 
harvested by centrifugation for 3 min at 3600 rpm. After washing with 10 ml H2O, the 
pellet was resuspended in 25 ml transformation solution (10 mM Tris-HCl pH 7.5, 
100 mM LiOAc, 10 mM DTT) and incubated at room temperature for 40 minutes with 
gentle shaking. The cells were centrifuged for 3 minutes and resuspended in 750 µl of 
transformation solution. 5 µl Mini-Prep DNA or 1 - 2 µg purified PCR product was 
provided in a tube, with 5 µl carrier DNA (DNA of salmon or herring testis, 10 mg/ml), 
50 µl LiT (10 mM Tris-HCl pH 7.5, 100 mM LiOAc) and 100 µl of cells was added and 
the mixture was incubated for 10 minutes at room temperature. 300 µl PEG solution 
(10 mM Tris-HCl pH 7.5, 100 mM LiOAc, 40% PEG-4000) was added and the cells were 
incubated for 10 minutes at room temperature. After the addition of 50 µl DMSO, the 
transformants were heat-shocked for 15 minutes at 42°C. The cells were centrifuged, 
resuspended in 1 ml of YPD and incubated for 60 to 120 minutes at 25°C or 30°C. After 
the incubation, the cells were centrifuged and washed with 1 ml of H2O. The pellet was 
resupended in 50 µl H2O and plated on selective medium. For plasmid transformations the 
cells were washed and plated immediately after the heat shock. To transform yeast cells 
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grown on plate, one loop of freshly restreaked yeast cells was washed twice in 1 ml of H2O 
and once with 1 ml LiT. The pellet was then resuspended in 25 ml transformation solution 
and incubated for 40 minutes at room temperature. All further steps were performed as 
described above. 
 
 
10 Preparation of genomic DNA  
 
10 ml of an overnight yeast culture was centrifuged (3 min, 3500 rpm) and washed with 
10 ml H2O. The cells were resuspended in 200 µl extraction buffer (2% Triton X-100, 
1% SDS, 100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0). 200 µl glass 
beads and 200 µl phenol:chloroform:isoamylalcohol (25:24:1) were added and the mixture 
was vortexed for 7 minutes. 200 µl of extraction buffer was added and shortly vortexed. 
After a centrifugation for 15 minutes at 15’000 rpm and 4°C the upper phase was removed 
and extracted with an equal volume of chloroform. Genomic DNA was precipitated using 
1 ml of 100% ethanol and incubation of the solution for 10 min at -20°C. After a 
centrifugation for 15 min at 4°C and 16’000 rpm, the pellet was washed with 300 µl of 
70% ethanol. The pellet was dried and resuspended in 30 µl TE/RNase A (10 mM Tris-
HCl pH 8.0, 1 mM EDTA pH 8.0, 10 ng/ml RNase A) and stored at -20°C. 
 
 
11 RNA extraction 
 
RNA was extracted from yeast cells according to a hot phenol procedure essentially as 
described before (Collart and Oliviero, 2001). When not indicated differently, the cells 
were grown in YPD or SD media to an OD600 of 0.8 and harvested by centrifugation for 
5 minutes at 3500 rpm. The cell pellet was washed with 10 ml ice-cold H2O. Cell pellets 
were resuspended in 600 µl TES (10 mM Tris-HCl pH 7.5, 10 mM EDTA pH 8.0, 
0.5% SDS). After the addition of 500 µl acid phenol (pH 5, Roth), the cells were incubated 
at 65°C and vortexed three times for 15 seconds, followed by an incubation time of 
15 minutes. This procedure was repeated at least four times. The samples were centrifuged 
for 5 minutes at 15’000 rpm at 4°C. The upper phase was transferred to 500 µl phenol and 
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extracted by vortexing three times for 15 seconds. After centrifugation the upper phase was 
transferred to 500 µl chloroform. The samples were vortexed again three times for 
15 seconds and centrifuged at 4°C. RNA was precipitated by the addition of 35 µl 3 M 
NaOAc and 1 ml 100% ethanol following the incubation for at least 2 hours at -20°C or 
15 minutes at -80°C. The RNA was pelleted by centrifugation for 20 minutes at 
15’000 rpm and 4°C. The pellet was washed with 500 µl 70% ethanol and dried in a 
speedvac for 3 minutes. The RNA pellet was dissolved in 100 µl H2ODEPC (0.1% DEPC) 
and the RNA concentration was measured using the NanoDrop (Thermo Scientific).  
 
 
12 Northern blotting 
 
15 µg of RNA was mixed with 20 µl formaldehyde loading buffer (50% formamid, 
6% formaldehyde, 0.4 M HEPES, 0.025% xylene cyanol FF, 0.025% bromophenol blue, 
15% glycerol) and denatured for 5 minutes at 65°C. The RNA was loaded on a 1.2% 
agarose gel (0.05 M HEPES pH 7.8, 1 mM EDTA) and 50 volts were applied for at least 
16 hours. The gel was washed 10 minutes with H2O, and then the RNA was partially 
hydrolysed in 75 mM NaOH for 20 minutes. The gel was neutralised by incubation in 
neutralising solution (0.5 M Tris-HCl pH 7.0, 1.5 M NaCl) for 15 minutes. This step was 
repeated, then the gel was incubated in 10x SSC (1.5 M NaCl, 0.15 M sodium citrate 
pH 7.0) and the RNA was transferred overnight to a Hybond-N+membrane (Amersham 
Biosciences) with 10x SSC. The RNA was UV cross linked and the membrane was 
wrapped with saran foil for storage. 
For hybridisation, the membrane was stripped if necessary for 1 hour at 70°C in 
0.1% SDS. For the hybridisation with a PCR probe, the membrane was pre-hybridised in 
pre-hybridisation buffer (50% formamid, 5x SSC, 5x Denhard’s solution, 1% SDS, 
0.2 mg/ml DNA of salmon or herring testis) in a Hybaid oven for 30 minutes at 65°C. The 
PCR probe was initially denatured for 3 minutes at 100°C and immediately put on ice. The 
probe was labelled with [α-32P]-dATP using the random prime labelling kit (Roche). After 
an additional denaturation step, 900 µl of pre-hybridisation buffer were added and the 
probe was filtered (0.22 µm) and added to the membrane. The membrane was hybridised at 
37°C over night. The membrane was washed with 6x SSPE, 1x SSPE 0.1% SDS, 
0.2x SSPE 0.1% SDS and 0.1x SSPE 0.1% SDS for 30 minutes each at 42°C. For oligo 
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primer hybridisation the membrane was pre-hybridised in oligo-prehybridisation buffer 
(4x SSPE, 5x Denhard’s solution, 0.5% SDS, 0.2 mg/ml DNA of salmon or herring testis). 
The probe was labelled with [γ-32P]-ATP using the enzyme T4 polynucleotide kinase 
(Fermentas) and after an incubation time of 30 minutes at 37°C the labelled oligo probe 
was filtered to the membrane and hybridised overnight at 37°C. The membrane was 
washed with 6 x SSC for 15 minutes at 30°C, 37°C and 42°C each. After the washing, the 
membrane was exposed to a phosphor imager screen for at least 1 day and visualised on a 
FLA-7000 phosphor imager (Fuji). 
 
 
13 Poly(A) length analysis 
 
Assays were performed essentially as described (Martin and Keller, 1998). 2 µg of total 
RNA was incubated with 400 ng recombinantly expressed yeast poly(A) polymerase (a gift 
from G. Martin, Basel) and 0.2 µl [α-32P]-cordycepin triphosphate (Perkin-Elmer) in 
reaction buffer (20 mM Tris-HCl pH 7.0, 50 mM KCl, 0.7 mM MnCl2, 10% glycerol, 
100 µg/ml BSA) for 30 minutes at 30°C in a total volume of 12 µl. After heat inactivation, 
RNA was digested with RNase A and RNase T1, followed by proteinase K treatment. 
Precipitated RNAs were resolved on 15%/8.3 M urea polyacrylamide gels, that were 
exposed and visualized on a FLA-7000 phosphor-imager (Fuji) 
 
 
14 RNase H digestion 
 
10 µg of total RNA was mixed with 2 µl of oligo primer (10 mM) and 4 µl H-buffer 
(100 mM KCl, 50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM DTT). The RNA was 
denatured for 5 minutes at 75°C and the pimers were annealed to the RNA by incubating 
for 1 hour at 37°C. 1 µl RNase H (Invitrogen) together with 0.5 µl RNase Out (Invitrogen) 
and 0.5 µl H-buffer were added and the RNA was digested for 1 hour at 37°C. 25 µl 
H2ODEPC was added and the RNA was extracted with 50 µl phenol:chloroform: 
isoamylalcohol (25:24:1). The RNA was precipitated with ethanol and resuspended in 
20 µl formamide loading buffer (98% formamide, 0.025% xylene cyanol FF, 0.025% 
 Material and Methods 
 135 
bromophenol blue, 10 mM EDTA pH 8.0). The RNA was separated on an 8%/8.3 M urea 
polyacrylamid gel for 8 hours at 300 V. The transfer to a Hybond-N+ membrane 
(Amersham, Bioscience) was performed in 0.5x TBE overnight at 30 V and 200 mA using 
a wet transfer blotting system (Biorad). The membrane was UV cross-linked and the 
membrane was wrapped in foil for storage.  
 
 
15 Isolation of M13 phages 
 
100 ml of 2x YT medium was inoculated with a one colony of the E. coli strain J101 and 
incubated overnight at 30°C. In the next morning, the culture is diluted to an OD600 of 0.1 
and incubated at 37°C until the culture reached an OD600 of 0.3 to 0.5. 50 µl of M13 phage 
containing CYC1 probe 1 to 6 or Actin (Birse et al., 1998) was each added to 2 ml of the 
E. coli culture and incubated for 5 minutes at room temperature. These 2 ml pre-cultures 
were used to inoculate 200 ml of 2x YT (pre-warmed), which were incubated at 37°C four 
5 hours. The cells were harvested by centrifugation for 15 minutes at 8000 rpm with a GS3 
rotor. The supernatant was collected and phage particles were precipitated overnight in 
solution I (1.25 mM PEG-8000, 0.125 M NaCl) at 4°C. DNA was pelleted by 
centrifugation for 1 hour at 13’000 rpm at 4°C in a SLA rotor. The supernatant was 
removed and the centrifugation was repeated for 20 minutes, followed by a complete 
removal of the remaining supernatant. The pellets were air-dried for 5 minutes and 
resuspended in 500 µl TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA). DNA was 
isolated by phenol extraction and precipitated by addition of ethanol and incubation for 15 
minutes at -80°C. DNA was collected by centrifugation for 20 minutes at 15’000 rpm at 
4°C and the pellet was washed with 500 µl 70% ethanol. The pellet was dried in the 
speedvac for 3 minutes and resuspended in 400 µl TE buffer. DNA concentration was 
measured with NanoDrop (Thermo Scientific). 
 
 
16 Transcriptional run on (TRO) 
 
TRO analysis was performed essentially as described by Birse et al. (1998). The yeast 
strains of interest were transformed with the plasmid pBD366 containing CUP-CYC1 or 
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pBD346 containing GAL1/10-CYC1. 50 ml cultures were grown in SD containing 0.2 mM 
CuSO4 or SGal to an OD600 of 0.1 – 0.2 harvested by centrifugation for 5 minutes at 3500 
rpm at 4°C. The cells were washed with 1 ml cold H2O and resuspended in 0.5% sodium-
lauryl-sarcosine sulphate. After 20 minutes incubation on ice, the cells were pelleted by 
centrifugation for 1 minute at 8’000 rpm at 4°C and the supernatant was removed 
carefully. The centrifugation step was repeated and the remaining liquid was removed 
completely with a pipette. The cells were resuspended in 60 µl TRO buffer (50 mM Tris-
HCl pH 7.7, 500 mM KCl, 80 mM MgCl2) in the presence of ATP, GTP and CTP (10 mM 
each) and 2 mM DTT. The transcription reaction was initiated by the addition of 3 µl [α-
32P]-UTP and allowed to proceed for 5 minutes at 30°C. The reaction was stopped by the 
addition of 900 µl AE buffer (50 mM NaOAc, 10 mM EDTA). Total RNA was then 
purified by hot phenol extraction (described above) and partially hydrolysed by incubation 
on ice for 5 minutes in the presence of 0.2 M NaOH and neutralised by the addition of 
20 µl neutralising solution (0.5 M Tris, 0.5 M HCl). 6.7 µg of M13 phage DNA was 
applied on a Hybond-N+membrane (Amersham, Bioscience) using a slot blot manifold 
(BioRad). DNA was denatured by incubating in denaturing solution (1.5 M NaCl, 0.5 M 
NaOH) and filters were neutralised in neutralising solution (1.5 M NaCl, 0.5 M Tris-HCl 
pH 7.2, 1 mM EDTA) and UV cross linked. Hybridisation of the labelled RNA was 
performed overnight at 42°C in hybridisation buffer (50% formamid, 6x SSPE, 
5x Denhard’s solution, and 0.1% SDS). Filters were washed for 15 minutes each with 2x 
SSC, 0.1% SDS at 42°C, 0.2x SSC, 0.1% SDS at 30°C and 0.1x SSC, 0.1% SDS at 37°C 
and exposed and visualized on a FLA-7000 phosphor-imager (Fuji). 
 
 
17 Cell growth and RNA extraction for microarray analysis 
 
An overnight pre-culture of wild-type S228C and pap1-1 were diluted to an OD600 of 0.05 
in SD medium and incubated at 25 °C until the culture reached an OD600 of about 0.3. 
Cordycepin was added to a final concentration of 20 µg/ml and cells were allowed to grow 
for 1 hour. Pap1-1 was additionally shifted to 37°C for 1 hour. All cultures were grown in 
triplicates. Cells were harvested by centrifugation and washed with cold H2O. The pellet 
was frozen in liquid nitrogen and stored at -80°C. RNA was extracted according to the hot 
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phenol method as described above. To further purify the RNA, the RNeasy Micro Kit 
(Qiagen) was used. 
 
 
18 Oligo array hybridisation and analysis of data 
 
10 µg total RNA was mixed with oligo(dT) and pdN9 primer (5 µg/µl each) and 1 µl of 
Ambion spike control. The RNA was denatured for 10 minutes at 70°C and chilled on ice 
for 10 minutes. Then, the RNA was reverse transcribed using superscript II (200 U/µl) 
(Invitrogen) and 0.6 µl of aa-NTP mix (25 mM dATP, 25 mM dGTP, 25 mM dCTP, 
12.5 mM dTTP, 12.5 amino-allyl-dUTP (Sigma)) for at least 2 hours at 42°C. The RNA 
was hydrolysed by the addition of 10 µl 0.5 M NaOH and 10 µl 0.5 M EDTA pH 8.0 for 
15 minutes at 65°C. The solution was neutralised with 25 µl 1 M HEPES pH 8.0. The 
DNA was cleaned from buffer remains and concentrated to a final volume of 9 µl using the 
Microcon-30 concentrator (Amicon). NHS-Cy3 and NHS-Cy5 dyes (Amersham) were 
resuspended in 10 µl DMSO. For the coupling reaction, 1 µl of the respective dye and 1 µl 
1 M sodium bicarbonate pH 9.0 was added to the DNA was incubated for 1 hour at room 
temperature. Remaining NHS-dye was aliquoted and dried in the speed vac for around 2 
hours and stored in a dessicator at 4°C. The labelled DNA was concentrated and purified 
using the Qia-quick PCR purification kit (Qiagen) by a final elution of 60 µl. The Cy3- and 
Cy5-labelled cDNA samples were mixed and concentrated in Microcon-30 concentrators 
(Amicon) to a final volume of 10.5 µl. Labelling efficiency was measured by NanoDrop 
using the microarray application.  
Nexterion oligo arrays were post-processed in blocking solution (5x SSC, 4 mg/ml 
BSA, 0.1% SDS) inside of the waterbath for 60 minutes at 42°C. The arrays were washed 
for 10 minutes in 0.3x SSC for three times, shortly rinsed by water and dried by 
centrifugation for 2 minutes at 500 g. The concentrated labelled DNA was mixed with 
MWG formamide buffer (Ocimun Biosolutions) and poly(A) RNA was added to a final 
concentration of 0.5 mg/ml. The hybridisation mix was incubated at 80°C for 10 minutes 
and loaded on the array. A coverslip was added on top and the array was enclosed in a 
slide chamber and hybridised in a waterbath overnight at 42°C. The arrays were washed 
for 12 minutes each in 2x SSC, 0.2% SDS, 2x SSC and 0.2x SSC and immersed with 
100% ethanol to fix the cDNA to the array. The arrays were dried by centrifugation and 
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scanned with Axon instruments scanner 4000 (Foster City, California, United States). 
Scanning parameters were adjusted to similar fluorescent intensities in both channels. 
Scanning data were collected with the software GENEPIX 3.0 (Axon Instruments) and 
spots with abnormal morphology were identified by eye and excluded from further 
analysis. Arrays were normalized by the Stanford Microarray Database (SMD) (Gollub et 
al., 2003). The calculated log2 ratios were imported into Acuity 4.0 (Axon Instruments) 
and filtered for regression correlation of greater than 0.5 (filters for large variations in the 
ratios of pixels within each spot) and a signal to noise ratio of greater than 2.5 (signal over 
background). Average log2 rations were calculated from the triple experiments for each 
gene spot. RNA were considered as increased when the log2 ratio was > 1 and decreased 
when log2 was < -1.  
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